Atrial natriuretic factor:integrated effects on blood pressure, natriuresis, and renal medullary blood flow in man by Janssen, Wilbert Martien Theodoor
  
 University of Groningen
Atrial natriuretic factor
Janssen, Wilbert Martien Theodoor
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
1994
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Janssen, W. M. T. (1994). Atrial natriuretic factor: integrated effects on blood pressure, natriuresis, and
renal medullary blood flow in man. Groningen: s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
ATRIAL NATRIURETIC FACTOR
Integrated effects on blood pressure, natriuresis,
and renal medullary blood flow in man
RIJKSUNIVERSITEIT GRONINGEN
ATRIAL NATRIURETIC FACTOR
Integrated effects on blood pressure, natriuresis,
and renal medullary blood flow in man
Proefschrift
ter verkrijging van het doctoraat in de
Geneeskunde
aan de Rijksuniversiteit Groningen
op gezag van de
Rector Magnificus Dr. F. van der Woude
in het openbaar te verdedigen op
woensdag 5 oktober 1994
des namiddags te 2.45 uur precies
door
Wilbert Martien Theodoor Janssen
geboren op 5 november 1958
te Breda
Promotores: Prof. Dr. P.E. de Jong
Prof. Dr. G.K. van der Hem
Copromoter: Dr. D. de Zeeuw
Referent: Dr. H. Beekhuis
Van alles wat er speelt in deze wereld, laat het vooral de kinderen zijn
(naar Loesje)
Promotiecommissie: Prof. Dr. H.A. Koomans
Prof. Dr. H.A.J. Struijker Boudier
Prof. Dr. W. Vaalburg
To the front-cover:
Painting by Wil Janssen-Wiltingh, visual artist: IJsselmeer (1993), oil/canvas, 60 x 80 cm.
Printing by Krips Repro, Meppel.
The manuscripts presented in this thesis were reproduced with permission from the publishers.
The studies described in this thesis were made possible by financial support from the Research Fund
Nephrology (RESNEF) in Groningen, and, for the largest part, by the Dutch Kidney Foundation (Nier
Stichting Nederland).
Printing of this thesis was financially supported by the Dutch Kidney Foundation (Nier Stichting
Nederland). Donations were also received from the Dr Saal van Zwanenbergstichting, and














Chapter 2: General Overview
Atrial natriuretic factor: its (patho)physiological
significance in humans.
Kidney Int 41:1115-1133, 1992.
SECTION I: BLOOD PRESSURE RESPONSE AND NATRIURESIS
Chapter 3: Effect of human atrial natriuretic factor on blood
pressure after sodium depletion in essential
hypertension.
Brit Med J 293:351-353, 1986.
Chapter 4: Involvement of atrial natriuretic factor in long-
term regulation of sodium-homeostasis in man.
Clin Nephrol 30(3):172, 1988.
Chapter 5: Antihypertensive effect of a 5-day infusion of
atrial natriuretic factor in humans.
Hypertension 13:640-646, 1989.
SECTION II: NATRIURETIC MECHANISM
Chapter 6: Renal tubular sensitivity to atrial natriuretic factor
in essential hypertension.
J Hypertens 12:439-447, 1994.
Chapter 7: Atrial natriuretic factor influences renal diurnal
rhythm in essential hypertension.
Hypertension 20:80-84, 1992.
Chapter 8: Atrial natriuretic factor-induced decreases in renal
blood flow in man: implications for the natriuretic
mechanism.
Clin Sci 77:55-60, 1989.
Chapter 9: Non-invasive measurement of intrarenal blood
flow distribution using a kinetic model of renal
123I-hippuran handling.
Am J Physiol, submitted.
Chapter 10: The effect of atrial natriuretic factor on intrarenal
blood flow distribution in man.








Chapter 11: Summary and look to the future









History probably will never reveal why it lasted till 1981 before de Bold et al [1]
described the existence of a 28-amino acid protein of cardiac origin with
antihypertensive and natriuretic properties, which accordingly was named the atrial
natriuretic factor (ANF) [2]. Indeed, the presence of granules in cardiac myocytes as
well as the depletion of these granules after extracellular volume expansion were
already observed in 1956 [3,4]. Moreover, an important relationship between changes
in extracellular volume and urinary sodium excretion was already noted in the fifties
[5,6]. In the sixties, many studies were performed to elucidate the mechanism of this
relationship. Several mechanisms were proposed such as dilutional effects, changes in
renal medullary blood flow or the existence of a "third factor", or "natriuretic
hormone" that would mediate extracellular volume-induced natriuresis apart from
glomerular filtration rate and aldosterone [7-8]. However, most of these hypotheses
could not be tested directly, until the discovery of ANF by de Bold et al offered a
clue to the long searched solution of the puzzle of the relation between extracellular
volume and urinary sodium excretion. Thereafter, the scientific and pharmaceutical
communities throwed themselves into the elucidation of the (physiological) signifi-
cance of ANF as if to make up for lost time.
In animal studies ANF was shown to decrease blood pressure, to increase urinary
sodium excretion and glomerular filtration rate, to increase or decrease renal blood
flow, and to suppress several elements of the renin-angiotensin-aldosterone axis [1,9-
10]. The mechanism of the ANF-induced natriuresis remained debated. Some
investigators forwarded the rise in glomerular filtration rate to be the main cause of
natriuresis [11]. Others focused on a direct tubular action of ANF. Numerous in vitro
and in vivo animal studies implied or denied the main site to be the proximal tubule,
Henle’s loop or the inner medullary collecting duct [12-15]. Moreover, an increase in
renal medullary blood flow was shown to be a possible important mechanism of the
natriuretic action of ANF [10]. An ANF-induced increase in renal medullary blood
flow was suggested by studies directly measuring the effects of ANF on medullary
blood flow using diverse techniques [10,16]. ANF was suggested to cause a washout
of the medullary interstitium, and to increase renal interstitial pressure, which both are
recognized to be related to increases in renal medullary blood flow [9,17-19]. At this
point in time, we and others started to study the systemic and renal effects of ANF in
man. Effects of ANF on blood pressure, urinary sodium excretion, glomerular
filtration rate, effective renal plasma flow and the renin-angiotensin-aldosterone
system (RAAS) could be measured directly. The possible effects of ANF in man on
proximal and/or distal tubular segments and on medullary blood flow however, had to
be estimated indirectly from free water and lithium clearance techniques and from
changes in urinary osmolality. Direct measurements of changes in medullary blood
flow, which might be an important mechanism to influence urinary excretion of




In Groningen, Navis, and before her Hoorntje and Prins had worked on the renin-
angiotensin-aldosterone system, studying in particular the natriuretic and systemic
hemodynamic effects of angiotensin-converting-enzyme-inhibitors (ACEi) [20-22]. In
this respect studies with ANF, known to counteract the RAAS [9], seemed logical. In
the studies with ACEi special attention was given to the chronic effects of ACEi.
Therefore, and because ANF seemed to be a continuously circulating hormone [23],
we designed our studies to investigate the effects of long-term continuously infused
ANF. At the time when we started working with ANF in Groningen in 1986 only a
few studies were available on the effects of ANF in humans. Weidmann et al had
described the results of short-term infusions of ANF in normal volunteers. Blood
pressure fell, whereas sodium excretion increased. They further observed a rise in
glomerular filtration rate with a concomitant slight decrease in effective renal plasma
flow [24]. Richards et al observed similar effects with bolus injections of ANF [25].
Our first studies (Section I, chapters 3-5) therefore were addressed to evaluate the
effects of different (long-term) infusion durations and (low) doses of ANF on
systemic blood pressure and natriuresis.
The studies in Section II were focussed on the natriuretic mechanism of ANF in
man. The first 2 studies in this Section (chapters 6 and 7) were addressed to the
tubular versus hemodynamic effects of ANF, and to the importance of blood pressure
for ANF-induced natriuresis in particular. The tubular site(s) of action of ANF were
evaluated with the use of free water clearance techniques (chapter 6). In particular,
the study was designed to asses a possible (medullary) tubular site of action of ANF,
since pressure related natriuretic effects are thought to affect sodium transport in the
proximal tubule and/or loop of Henle [26,27]. To elaborate the importance of blood
pressure for ANF-induced sodium excretion further, the relation between the diurnal
rhythms of blood pressure and urinary sodium excretion as well as the effect of ANF
on this relationship were evaluated in patients with essential hypertension (chapter 7).
Since the mechanism of the ANF-induced natriuresis had also been associated with
(intra)renal hemodynamic changes we designed the last studies of this thesis (chapters
8-10) to offer more insight in the effects of ANF on total renal blood flow and
intrarenal blood flow distribution in man. Whereas in general in many animal studies
ANF was shown to increase renal blood flow, in man ANF caused effective renal
plasma flow to decrease. Since measurements of effective renal plasma flow do not
account for possible changes in hematocrit and the renal extraction of hippuran, we
measured the effects of ANF on these parameters, thus being able to calculate ANF-
induced changes in total renal blood flow (chapter 8). In a further study the effects of
ANF on intrarenal hemodynamic function was explored. To be able to measure non-
invasively and directly (changes in) renal medullary blood flow in man a new method
was developed based on the kinetic modeling of 123I-hippuran renography. This
method was evaluated in dogs (chapter 9), and was finally applied to human
renography data to test the hypothesis that ANF predominantly decreases cortical
blood flow and might increase renal medullary blood flow (chapter 10).
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Chapter 1
Chapter 2 gives a general overview over studies in literature dealing with the
(patho)physiological significance of ANF. The thesis ends with a summary and look
to the future (chapter 11).
In summary, in this thesis the following questions will be addressed:
1. what are the effects of different long-term infusion durations of low doses ANF
on blood pressure and urinary sodium excretion ?
2. what is the mechanism of the ANF-induced natriuresis in man:
- does ANF induce an increase in GFR ?
- does ANF inhibit (proximal and/or distal) tubular sodium reabsorption ?
- are there indications for a blood pressure dependent mechanism of ANF-
induced natriuresis ?
- does ANF interfere with the RAAS ?
- does ANF induce an increase in renal medullary blood flow ?
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Chapter 2
The regulation of sodium and volume homeostasis has been a topic of research for
many decades. Upon the discovery of many new exciting hormone systems, such as the
renin-angiotensin-aldosterone system, the prostaglandin cascade, and the "natriuretic
hormone," exhaustive attempts have been made to obtain insight into the way the human
body is so effectively able to preserve its internal milieu. History has learned, however,
that although these hormones all have their specific place, the circle explaining the exact
mechanism of volume regulation has not yet been closed. The discovery of the cardiac
atrial peptide(s) and their functional properties, elegantly reviewed by Maack et al, is
most exciting in this context [1]. Indeed, the logic of a "hormone" that signals from the
heart to the kidney appears so simple that it may indicate that we come close to the basic
understanding of volume homeostasis. A more detailed understanding of the functions
of this peptide would not only have tremendous physiological and pathophysiological
significance, but it would also add new therapeutic approaches to the treatment of the
many diseases that are accompanied by volume overload.
A mountain of scientific publications appeared after the pioneer work of de Bold et
al showing that the cardiac atria contain a powerful substance capable of reducing
systemic blood pressure and inducing natriuresis [2]. This data offered us insight into the
production and function of atrial peptides. However, it also brought many areas of
conflict. The most trivial in this respect is the difference in nomenclature. Although the
term "atrial natriuretic factor" has been advocated as the trivial name [3], alternatives
such as atrial natriuretic peptide are still being used. For practical purposes we will refer
to atrial peptides as atrial natriuretic factor, in short ANF. Of more importance are the
various discrepancies in the data concerning the effects and mechanism(s) of action of
ANF. A list of reported actions is shown in Table 1. Only few of these effects remain
relatively non-controversial such as the hemoconcentration and the natriuresis following
ANF administration. As far as the other alledged effects are concerned, one may find
data that suggest either no or even opposite effects, for example regarding changes in
blood pressure, in GFR, in renal blood flow, and in hormone interactions. We feel that
a large proportion of these discrepancies can be explained by a few basic variations in
the used protocol of the different studies, as listed in Table 2.
The purpose of this review is not to reiterate the numerous animal studies which
form the backbone of our current understanding of the role of ANF and which have been
interpreted in many excellent previous reviews [4-14]. We will mainly focus on the
available human data and make an attempt to relate the current knowledge on ANF to
its significance for human physiology and pathophysiology, taking into account as much
as possible the above-mentioned factors of bias (Table 2).
RELEASE
Production site
The main production site of ANF is, at least in mammalian vertebrates, localized in
the cardiac atria. Kisch [15] and later Jamieson and Palade [16] referred to these sites as
8
General overview
Table 1. Reported effects of atrial natriuretic factor (ANF) in humans
1. Systemic effects
- blood pressure fall
- hemoconcentration
2. Hormonal effects
- fall in plasma renin (activity)
- fall in aldosterone, cortisol and rise in testosterone levels
- inhibition of arginine vasopressin secretion and/or effects
- induction of pancreatic juice secretion
- modulation of insulin secretion and/or metabolism
3. Renal effects
- rise in glomerular filtration rate
- fall in effective renal plasma flow
- rise in filtration fraction
- rise in renovascular resistance
- rise in urinary volume and electrolytes
4. Central nervous system effects
- modulation of sympathetic activity
- increase in heart rate
- increase in lipolysis
- effects on blood pressure-/volume-regulatory regions in the brain
5. Cardiac effects
- coronary vasodilation
- left ventricular performance
- cardiac output reduction
6. Pulmonary effects
- relaxation of vascular smooth muscle cells
- relaxation of the trachea
dense bodies. Many years passed before these granules were identified as the main
production and storage sites of precursor and perhaps active ANF both in animals and
in humans [17,18]. Many elegant animal experiments have subsequently confirmed the
presence of ANF in these granules and have shown that the contents of these stores can
be depleted and refueled by physiological and non-physiological stimuli [19-22].
Although the heart was thus recognized to be not only a pump but also a secretory organ
for a hormone [23], we should not be trapped by oversimplifying this concept. For many
years the renin-angiotensin system was believed to be located in a few single organ
systems. This led to rather undifferentiated models of its (patho)physiological actions.
However, with the use of new cell biology techniques, mRNA for the different
components of the system has been identified in many other tissues. Similarly, coding
genes for ANF or ANF-like products have been found in other tissues than the cardiac
atria, such as the cardiac ventricle, central nervous system, blood vessels, adrenals and
digestive tract [13]. The precise function of this extra-atrial ANF, be it endocrine,
paracrine, and/or autocrine sites, has yet to be established. Clearly the human cardiac
atria produce the major fraction of circulating ANF.
Formation
In human atrial tissue three distinct peptides have been distinguished: α, β, and γANF
[24,25]. These are all derived from the 151 amino acid precursor molecule
9
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Table 2. Factors determining the ANF response
1. Species difference
2. Dose of the administered ANF
3. Duration of the ANF administration (length of observation period)
4. Sodium/volume status of the studied subject
5. Blood pressure of the studied subject
6. Posture of the studied subject
(prepropeptide), consisting of a 126 amino acid propeptide (γANF) and an N-terminal
signal polypeptide. From the propeptide, the 28 amino acid αANF is cleaved from the
carboxy-terminus, leaving the N-terminal γANF fragment. The synthesis of the
antiparallel dimer of αANF called βANF is not yet understood. All these peptides have
been identified in human plasma, however in distinct quantities [26-29]. The most
predominant are αANF and the N-terminal γANF fragment, whereas the propeptide is
found in abundant quantities in the granular atrial stores and only in very small quantities
in human plasma in some patients [30]. This suggests that the processing of the
propeptide into the αANF and N-terminal fragment occurs just before, during or just
after secretion from the cardiac stores.
As far as the biological activity of the different peptides is concerned, the propeptide
probably only has a delivery role for αANF, whereas the latter determines the biological
responses. The function of βANF remains uncertain.
Cardiac release triggers
The mechanism that results in a release of ANF from the cardiac atria appears to be
multiple. Teleologically, atrial pressure or atrial wall stretch as a mechanism of release
of ANF would ideally fit into the concept of a "third factor" in the regulation of volume
homeostasis. Indeed, many animal studies have shown that a directly induced increment
in atrial pressure and/or in atrial stretch results in ANF release [31]. However, a large
number of other trigger mechanisms have been proposed including the baroreceptor
system [32], the frequency of atrial contractions [33], intravascular sodium/volume [34],
and adrenal and pituitary gland hormones [35,36]. In human studies, many authors have
established a relation between atrial pressure/diameter and plasma ANF levels in disease
states, suggesting that patients with high atrial pressures (or large atrial diameters) have
an increased cardiac ANF release [37-40]. However, these cross sectional studies lack
evidence for the atrial pressure/diameter to be the direct cause of the increased ANF
levels. More convincing in this respect are the studies showing that cardiac perturbations
(such as atrial or ventricular pacing) result in an increase of right atrial pressure, followed
by an immediate cardiac release of ANF [41-44]. These findings are supported by the
elegant study of Schwab et al showing that an imposed increment of right atrial pressure
in patients supported with the artificial Jarvik-7 heart, results in an immediate ANF
release [45]. In addition, several other manipulations including (isotonic or hypertonic)
volume expansion [46-48], changes in posture [49], head-out water immersion [50], an
increase in dietary sodium intake [46,49] and mineralocorticoid [51], norepinephrine [52],
10
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and angiotensin II [52,53] administration have been advocated to lead to a rise in ANF,
C 
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Figure 1. The effect of a
two-hour infusion of synthetic
human αANF (1 µg/min) on
plasma levels (PirANF) in 7
healthy subjects. irANF levels
show a cons iderab le
individual variation in
response to the same amount
of infused ANF. The induced
irANF levels correlated with
the induced rise in fractional
sodium excretion (∆CNa/GFR).
whereas a fall in plasma ANF levels was induced through measures like furosemide
administration [47,48] and sodium depletion [54]. Since several of these studies show a
close correlation between the degree of change in intravascular volume and the ensuing
ANF secretion, it is tentative to conclude that all these maneuvers act via the same
trigger mechanism, that is, a change in atrial wall tension, either directly or via a rise
in atrial pressure, leading to a change in the release of ANF.
Plasma levels
To date no world standard is available as to how to measure human ANF. It has
become clear that, despite the introduction of an international standard ANF sample [3],
various parameters may introduce bias such as the use of a plasma extraction procedure
[26] and the source of the antibody used [55]. Moreover, since antibodies are directed
against the C-terminal sequence one may not be certain whether one is measuring the
biologically active αANF, the precursor molecule, or degradation products. For this
reason, it has been suggested that the term immunoreactive ANF (irANF) be used for
data derived from RIA ANF measurements [3]. Normal levels of irANF are not only
hard to define because of the lack of assay standardization, but also because of the fact
that the condition of the "normal" subject varies within and between studied populations.
Factors like the sodium/volume status [46], systemic blood pressure [56,57], posture
[49,58], age [58-61], heart- and renal function [37,62], and time of sampling [63-65] do
have an effect on the outcome of the measurement. Thus, it is not surprising taking into
account all the above-mentioned variations, that we find "normal" values for plasma
irANF in healthy men (younger than 65 years) to range from 10 to 70 pg/ml. In this
respect a parallel can be drawn with the broad range of "normal" values of plasma renin
activity. An underestimated item concerning the possible bias present in defining the
11
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normal values of plasma irANF is the variation in breakdown of ANF. Obviously, plasma
levels depend on release as well as on plasma clearance. Interestingly, we found that a
1 µg/min exogenously infused synthetic human αANF in different supine healthy subjects
on a standardized sodium intake results in considerably different increments of plasma
irANF levels between the individuals (Figure 1) [66]. Similarly, Gillies et al found that
during a constant infusion of αANF in healthy volunteers a change in posture induced
a varying increment in irANF levels [67]. The measured change in irANF levels induced
either by physiological maneuvers or by exogenous infusion may thus well be
confounded by a change in plasma irANF clearance. Thus, it appears to be at least
speculative to assess a normal range of plasma irANF considering the above-mentioned
factors that have a direct or indirect impact on the irANF level itself. Moreover, these
attempts to define a "normal" irANF level lead inevitably to defining categories of
subjects with "abnormal" levels (such as in the case of certain disease states). In light of
the above-mentioned bias, we feel that interpretations of "static" irANF levels between
groups or laboratories remain extremely hazardous, although sometimes they are our only
tool. In contrast, data on changes of irANF levels within individuals appear to be more
valid.
Clearance
The data on human irANF (pharmaco)kinetics are rather uniform: the distribution
volume appears to be 10 to 17 liters, plasma half-life 2.5 to 4.5 minutes, and the mean
plasma clearance 1.7 to 3.9 l/min, possibly depending on the investigated dose [68-70].
It was established that irANF is not, or is only very slowly broken down by circulating
plasma enzymes [8]. Multiple organs effectively extract ANF from the blood: the liver,
kidney and lower limb all extract approximately 20 to 50% of the irANF influx, whereas
the data on lung extraction vary from negligible to 20% extraction [70-73]. This removal
from the vascular compartment may either occur through receptor binding and subsequent
transfer, or through ANF degradation by specific or non-specific enzymes located within
these tissues [74]. The kidneys appear to be one of the major sites of plasma extraction,
since renal extraction of irANF is 50% and since the kidneys are the organs with the
highest blood flow per gram of tissue. Indeed, Vierhapper et al calculated the renal
clearance to be approximately 20% of the total metabolic irANF clearance [70]. This
renal clearance appears to occur along at least two different pathways. First, part of the
circulating ANF is filtered, reaching the proximal tubule, where it is degraded by a
specific enzyme, neutral endopeptidase 24.11 [75-78]. Apparently, some of the ANF
escapes this degradation and is retrieved in the final urine [79]. The function of this
degradation is shown by Margulies et al, who found that infusion of an inhibitor of this
enzyme enhances the effects of intrarenally infused ANF [80]. The second pathway is
formed by receptor binding [81,82]. These so-called clearance receptors (C-receptors,
vide infra) are capable of binding ANF, followed by a rapid cell internalization of the
receptor-ligand, and subsequent lysosomal hydrolysis of ANF [82]. The major part of the
renal C-receptors are found in the glomeruli [81,83]. Which of these two pathways
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constitutes the predominant ANF-clearance function remains to be established.
Interestingly, Suzuki et al demonstrated in the rat that non-filtering kidneys still extract
a major portion of infused ANF [81].
In summary, the atrial ANF release in humans appears to be predominantly regulated
by the many factors that influence atrial wall tension/stretch. The subsequently released
ANF is very rapidly removed from the circulation by different tissues, of which the
kidney appears to be one of the important organs. Apparently, large variations can be
found between individuals with respect to both ANF release as well as plasma clearance,
which may account (besides lack of assay standardization) for the wide normal range of
irANF in normal individuals.
RECEPTORS
The current knowledge on ANF-receptors is derived from animal studies, as tools for
human receptor studies are limited. In the following paragraph we will try to briefly
summarize some of the data relevant to this review. For more detailed information we
refer to previous reviews [83-89].
Specific binding sites for ANF are localized in various animal tissues, particularly
those known to be important in the homeostasis of volume and blood pressure such as
vascular tissues, specific brain areas, adrenal glomerulosa cells, and several renal sites.
In the kidney vascular ANF binding has been demonstrated, both by autoradiographic and
immunohistochemical techniques, in the renal artery wall [90,91], the glomeruli [90-92]
and the descending vasa recta [90,93,94]. Data on the presence of ANF receptors at the
afferent and efferent arteriole are conflicting [91,94]. Tubular ANF receptor binding sites
have been observed in the inner medullary collecting tubule (IMCD) [91,93]. The other
tubular segments seem to be devoid of ANF receptors, although some of the
above-mentioned studies reported weak binding of 125I-ANF at the proximal tubule.
Figueroa et al recently demonstrated ANF localization in human distal convoluted tubular
cells besides collecting duct cells [95]. Intriguingly, animal studies on the distribution of
ANF binding sites within the kidney show that the majority of ANF binds at a cortical
level, whereas less than 2% is found in the renal papilla. However, the density of these
latter sites is fairly high [81,83].
Quantitative analysis of ANF binding data and affinity labeling and cross linking
studies have shown a heterogeneity in ANF receptors. Recent evidence points to the
existence of at least two independent ANF receptors [96-98]: a protein with an apparent
molecular mass of 70 kDa and one of 130 kDa. The latter one is coupled to guanylate
cyclase. Upon ANF binding to this site, cGMP formation is also stimulated in humans
[99], eliciting a cascade of cellular responses leading to vasodilation, as well as, albeit
preliminary evidence, to inhibition of renin secretion and sodium transport in kidney cells
[86,88]. Moreover, the different biological effects have been correlated with rises in
plasma and/or urinary cGMP levels. For this reason this 130 kDa protein has been
labeled as the biologically active receptor: B-receptor. Whether other signal transductions
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beside cGMP, such as cAMP, are involved with (B-)receptor function remains to be
elucidated [100,101]. The 70 kDa receptor appears not to be coupled to guanylate
cyclase, and does not appear to evoke a biological response. Upon binding of ANF to
this receptor, the complex is internalized, the receptor recycles, and ANF undergoes
lysosomal hydrolysis [82]. This biologically silent receptor is therefore called the
clearance receptor, C-receptor. Very recently a third receptor type coupled to guanylate
cyclase was defined. This receptor is almost identical to the 130 kDa receptor, but is
mainly activated by brain natriuretic peptide [102]. Its function is as yet unknown.
Interestingly, the distribution of B- and C-receptors over different tissues is not
uniform [103]. Within the kidney Nussenzveig et al demonstrated that C-receptors
constitute 90% of the total ANF binding in glomeruli, 30% in mesengial cells, and 50%
in the renal papilla [83]. This anatomical heterogeneity suggests again that each receptor
has a specific function.
Important for the understanding of the variation of ANF effects under specific
conditions may well be whether B- and/or C-receptor numbers can be regulated. There
is indeed some evidence suggesting that high ANF levels may down-regulate
ANF-receptor numbers and cGMP formation [104]. Interestingly, in vivo changes in
sodium intake appeared to affect mainly the C-receptor density [105,106], whereas such
an effect has also been suggested for angiotensin II [107,108]. Despite these interesting
findings, we should realize that in some studies these phenomena may have been biased
by increasing receptor occupancy by higher ANF levels. Furthermore, if down-regulation
does occur in certain situations, it is important to differentiate between B- and
C-receptors, since down-regulation of the C-receptor results in increased ANF levels
which could in turn enhance the B-receptor mediated response [109]. This differentiation
has not been made in most of the in vivo ANF studies to date.
In summary, at least two types of ANF receptors, a biologically active B-receptor and
a clearance C-receptor, are present in many tissues involved in the regulation of blood
pressure and volume homeostasis. The ratio of the subtypes of ANF receptors varies
between tissues. Whether or not the prevailing physiological status may modulate the
effects of ANF administration through (differential) receptor-number regulation of the
ANF receptor subtypes in the various tissues remains to be elucidated.
EFFECTS OF ANF ADMINISTRATION
There are many problems when attempting to classify the vast number of reported
effects of ANF because of the apparent non-uniformity of the current data. Certainly, it
is tempting to simply follow up on the classical first experiments on ANF infusion in
animals and humans which show a fall in systemic blood pressure, a rise in hematocrit
and a clear natriuresis [2,110-112]. However, the results of later human studies cast
serious doubt as to whether one may assume the ANF function to range over this specific
spectrum of effects. Although natriuresis was reported in nearly all studies, blood
pressure effects were highly variable, and hormonal effects were added to the list of ANF
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functions. Interestingly, all studies used different protocols with respect to ANF dose,
duration of ANF infusion, and observation time. Moreover, most of the studies on ANF
were uncontrolled for the preexisting volume/sodium status, prevailing systemic blood
pressure, or posture of the studied individual. Thus, the study protocol may have
influenced the outcome of a particular study. In the next paragraphs we will focus on the
systemic, hormonal and renal effects of ANF, with special emphasis on the factors that
determine the human response.
Systemic effects
Pharmacological doses of ANF almost consistently result in an immediate systemic
blood pressure fall in animals. The hypotensive mechanism involved has been studied
extensively. Although in vitro studies [1] in isolated vessels demonstrated the
vasodilatory capacity of ANF, the role of systemic vasodilation in the hypotensive effect
in the intact animal remains controversial, since total peripheral resistance remains
constant or even increases [113-117]. The hypotensive action appears rather to be the
result of a fall in cardiac output, most likely due to a reduced filling pressure [115,116].
It has been suggested that reduced venous tone and decreased blood volume may
contribute to the reduction in filling pressure. Indeed, ANF has been demonstrated to
induce an extravascular fluid shift, resulting in hemoconcentration [118].
In humans, pharmacological doses of ANF also elicit an acute fall in systemic blood
pressure. However, the acute hypotensive mechanism appears to be different from that
in animals. Bussien et al suggested that vasodilation plays an important role [119].
Indeed, heart rate almost invariably acutely rises upon ANF bolus injection or ANF
infusion [110-112,119,120]. Furthermore, cutaneous vasodilation occurs upon systemic
ANF administration, and forearm resistance falls upon local ANF infusion [121,122].
Species differences may explain the different vascular response between animals and
humans [123]. On the other hand, the heterogeneity in the response of the different
vascular beds studied in animals and humans may play a role [1]. Similar to the animal
data, human studies show the rapid hemoconcentrative effect of ANF [12,120,124], as
well as a fall in cardiac output [125]. However, no effects on cardiac output have been
reported [126]. Although it seems appropriate to assume that a combination of
vasodilation and/or extravascular fluid shift, and/or a fall in cardiac output underly the
ANF-induced acute fall in systemic blood pressure in humans, the presence and relative
contribution of each of these factors has yet to be established. This is particularly
important since relations between these factors and the blood pressure response are not
always present [120,124].
Interpretation of the mechanism(s) that play a role in the hypotensive response to
ANF, or even the presence of a systemic hemodynamic response, are confounded by the
fact that this response depends on certain protocol conditions, such as the ANF dose, the
duration of the ANF infusion, and possibly the sodium/volume status of the studied
subject. Obviously, the dose of the administered ANF influences the type and magnitude
of the response [127-129]. The early high-dose human experiments of Richards et al and
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Weder et al showed that 100 µg ANF as a bolus injection or 2 to 30 (!) µg/min as a
sustained infusion caused a dramatic fall in systemic blood pressure similar to that
observed in animal experiments [110,129]. However, many later human studies have
employed much lower doses, even as low as 0.16 µg/min, showing no hypotensive effect
at all or even a small pressor effect [127,130-136]. Richards et al elegantly showed that
inhibition of the enzyme that degrades endogenous ANF, leading to a very small but
significant increase of plasma irANF levels, does not have any effect on systemic blood
pressure [137]. Thus, it seems valid to state that only high doses of ANF (leading to
supraphysiological irANF plasma levels) result in an immediate fall of systemic blood
pressure. Interpretation of the data on the effect of low-dose ANF on blood pressure is
complicated by the differences between studies as far as the duration of the ANF
infusion. Whereas many studies have shown that low-dose infusions (leading only to high
range physiological irANF plasma levels) have no effect on blood pressure when given
over a period of maximally six hours, we found in a five-day infusion study that similar
low-dose ANF results in a distinct blood pressure fall only after 12 hours from the start
of infusion (Figure 2) [138]. Similar observations have been made showing a delayed
hypotensive effect after prolonged ANF infusion (or endogenous ANF breakdown
inhibition) both in animals [139-143] and in humans [144]. Apparently, the duration of
infusion does play a role in the outcome of a blood pressure response in such low-dose
infusion studies.
How may we interpret these findings? At least three mechanisms have been suggested
to explain this delayed response: systemic vasodilation, decreased circulating volume
(through extracellular volume shifts and/or negative sodium balance caused by the
sustained natriuresis), or a combination of both. Both could well be a result of a direct
action of ANF on the systemic and renal vasculature, and/or an indirect action through
inhibition of the renin-angiotensin-aldosterone system [139]. The cited long-term infusion
studies in humans both show that an ANF-induced negative sodium balance may play
an important role [138,144]. Indeed, figure 2 shows that the fall in blood pressure is
preceded by a sustained natriuresis causing a negative sodium balance [138]. Garcia et
al had suggested a similar mechanism in an animal study [141]. However, systemic
vasodilation cannot be ruled out as an important determinant of the blood pressure
response. In this context it is important to note that this delayed blood pressure lowering
response was only found to occur in hypertensive animal models and hypertensive
patients, and not in the normotensive controls.
Another complicating factor in unraveling an ANF dose-response relation is probably
the sodium/volume status of the studied subject. A higher sodium intake will result in
enhanced irANF levels and a lower activity of the renin-angiotensin-aldosterone system,
and both are most likely associated with a lower response to circulating/exogenous ANF
(vide supra). We indeed observed in humans that the blood pressure response after
low-dose ANF infusion is enhanced in a sodium deplete state compared to a sodium
replete state [127]. Similar observations were made when analyzing the studies of
Gaillard et al and Cuneo et al [145,146]. In both studies diastolic blood pressure tended
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with essential hypertension. The top panel shows the rise of plasma irANF levels (mean±SEM) before,
during, and after infusion. The middle panel shows the significant fall in both systolic and diastolic blood




to fall more during the low sodium diet, although no statistical significance in the
difference was reached. In contrast, others found no significant difference in the blood
pressure response during different sodium intakes [120,129,147]. However, comparison
between these studies with respect to the possible difference in response on different
sodium intakes remains difficult, since different ANF dose and infusion protocols were
used.
In summary, high ANF doses will elicit a rapid fall in systemic blood pressure,
probably mediated through acute systemic hemodynamic changes. Lower dose ANF
infusions (or ANF breakdown inhibitors), mimicking physiological changes in irANF
levels, have no immediate effect on systemic blood pressure. However, prolonged
infusion of low-dose ANF will eventually induce a fall in blood pressure, probably
mediated through a combination of factors including the sustained natriuretic effect of
ANF. Because of the non-physiological irANF plasma levels reached during high-dose
studies, we tend to conclude that ANF has no physiological significance as far as the
short term regulation of systemic blood pressure is concerned.
Hormonal effects
ANF has been found to induce changes in plasma renin (PRA), aldosterone (PAC),
catecholamines, cortisol, arginine vasopressin (AVP) and dopamine. Again, a wide
variety in responses to ANF infusion has been reported in humans. During high doses
of ANF, PRA and PAC remain unchanged [110-112] or increase [147], the latter
probably reflecting an activation of the renin-angiotensin-aldosterone system (RAAS)
secondary to a hypotensive action and/or volume depletion through ANF. Low-dose
studies, however, more or less consistently show that PRA and PAC fall upon ANF
infusion [131-134,148]. Interestingly, Richards et al showed in humans that PRA and
PAC also fall after inhibition of the enzyme that degrades endogenous ANF, which had
led to small but significant increases in plasma irANF levels [137]. The effect of ANF
on renin and/or aldosterone appears to be dependent on the sodium state of the infused
subject [146,147]: a low sodium diet enhances the suppressive effects of ANF on PRA
and/or PAC, compared to a high sodium diet. This phenomenon suggests that activation
of the RAAS enhances the suppressive reponses of ANF on exponents of this system.
Indeed, Richards et al found that the PRA/PAC suppression, following endopeptidase
inhibition, was more pronounced in standing compared to supine position [137]. Since
most of the current (human) studies have not controlled for sodium intake adequately,
it is hard to align all the data. However, there is ample evidence that ANF has a (direct)
inhibitory effect on exponents of the RAAS. What the exact mechanism of this
suppressive effect of ANF on renin is, remains uncertain. In vitro animal studies on
juxtaglomerular cells are conflicting, reporting stimulation [149] as well as inhibition
[150,151]. As far as aldosterone is concerned, in vitro studies generally agree on ANF
causing an inhibition of aldosterone release from adrenal cortical cells. This appears to
be the result of an inhibition of angiotensin II stimulated aldosterone secretion [152-154].
As far as effects of ANF on norepinephrine, most human studies agree on a rise of
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this hormone paralleling the ANF-induced rise in heart rate [112,134,146,147]. This
action appears dose related [134] and is enhanced by sodium depletion [146]. Some
low-dose infusion studies, however, fail to demonstrate any effect on norepinephrine
[131-133]. The most likely explanation for this discrepancy is that the high-dose ANF
studies usually evoke a fall in systemic blood pressure resulting in a probably
baroreflex-mediated activation of the sympathetic nervous system. Similarly, low-dose
ANF infusions have no significant effect on cortisol and/or dopamine production. Both
high- and low-dose ANF infusions in salt replete and deplete conditions also appear not
to affect AVP plasma levels [128,146], although a role for ANF in modulating the renal
action of AVP may exist [155].
Thus, as far as the effects of ANF on hormonal production in humans is concerned,
low dose ANF only has been found to inhibit the renin-angiotensin-aldosterone system,
is possibly mediated through direct action(s) of ANF. For other hormonal systems the
effect is at least not detected, or if present, possibly mediated through indirect activations
ensuing from ANF actions on blood pressure and/or volume related parameters.
Renal effects
The namegiving of ANF leaves no doubt as to what was initially thought to be the
prime function of this peptide. Indeed, at first the renal effect seemed to be rather
straigthforward: "natriuretic". However, the picture has become much more complex,
since various investigators have brought forward multiple renal ANF actions: increase
of different urinary electrolytes, renal hemodynamic changes, and changes in hormones
(vide supra) that affect renal functions. Whether one should look at these different areas
as part of an integrated renal ANF response is hard to discern. Not only are we
confronted with considerable discrepancies and variations in the data reported within each
separate area, the interpretations are also limited because of the intricate interplay
between the different areas. We will therefore first discuss the effects of ANF on
electrolyte excretion and renal hemodynamics separately, and will try to combine the
observations by identifying the possible mechanism of these renal ANF actions.
Electrolyte excretion
As far as the data on renal excretory function are concerned, there is no doubt that
ANF causes an increase in urinary volume and sodium output. In addition, many authors
have reported changes in other urinary electrolytes: urinary chloride, potassium, calcium,
phosphate, magnesium, as well as a rise in urinary protein (albumin) and free water
excretion; urinary osmolality is frequently reported to fall [110-112,127-135,138,
145,146,156,157]. However, the presence and/or magnitude of the response of each
parameter varies considerably from study to study. As discussed in the paragraph on
systemic effects, the renal response also appears to be determined by factors like ANF
dose, infusion time, and the conditions determining the sensitivity to exogenous ANF
infusion.
As far as the natriuretic response is concerned, Cody et al showed that one hour
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infusions of doses varying from 0.6 to 6 µg/min ANF in healthy volunteers resulted in
increasing plasma irANF levels and increasing sodium output up to three times the
control value [157]. However, the variations within one dose group were considerable.
Weder et al tested the effect of moderate to extremely high dose of ANF (from 2 to 30
µg/min) in essential hypertensives and found a clear relation between dose and natriuretic
response [129]. Although there apparently is a clear dose natriuretic-response relation,
the threshold varies considerably. Whereas Cody et al determined the threshold natriuretic
response to be at ±1.8 µg/min ANF dose, we and others observed distinct natriuretic
reponses at lower doses [128,130-133,138,148]. Richards et al demonstrated that even
small rises in endogenous irANF (from 10 to 15 pmol/l) result in a rise in urinary cGMP
excretion as well as a clear natriuresis [137]. Factors other than the infusion dose itself
may determine the characteristics of the relation. First of all, the level of plasma irANF
reached by the constant infusion (or bolus injection) must be taken into consideration.
Despite a standardized infusion protocol, we observed marked individual differences in
the levels of irANF induced by the same amount of infused ANF [66]. Interestingly, a
close correlation was found between the irANF level and the degree of natriuresis (Figure
1). Thus, similar amounts of ANF infused in different individuals need not evoke a
similar natriuretic response. Another important factor that may explain the observed
differences in the ANF natriuretic response and/or threshold is to be found in the
duration of the ANF infusion time period. The first low-dose (0.6 µg/min) infusion study
by Cody et al measured no natriuretic effect during a one hour ANF infusion time [157].
However, in (approximately similar) low-dose studies of Biollaz et al, Anderson et al,
and Solomon et al changes in natriuresis plateaued after ±3 infusion hours and reached
only values significantly different from placebo in the second or third hour of infusion
[128,130,133]. In contrast however, Richards et al found natriuretic effects already in the
first 30 minutes using a dose as low as 0.16 µg/min, where this effect appears to be
maximal already in the second half hour of infusion and only slightly falls during the
following periods of the three infusion hours [132] (Figure 3). Interestingly, in this study
cGMP levels reached maximum (compared to placebo) in the third infusion hour. Thus,
in determining an accurate ANF natriuretic threshold or sensitivity one may have to take
into account the infusion duration or at least the time needed for the effect to plateau.
Moreover, the natriuretic response varies with the preexisting volume/sodium balance and
the preexisting systemic blood pressure level. Several studies have shown that both bolus
and constant infusion of similar amounts of ANF in the same subject in balance on a low
and high sodium intake results in a quantitatively lower natriuresis during the period with
the low sodium diet [120,145,146]. However, the relative rise in ANF-induced sodium
excretion is much higher during the low sodium intake compared to the high sodium
intake. Whereas some of the authors interpret their data to reflect a reduced natriuretic
sensitivity to ANF during the low sodium intake, one could also argue that this represents
an increased sensitivity of the natriuretic response to ANF, parallel with the enhanced
sensitivity of the RAAS and blood pressure response to ANF during sodium depletion.
Interestingly, Clinkingbeard, Sessions and Shenkar only observed a significant natriuretic
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The top panel shows the urinary sodium excretion before, during, and after placebo ( ) and ANF ( )
infusion. The bottom panel shows the course of urinary cGMP. For both variables excretion rates were
significantly greater during ANF than during placebo infusions (p<0.001).
effect of a low-dose ANF infusion during a low dietary sodium intake, not on a high
sodium intake [136]. Maybe even more important, the prevailing systemic blood pressure
plays a role in determining the natriuretic response. Richards et al showed that a lower
preexisting blood pressure level attenuated the natriuretic response in healthy subjects and
hypertensive subjects [158]. Moreover, one also has to take into account what effects the
infused ANF has on the individual systemic blood pressure. If it lowers blood pressure
then antinatriuretic mechanisms may be triggered, thus counteracting and attenuating the
natriuretic action observed in that individual [127]. This becomes even more important
since the blood pressure response to ANF is also sodium intake dependent (vide supra).
In general, at least three other electrolytes are affected by ANF infusion: urinary
chloride, calcium and magnesium, which all increase. The latter two are quantitatively
much less affected by ANF compared to sodium. Therefore, it is harder to pick up a
statistical significance. Again, the effects on these electrolytes appear to be dependent on
dose and duration of ANF infusion. This may explain why studies using low-dose and
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short infusion times fail to observe a change in urinary excretion of these electrolytes,
whereas short-term high-dose and long-term low-dose studies report a significant
increase. The same applies to the ANF-induced rise in free water excretion and the fall
in urinary osmolality. The effects of ANF on phosphate excretion vary. Although a dose
and duration of ANF infusion appear to play a role, even very small increments of
plasma irANF may elicit a small but significant increase in phospate excretion [137]. In
general, potassium excretion is not affected by ANF infusion even at higher doses,
although again exceptions are present.
From all the above data it seems safe to conclude that the main effect of exogenous
ANF on renal excretory function remains its natriuretic and chloriuretic action. A dose
response relation is present. However, since many factors appear to determine the
individual response, the threshold for a natriuretic reponse to exogenously infused ANF
remains hard to define, but it may well be below 0.16 µg/min, at which dose irANF
levels are approximately doubled. The natriuretic effect appears to increase during
infusion and may only reach plateau on an hour time scale. These data and the fact that
inhibition of endogenous ANF breakdown, all leading to very mild elevations in plasma
irANF levels, still result in a clear natriuresis, underscore the potential physiological role
of ANF in sodium homeostasis. Whether changes in other electrolytes and water handling
are quantitatively relevant remains yet to be determined. Certainly, they may be of
extreme importance in unraveling the mechanism(s) of the natriuretic action of ANF, and
as such they will be discussed in another section (vide infra).
Renal hemodynamics
The profile of the renal hemodynamic changes induced by ANF infusions in humans
is not quite uniform.
As far as GFR is concerned the first human studies demonstrated a slight but
significant rise in EDTA clearance upon ANF infusion [112]. These data were compatible
with the general concept derived from the first animal studies that ANF causes a clear
GFR rise. However, these first human studies (like the animal studies) were carried out
with high doses of ANF. Although later studies in anesthetized animals using much lower
doses of ANF still demonstrated a rise in GFR, many later human studies using lower
ANF doses failed to detect a significant effect on GFR [128,131-135,159]. It is hard to
explain this discrepancy between animal and human studies. It could be that apart from
(unproven) species differences, the anesthesia (in animals) plays a role, since anesthesia
(and surgery) could potentiate the ANF effects directly and/or indirectly because of a
stimulated RAAS. Furthermore, some caution is warranted before concluding that GFR
is not affected by ANF, since the different techniques used to measure GFR do have their
inaccuracies, and it may well be that we fail to detect subtle GFR changes in humans.
The mechanism by which ANF may increase GFR is still debated. Pre-glomerular
vasodilation [160-162] might lead to increased transmission of systemic blood pressure
into the glomerular capillaries, leading to increased glomerular pressure. In addition,
postglomerular vasoconstriction has been suggested to occur upon ANF infusion
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Figure 4. The effect (mean±SEM) of a
1 µg/min infusion of synthetic human αANF on
renal blood flow (RBF) and renal vascular
resistance (RVR) in 7 healthy volunteers. RBF
data are derived from measurements of
effective renal plasma flow (131I-hippuran
clearance) corrected for renal extraction of
this tracer, and arterial hematocrit. Asterisk(s)
indicate a significant (p<0.05) difference from
control values.
changes in the capillary permeability of the glomerular basement membrane leading to
an increased GFR [164].
With respect to the effect of ANF on renal blood flow, the first human report
mentioned no significant effect of a high ANF dose on effective renal plasma flow
(ERPF)[112]. Later studies, however, using lower ANF doses showed a significant fall
in ERPF varying from 20 to 30% [128,131,133]. Interestingly, Richards et al as well as
Brown and O’Flynn found no effect on ERPF using even lower doses [132,135]. Apart
from these dose differences the duration of the ANF infusion also appears to play a role.
Biollaz et al found that low-dose ANF will elicit its ERPF lowering effect only in the
third hour of infusion [128]. This suggests
that even low-dose ANF may affect ERPF
only with an increased time lapse. Thus,
although high doses of ANF do not appear
to lower ERPF (maybe due to renal
autoregulation upon the distinct systemic
blood pressure fall), one would tend to
conclude that ANF causes a
(time-dependent) fall in ERPF. This is in
agreement with the early animal studies,
showing a fall in renal blood flow [1].
There are some pitfalls in the technique of
measuring renal blood flow in humans. In
all cases either a radioactive or
non-radioactive PAH-like tracer is used to
assess ERPF. The use of this tracer in
estimating drug-induced changes in renal
blood flow is only valid when renal PAH
extraction is not affected by the drug, and
if hematocrit remains unchanged. ANF
certainly induces a rise in hematocrit
[131,147] and may well lower PAH
extraction. We however, established that
hippuran extraction in healthy human
volunteers was not lowered upon ANF
infusion but appeared to rise somewhat
[165]. When we calculated renal blood
flow by correcting ERPF for changes in
extraction and in hematocrit, we found
that 1 µg/min ANF had a significant
lowering effect on renal blood flow
(Figure 4). Since systemic blood pressure
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did not fall in this study, we calculated that total renal vascular resistance increased
significantly upon ANF infusion. Thus, the fall in ERPF as reported by many
investigators in humans most likely reflects a true fall in renal blood flow.
Summarizing the above data on renal hemodynamics, in humans GFR remains stable
or slightly increases at higher ANF infusion doses, whereas ERPF falls or remains equal
depending on the ANF dose and observation time. These data imply that filtration
fraction (FF) should rise, as is indeed observed by most investigators. These changes in
glomerular hemodynamics are most likely caused by preglomerular vasodilation and
postglomerular vasoconstriction. Whether "pretreatment" parameters, such as blood
pressure and sodium status, which may influence vasomotor tone of both vessels,
determine the hemodynamic response to ANF remains to be clarified.
Mechanism of natriuretic action
Reviews of the data of animal experiments have brought forward three different
hypotheses to explain the natriuretic effect of ANF: 1) alterations in renal hemodynamics,
2) alterations in tubular sodium reabsorption, 3) renal medullary washout. It is intriguing
to notice that one may find extreme standpoints between the advocates of the different
mechanisms. Apparently, experimental conditions and/or species differences determine
the response to ANF at different renal levels. Moreover, as has been demonstrated in the
above paragraphs, ANF doses and infusion time may also explain many discrepancies.
To evaluate the mechanisms in play for the human situation, we are bound to address the
kidney as a complex integrated black box, with its obvious limitations in dissociating the
different levels at which renal sodium handling is influenced. Although this has obvious
disadvantages, we would like to stress that even data from animal experiments on
isolated tissues, which form the foundation of many novel concepts, may confuse us as
to the actual in vivo ANF actions.
As far as renal hemodynamic effects are concerned to explain ANF induced
natriuresis, several mechanisms have been proposed. Firstly, the rise in GFR increases
the filtered sodium load [163]. Secondly, changes in peritubular hemodynamics may
result in decreased proximal tubular sodium reabsorption [166]. Lastly, redistribution of
blood flow within the kidney may lead to increased natriuresis [1,167]. Whatever the
mechanism, the natriuretic effects of ANF have been clearly dissociated from the renal
hemodynamic effects in humans, since in the absence of "detectable" renal hemodynamic
effects one does observe natriuresis [112,128,131,132,159,168]. This has led many
investigators to conclude that, although renal hemodynamic effects may indeed enhance
ANF-induced natriuresis, under physiological conditions "direct" tubular effects are of
prime importance. In our opinion, such a general conclusion, denying a role for renal
hemodynamic effects of ANF, is still rather premature. It should be stressed that the
detection of changes in GFR and ERPF in man is limited with the current techniques. An
important study in this respect is reported by Mejia et al, demonstrating that small (such
as 5%) changes in GFR, which certainly may escape detection, can produce significant
alterations in sodium excretion, independent of changes in tubular sodium handling [169].
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The fact that ANF is reported to induce a preglomerular vasodilation both in animal and
in humans would favor a hemodynamic role for the natriuresis. It is harder to reconcile
the observation of an ANF-induced postglomerular vasoconstriction with a
hemodynamically mediated natriuresis, since the first would lead to a rise in peritubular
oncotic pressure and thus to antinatriuresis. On the other hand Mendez et al suggested
that ANF had an opposite effect on peritubular oncotic pressure [166]. Clearly, this needs
further studies. Furthermore, we can also not exclude that, although renal blood flow
(ERPF) may fall or remain unchanged in humans, redistribution of blood flow and thus
increased flow to medullary nephron populations still occurs.
As far as tubular effects are concerned, mainly two different sites have been
investigated in humans: an effect of ANF on proximal sodium reabsorption and an effect
of ANF on distal sodium reabsorption. Evidence has been built up suggesting that ANF
acts on proximal sodium handling in humans. A decrease in proximal sodium
reabsorption is suggested by the fact that many human studies, even those inducing small
increments in plasma irANF levels, show the natriuresis to be accompanied by significant
increases in either urinary phosphate and/or fractional lithium clearance, both being
markers for proximal solute handling [135,137,160,168,170-172]. In addition, free water
excretion also increases upon ANF infusion [66,112,134,168,171], which is compatible
with an effect of ANF on a tubule segment proximal to the diluting segment [168]. We
demonstrated that this rise in free water excretion correlates with the rise in fractional
sodium excretion [66]. All these factors make the suggestion of a proximal natriuretic
effect of ANF rather strong. Most likely, this effect is indirect and mediated via an effect
of ANF on the RAAS. Not only are ANF receptors not found in the proximal tubule of
animals (vide supra), there also was no direct ANF effect demonstrable in this isolated
tubule segment [173]. ANF has been shown to inhibit the RAAS (vide supra), and since
angiotensin II at physiological concentration promotes sodium reabsorption in the
proximal tubule, an inhibiting effect of ANF could well explain the proximal tubular
natriuretic response [164]. Indeed, studies in humans have shown that the ANF-induced
natriuresis could be attenuated by inhibition of angiotensin II formation [174]. Most
investigators agree that this proximal effect cannot fully explain the natriuretic properties
of ANF. Distal tubular effects of ANF are suggested by the rise in the urinary excretion
of calcium and magnesium, and the absence of a kaliuretic effect (vide supra). Indeed,
animal studies showed that ANF inhibits sodium reabsorption in the collecting ducts,
probably the IMCD. Without this effect the increased distal delivery would cause less
natriuresis [175-177]. In humans, Biollaz et al calculated that the distal tubule is unable
to adequately compensate for the increased sodium load from the proximal tubule [168].
Moreover, we have demonstrated that ANF induces a decrease in free water reabsorption
in a state of maximal urinary concentration, and that the fall in free water reabsorption
correlates with fractional sodium excretion [66], suggesting a distal tubular effect of
ANF. Rabelink et al showed that besides the IMCD, earlier aldosterone-sensitive
segments may also play a role [172]. All these factors, together with the presence of
ANF receptors on distal nephron sites (vide supra), suggest that distal tubular sites
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(presumably the IMCD) play an additive role in the ANF-induced natriuresis. Whether
or not intermediate segments such as the loop of Henle play a role in humans, remains
uncertain.
As far as renal medullary washout and its role in ANF-induced natriuresis is
concerned, it is clear that this cannot be looked upon as a separate entity, but more likely
as a consequence of the hemodynamic and/or tubular ANF effects. Nevertheless, it may
certainly contribute to the ANF-induced natriuresis [1,164]. Animal experiments have
elegantly shown the loss of a medullary solute gradient after ANF infusion [178].
Moreover, almost all human studies have demonstrated a marked fall in urinary
osmolality (vide supra), which could certainly be in line with a medullary washout.
Which parameters could evoke a loss of the medullary solute gradient? First of all, an
increased blood flow to the medullary nephrons (despite the fall in total renal blood flow)
could lead to washout. Indeed, animal experiments have shown such an ANF effect
[1,164,167]. In addition, the increase in tubular flow via an increased GFR and reduced
proximal sodium/water reabsorption, and the reduced sodium reabsorption in distal
nephrons, all favor a loss of the medullary solute gradient.
Thus, the mechanism(s) of the ANF-induced natriuresis in humans appears to be
multifactorial: a (small) rise in GFR and/or a reduction in proximal tubular sodium
reabsorption (probably angiotensin II mediated) leads to an increased distal solute
delivery, whereas more distally located tubular segments (most likely the IMCD) add to
this effect by not reabsorbing this excess solute. Medullary washout contributes to the
natriuresis either as a result of the mentioned natriuretic factors or as an ANF-induced
phenomenon on its own.
PATHOPHYSIOLOGICAL ROLE
The vasodilatory and natriuretic properties of ANF, as discussed above, obviously are
of interest with regard to pathophysiological disorders associated with vasoconstriction
and/or sodium retention. Thus, the (genetically determined) vasoconstriction and (subtle)
renal sodium retention of essential hypertension has intrigued many investigators having
them question whether there is a deficiency in the release of ANF or whether there is a
diminished vascular and/or renal target-responsiveness to ANF. Similar questions have
been raised with regard to the pathophysiological role of ANF in disorders with avid
sodium retention and edema formation such as congestive heart failure, liver cirrhosis,
and the nephrotic syndrome.
Essential hypertension
Plasma irANF levels in adult patients with established essential hypertension (EH)
show a broad range in almost all studies. Mean irANF levels are reported to be similar,
higher, or even lower in EH compared to normotensives [179-182]. An explanation for
this phenomenon may be found in the heterogeneity of the EH population. Well known
is the marked difference in PRA levels between patients with EH. Since, irANF plasma
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levels are reported to inversely correlate with PRA [57,61,179], one might argue that this
explains the broad irANF level spectrum. Moreover, high irANF levels are often found
when the study group consists of severe hypertensive patients with possible end-organ
damage [57,182]. Thus, irANF levels may be secondary to the higher blood pressure
(vide infra), to the incipient cardiac and renal failure or left ventricular hypertrophy
[182]. Although these factors may explain the large variation in irANF levels, the
question remains whether the direct comparison with "normal" levels is valid?
Interestingly, normal levels of irANF in patients with mild EH have been argued to
indicate a relative deficiency of ANF release. This hypothesis is based on the fact that
both the higher blood pressure and the increased central blood volume in EH compared
to control should have enhanced the ANF release [57]. In favor of such a possible
deficiency of ANF release are recent findings that off-spring of hypertensive parents
show an attenuated ANF release upon a high sodium intake [183,184]. Obviously, more
direct evidence of an altered relationship in EH between irANF, PRA, and sodium intake
("irANF-PRA-sodium-profiling"), as well as between atrial pressures, central blood
volume and ANF release, is needed to clarify this issue.
Studies on ANF responsiveness in EH have focused on a possibly diminished
response as far as blood pressure and natriuresis are concerned. However, several studies
using high as well as low doses of ANF have reported both an attenuated and an
enhanced blood pressure-lowering response in EH compared to normotensives
[144,158,185-187]. Similar decreases in blood pressure also have been reported [188].
Certainly, differences in the doses of ANF, duration of observation and sodium intake
may underly these discrepancies. As far as the natriuretic response is concerned, both
short-term, long-term and low-, high-doses of ANF are found to cause an equal or
enhanced natriuresis in EH as compared to normotensives [144,158,185-187,189].
However, the comparison with normal volunteers should take into account differences
in initial conditions such as blood pressure, plasma irANF level and PRA. All these
factors have been suggested to influence the ANF-induced natriuretic response. A similar
natriuretic response comparing normotensives and hypertensives only differing in either
a higher blood pressure, a lower irANF level or higher PRA levels, may suggest a
relatively attenuated renal sensitivity to ANF. On the other hand, higher irANF and/or
lower PRA levels in hypertensives may suggest an enhanced renal responsiveness. In
addition, the natriuretic response may also be influenced by the degree of ANF-induced
blood pressure fall, since the latter would result in an anti-natriuretic effect.
In summary, irANF levels in EH vary over a wide "physiological" range, and can be
interpreted to reject as well as support the hypothesis of a deficiency of ANF release in
EH. Similarly, data on blood pressure response as well as natriuretic response to ANF
may be interpreted to reflect a normal, attenuated, or even enhanced response. The
greatest challenge in clarifying the role of ANF in EH to date therefore is to define the
importance of the differences in baseline sodium intake, blood pressure, PRA and irANF




In patients with congestive heart failure (CHF) plasma irANF levels are invariably
found to be elevated. These elevated irANF levels increase with the stage of the disease
and correlate with right and/or left atrial pressures [37,190,191]. Therefore, plasma irANF
levels may be of good diagnostic value in evaluating the hemodynamic status and may
have prognostic significance in CHF [190]. In patients with liver cirrhosis plasma irANF
levels are reported to be normal [192-195] or slightly elevated [196]. Henriksen et al
observed normal irANF levels despite a significantly reduced central blood volume [195].
The ANF release following head-out-water-immersion was found to be exaggerated
[192], comparable [197], as well as blunted [193] in these patients compared to control
subjects. The reason for this variability is unknown, but may be related to the
heterogeneity in etiology, the stage of the cirrhosis, or diuretic use [194]. Also the
amount of sodium intake may be important. Epstein et al for instance studied the effect
of head-out-water-immersion on ANF release during a 10 mmol sodium intake [192].
One may expect irANF levels then to be low and ANF storage sites to be full. This may
explain why they found an exaggerated response, whereas Gerbes et al, who used a 150
mmol sodium intake, observed a blunted response [193]. In patients with the nephrotic
syndrome, data on irANF levels are conflicting, and normal as well as two times higher
or lower values are reported [198-200]. During acute volume expansion irANF is released
into the circulation in both nephrotic subjects and in patients with renal failure [200,201],
at least as much as in normal controls. Thus, evidence for a deficient ANF synthesis or
release in these edematous disorders is virtually absent.
As far as the effects of ANF infusion, CHF patients show a decrease in systemic
vascular resistance and an increase in cardiac output and sodium excretion. Effects of
high-dose ANF infusions in CHF for 30 to 240 minutes showed that ANF can decrease
pulmonary capillary wedge pressure, and systemic (and pulmonary) arterial pressure,
whereas it increased cardiac index [157,202-206]. These cardiovascular effects appear to
be at least as high in CHF as in normal controls. In contrast, the natriuretic effect of
these doses of ANF appears to be blunted. However, lower doses of ANF for up to four
hours have been reported to increase sodium excretion without significant effects on
cardiovascular parameters [207]. Thus, in CHF a renal hyposensitivity to ANF may exist
in the presence of high irANF levels. It may also be secondary to a low renal perfusion
pressure and/or the activated state of sodium retaining systems. ANF infusion may have
no natriuretic effect in this latter state, since it may not overcome the prevailing sodium
retentive mechanisms at the proximal tubular level. The action of ANF on the IMCD
may consequently be without effect, and thus no natriuresis occurs. Alternatively, the
high doses of ANF may have elicited systemic effects which in turn attenuated the
natriuretic actions of ANF.
In patients with liver cirrhosis, the hypotensive action of exogenous ANF appears to
be marked, whereas the natriuretic effect of ANF appears to be minimal [208,209],
compared to controls [196]. In cirrhosis high levels of endogenous irANF, in contrast to
CHF, cannot be held responsible. Some studies point to the importance of the high initial
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levels of PRA or PAC and the incomplete suppression of these parameters [210]. Using
head-out water immersion experiments, Epstein et al have shown that the elicited increase
in irANF levels dissociates from the rise in sodium excretion [192], distinct from normal
controls. During identical experiments Skorecki et al were able to distinguish renal
responders versus non-responders [197]. In these groups baseline as well as
immersion-induced rises in plasma irANF and cGMP were comparable, indicating that
in both groups ANF release and coupling to its cGMP-linked receptors are functioning.
Both groups, however, differed in their PRA and PAC levels, which were ±fourfold
higher in the non-responders. These data are similar to those of Gerbes et al, who
furthermore showed that ANF to PAC ratios correlated closely to basal and stimulated
natriuresis [193]. Interestingly, urinary potassium excretion increased progressively and
markedly in cirrhotic subjects, in contrast to normal subjects [192,197,210]. Thus, in
some patients with cirrhosis of the liver a distal tubular resistance to ANF may exist, and
elevated PRA or PAC levels may serve as mediator or as marker to such a relative renal
hyposensitivity to ANF in these patients.
Administration of exogenous ANF to patients with the nephrotic syndrome showed
that blood pressure, hematocrit, and renal hemodynamic and natriuretic effects were
comparable to those in normal controls [199,211]. The subjects enrolled in these studies
were with or without edema, but none had extremely avid sodium retention. Peterson et
al investigated the effects of head-out water immersion in patients with the nephrotic
syndrome with avid sodium retention, and observed a blunted natriuretic response and
suggested that this could be due to a relative hyporesponsiveness of the distal tubule to
ANF [200]. However, unlike patients with cirrhosis of the liver, a natriuretic response
was not absent. Interestingly, several studies indicated that exogenous ANF, already at
doses that induce minor increments in plasma irANF cause an increase in proteinuria in
patients with the nephrotic syndrome [198], an effect also found in normal and
hypertensive subjects [156,212]. These findings provide evidence for some interesting
feedback mechanisms: sodium retention with associated hypervolemia will induce ANF
release, which in turn may aggravate or contribute to the development of proteinuria with
an associated tendency to hypovolemia. This may then lead to, or enhance (further)
sodium retention by increasing sodium retaining factors and by decreasing ANF release.
Finally, a diminished responsiveness to ANF (during avid sodium retention?) may be a
further complicating factor. Administration of exogenous ANF to patients with chronic
renal failure yielded conflicting data. Whereas Suda et al found a 2.5-fold increase in
urinary sodium excretion, despite a marked fall in blood pressure during low-dose ANF
infusion, Burnier et al did not find any effect using the same dose [213,214]. The reason
of this discrepancy as yet is unclear.
In summary, ANF synthesis and/or release does not appear to be deficient in
congestive heart failure, liver cirrhosis, the nephrotic syndrome, or chronic renal failure
[215]. However, the endogenous ANF system obviously is not capable of preventing the
vasoconstriction and sodium retention in these edematous disorders. Nevertheless, ANF
still may have a counterregulatory, albeit weak, role against the activated vasoconstrictory
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and sodium retaining systems in these disorders such as the RAAS, the sympathetic
nervous system and vasopressin. Finally, a negative role for ANF in the formation of
edema deserves further attention.
PHYSIOLOGICAL ROLE
Despite the vast current knowledge concerning the effects of ANF, the fundamental
function of this peptide is still unknown. Although two main potential functions have
been brought forward, that is, the regulation of (blood) pressure and the regulation of
volume homeostasis, these areas are still under heavy debate in the recent literature.
Vasan, Seshadri and Narula state that ANF is just a "vestigial non-functional agent"
[216]. Similarly Goetz concludes that ANF may be of importance in physiological
pressure regulation, but that it has no physiological significance in the regulation of our
daily sodium homeostasis [217]. In contrast, Richards and Crozier find the data strongly
in support of a fundamental role for ANF in pressure and volume homeostasis in humans
[218]. Similarly, Blaine argues that ANF is a necessary but not sufficient condition to
induce natriuresis [219]. In our opinion, most of these differences in standpoints are due
to the different routes of approach in defining the physiological significance of ANF. At
the risk of designing a new false route we will try to come to the conclusion that ANF
is not vestigial but an important regulatory hormone at least in the area of
sodium/volume homeostasis.
Clearly, to define whether or not ANF has a regulatory role one needs to define what
the supposed hormone has to regulate. It is obvious from this monograph that in our
opinion only the lowest dose studies may serve to identify the candidate target tissue(s),
since high-dose studies result in "unphysiological" plasma irANF levels. We argue that
this leaves only the renal electrolyte excretion and the RAAS as parameters affected by
short-term ANF infusions leading to physiological elevations of plasma irANF. Whether
or not extravascular fluid shifts occur at these doses is to our knowledge not clearly
established. Probably the best example of a study showing these low-dose ANF effects
is that of Richards et al [132]. In this study ANF infusion only doubled irANF levels
which coincided with an increase in sodium excretion compared to placebo infusion
(Figure 3). Whether or not endogenous irANF levels regulate sodium homeostasis on a
daily basis is not proven by such experiments. However, Richards et al also demonstrated
that small increases in endogenous plasma irANF levels, induced by endopeptidase
inhibition, result in a natriuresis [137]. Furthermore, Bell et al, studying diurnal rhythms
of irANF, cGMP, PRA and PAC, found that diurnal changes in sodium excretion could
be at least partially explained by changes in endogenous irANF levels [65]. In this
respect our study on the diurnal sodium rhythm may be of importance [220]. We studied
the effects of a continuous infusion of 0.2 µg ANF/min during five days in patients with
essential hypertension, thereby leveling off any possible daily variations in endogenous
ANF release. This ANF infusion did not only induce a negative sodium balance, but also
affected the diurnal sodium rhythm by shifting the peak time. This latter phenomenon
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remained in effect over the total five day infusion period (disappearing during recovery),
despite the fact that sodium balance was again reached after two infusion days.
Interestingly, no change in the diurnal levels of PRA was found in this study. Thus,
endogenous irANF variations may be present and determine (part of) the diurnal rhythm
characteristics of sodium excretion. However, to further establish such a physiological
significance of ANF in sodium homeostasis we need to confirm that the endogenous
ANF release is evoked by changes in the intricate balance between daily sodium input
and output. Indeed, infusion of saline results in a rise of irANF. However, studies on oral
intake of food containing high and low amounts of sodium fail to observe a postprandial
increase in plasma irANF [217]. This led Goetz to conclude that ANF is not involved in
sodium/volume homeostasis [217]. However, this conclusion is mainly based upon
measurements of irANF plasma levels, of which the accuracy is debatable (vide supra).
Moreover, the sample time was in the order of half an hour. Considering the relatively
short biological half-life of irANF and the rapidly pulsatile alterations in diurnal plasma
irANF levels observed in healthy subjects [221], fast changes in plasma irANF levels
may have been missed. On the other hand, Sagnella et al elegantly demonstrated that
small increments in dietary sodium intake over a period of several days, were
accompanied by gradual increases in plasma irANF [222]. Nonetheless, there certainly
remain as yet unexplained settings in which endogenous irANF levels do not correspond
with (changes in) urinary sodium excretion [217].
We can, however, not deny looking at the host of data summarized in the above
paragraphs, and so elegantly phrased by Blaine: (1.) that ANF has the physiological
characteristics to be a mediator of body fluid regulation; (2.) that ANF satisfies the
conditions to be a component of a physiological feedback-controlled system; (3.) that
ANF is part of a highly complex integrated system and is one of several jointly necessary
factors that must occur simultaneously to effect natriuresis; (4.) that ANF at physiological
relevant plasma concentrations can elevate urinary sodium excretion for long time
periods. Although, the lack of a demonstrable rise in postprandial irANF levels may be
valid, it is at least hazardous to exclude ANF from a role in sodium/fluid homeostasis
only based on this discordant finding. In this respect, we should have learned from the
experiences with the history of the RAAS. Only when effective inhibitors of the different
components became available we started to understand its true significance. Preliminary
results with substances that inhibit the breakdown of endogenous ANF indeed appear to
have significant natriuretic properties [137,223-225]. Further studies also on the effects
of ANF-receptor agonists or antagonists are clearly needed to unravel the regulatory
significance of ANF in humans.
THERAPEUTIC APPLICATIONS
From the above we may define at least two areas in which a possible therapeutic
application of ANF may be found. Firstly, it may be useful in the treatment of high
blood pressure. This may not only be based upon the specific vasodilatory and diuretic
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effects of ANF, but also on the fact that ANF may be hypothesized to play a role in the
actual cause of high blood pressure in essential hypertension (vide supra). We have
indeed shown that a "physiological" dose of ANF certainly is capable of reducing
systemic blood pressure over a long period of time in patients with essential hypertension
[138]. In this study we showed that a continuous five day infusion of synthetic human
ANF (0.2 µg/min), leading to a doubling of plasma irANF levels, resulted in a gradual
fall of both systolic and diastolic blood pressure by 11 and 10 per cent, respectively
(Figure 2). The response was observed in all six studied patients, and blood pressure
recovered slowly to control values after cessation of ANF infusion. This observation is
confirmed by the study of Cusson et al, who showed that a 12-hour low-dose ANF
infusion slowly lowered the blood pressure in essential hypertensive patients, and not in
normotensive controls [144]. Secondly, ANF could serve as a diuretic in disease states
that are accompanied by sodium/volume retention such as congestive heart failure (CHF),
liver cirrhosis, renal failure, and the nephrotic syndrome. Studies in CHF demonstrated
an increased cardiac performance after bolus injections of ANF [202,204]. Crozier et al
however, failed to show beneficial effects of ANF given each day as a bolus over a
period of 14 days [226], which may be due to the bolus administration protocol. Until
now the longest ANF infusion protocol in congestive heart failure is to our knowledge
24 hours. This study in patients with CHF showed a clear, although transient,
improvement in different cardiac indices [227]. In patients with liver cirrhosis one may
discern responders and non-responders as far as natriuresis is concerned (vide supra). The
non-responders show a clear attenuation of the natriuretic response to ANF. In patients
with the nephrotic syndrome ANF appeared to enhance the urinary protein excretion
[198]. Chu et al suggested the potential use of ANF as a coronary dilator [228]. Thus,
a therapeutic potential for raising endogenous irANF levels might be expected in patients
with essential hypertension and CHF. The therapeutic use in other disease states remains
questionable.
What has hampered further therapeutic developments was the fact that the formulation
of ANF was such that it could only be given intravenously. Attempts to alter the
administration route such as intranasal aerosol application have not been successful, since
this did not result in demonstrable absorption [229]. More promising are the ongoing
efforts to design inhibitors of the breakdown of endogenous ANF (atriopeptidase
inhibitors). Preliminary results with these drugs in animal and human studies look
promising [137,223-225]. The disadvange of these atriopeptidase inhibitors is that their
action theoretically depends on the endogenous production (rate) of ANF. Thus, with
even more interest we will welcome the ANF receptor (ant)agonist [109] not only as a
potential drug for patients with essential hypertension or CHF, but also to further unravel




The first human studies using relatively high-doses of ANF revealed similar effects
as observed in the preceeding animal reports, including effects on systemic vasculature
(blood pressure fall, decrease in intravascular volume), renal vasculature (rise in GFR,
fall in renal blood flow), renal electrolyte excretion (rises in many electrolytes), and
changes in release of a number of different hormones. Whether all these changes are the
result of direct ANF effects or secondary to a (single) primary event of the hormone
remains to be determined. Certainly, it has been proven that more physiological doses
of ANF fail to induce short-term changes in many of these parameters leaving only a rise
in hematocrit, natriuresis and an inhibition of the RAAS as important detectable ANF
effects in humans. This leads us to hypothesize that ANF is a "natriuretic" hormone with
physiological significance. The primary function in humans is to regulate sodium
homeostasis in response to changes in intravascular volume (cardiac atrial stretch).
Induction of excess renal sodium excretion and extracellular volume shift appear to be
the effector mechanisms. The exact mechanism of the natriuresis in humans still needs
to be resolved. It appears however, that possibly a small rise in GFR, a reduction in
proximal and distal tubular sodium reabsorption, as well as an ensuing medullary
washout, are of importance. The pathophysiological role of ANF in human disease is
unclear. One may find elevated plasma irANF levels and/or decreased responses to
exogenous ANF in some disease states. Whether these findings are secondary to the
disease state rather than the cause of the disease remains to be resolved. Therapeutic
applications for ANF, or drugs that intervene in its production or receptor-binding, seem
to be multiple. Most important could be the antihypertensive effect, although areas such
as congestive heart failure, renal failure, liver cirrhosis and the nephrotic syndrome
cannot be excluded.
Although the data that have been gathered to date allowed us to draw some careful
conclusions as to the (patho)physiological role of ANF, the exact place of ANF in
sodium homeostatic control must still be better defined. To achieve this, we will need
more carefully designed low-dose ANF infusion, as well as ANF-breakdown inhibitor
studies. Even more promising, however, is the potential area of studies open to us when
ANF-receptor (ant)agonists become available for human use.
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EFFECT OF HUMAN ATRIAL NATRIURETIC FACTOR
ON BLOOD PRESSURE AFTER SODIUM DEPLETION
IN ESSENTIAL HYPERTENSION
Wilbert M T Janssen, Paul E de Jong, Gjalt K van der Hem, and Dick de Zeeuw




Human atrial natriuretic factor was infused over four hours in three patients with
essential hypertension. When the patients had a sodium intake of 200 mmol (mEq) daily
an infusion of 0.5 µg atrial natriuretic factor/min caused no significant change in blood
pressure, whereas an infusion of 1.0 µg/min caused a gradual decrease in blood pressure
and an increase in heart rate. After two to three hours of infusion with the higher dose
two patients showed a sudden decrease in heart rate, with symptomatic hypotension.
When the same patients had an intake of 50 mmol sodium daily their blood pressure was
more sensitive to infusion of atrial natriuretic factor; one patient again developed
symptomatic hypotension, this time during an infusion of 0.5 µg/min. During all infusions
distinct natriuresis occurred irrespective of whether blood pressure was affected.
Prolonged, relatively low-dose infusions of atrial natriuretic factor can cause
unwanted symptomatic hypotension. The effect on blood pressure is enhanced after
sodium depletion, and blood pressure should be monitored carefully during longer
infusions of atrial natriuretic factor in patients with essential hypertension.
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INTRODUCTION
Atrial natriuretic factor induces a decrease in blood pressure. Most studies have
reported the effects of either bolus injections of atrial natriuretic factor [1], or infusions
for 30 to 60 minutes [2,3]. The antihypertensive response in those studies was quite
different. In addition to the different modes of administration of atrial natriuretic factor
the state of the renin-angiotensin-aldosterone system might play a part [4]. We therefore
studied the effects of long infusions of various doses of atrial natriuretic factor under two
conditions of sodium balance in patients with essential hypertension.
SUBJECTS AND METHODS
Human atrial natriuretic factor dissolved in 5 g mannitol/100 ml (L-346,670, MSD-
RL, Rahway, New Jersey, USA) was infused at different doses (0.125, 0.25, 0.5, and 1.0
µg/min) in three patients with essential hypertension (two men and one woman aged
35-54 with diastolic blood pressure > 100 mmHg and normal renal function). For at least
two weeks before the study the patients did not take any drugs and received a diet
containing 200 mmol (mEq) sodium daily. Two days before the first infusion of atrial
natriuretic factor they were admitted to hospital, where they had absolute bedrest and
received a constant daily intake of sodium and fluid until the end of the study. The
infusions of atrial natriuretic factor were then repeated after a two week run in period,
during which the patients received 50 mmol sodium daily.
During the study the patients adhered to a rhythm diet consisting of equal amounts
of sodium, potassium, and liquids every two hours. Blood pressure was recorded
continuously at two minute intervals from 10 AM to 6 PM with a non-invasive automatic
device (Dinamap®, Criticon Inc, Tampa, Florida, USA). Urine was collected by
spontaneous voiding every hour from 8 AM to 6 PM. Baseline values were measured from
10 AM till noon, and from noon to 4 PM atrial natriuretic factor or placebo (solvent) was
infused. Measurements were confirmed till 6 PM.
RESULTS
Placebo infusions resulted in a variation of blood pressure from +4% to -7% during
the periods of both high and low salt intake. During the diet of 200 mmol sodium daily
an infusion of 1.0 µg atrial natriuretic factor/min initially induced a gradual decrease in
blood pressure of about 10% and an increase in heart rate (Figure 1). After two to three
hours, however, blood pressure suddenly decreased in patients 1 and 3, with a
concomitant decrease in heart rate. These two patients had severe symptoms of
hypotension with cold sweating and dizziness, and the infusion had to be stopped.
Symptoms resolved within a few minutes, and blood pressure gradually increased again.
In contrast, no decrease in blood pressure or even a pressure response occurred during
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measurements over 30 minutes) and sodium excretion during a diet of 200 mmol sodium daily in three
patients with essential hypertension. Values directly before infusion was stopped in patients 1 and 3 are
means of three recordings taken at one minute intervals. ANF = atrial natriuretic factor.
the infusion of 0.5 µg atrial natriuretic factor/min. Natriuresis was induced by both doses.
When the patients had a daily intake of 50 mmol sodium, however, the infusion of
0.5 µg atrial natriuretic factor/min caused a significant decrease in blood pressure. A
hypotensive response similar to that observed after the infusion of 1.0 µg/min during the
high sodium intake was observed again in patient 1 after two and a half hours of
infusion. The effect on blood pressure of infusions of 0.25 and 0.125 µg/min during this
low sodium diet was less pronounced. A dose-response curve for both sodium intakes
was constructed (Figure 2); during low sodium intake the curve shifted to the left. At the
low sodium intake natriuresis was again observed at all doses of atrial natriuretic factor.
DISCUSSION
The gradual decrease in blood pressure and increase in heart rate, initially observed
during the infusion of 1.0 µg atrial natriuretic factor/min in patients receiving a high salt
intake, is characteristic of treatment with a vasodilator and is compatible with data from
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Figure 2. Percentage change in diastolic blood pressure at end of infusion of atrial natriuretic factor
0 0.125 0.25 0.5 1.0







plotted against infusion dose. Black symbols indicate data obtained during high sodium diet; open
symbols indicate data obtained during low sodium diet. DBP = diastolic blood pressure.
l/O = patient 1; t/ = patient 2; / = patient 3.
animal experiments [5]. After two to three hours, however, the heart rate suddenly fell
in parallel with a severe hypotensive collapse (Figure 1). Such an occurrence has not, to
our knowledge, been reported previously. Other workers have used bolus injections of
100 µg atrial natriuretic factor or infusions of 3 µg/min for 30 to 60 minutes without
observing symptomatic hypotension [2,3]. The difference in duration of administration
of atrial natriuretic factor might be responsible for our observation; a cumulative effect
of atrial natriuretic factor is less likely as it is rapidly metabolized [3].
We showed that salt depletion increases the effect of atrial natriuretic factor on blood
pressure (Figure 2). This emphasizes the potential risk of infusion of atrial natriuretic
factor in essential hypertension. Even low doses that do not influence the blood pressure
during high salt intake cause a hypotensive collapse during low salt intake. Because of
the pronounced and reproducible symptomatic hypotension that we observed no more
patients were enrolled in this study. During all infusions of atrial natriuretic factor, even
51
Chapter 3
at doses that did not decrease blood pressure, sodium excretion increased, suggesting that
it is not only natriuresis that is responsible for the change in blood pressure.
We conclude that atrial natriuretic factor can induce a gradual decrease in blood
pressure, sometimes followed by symptomatic hypotension, which occurs suddenly. This
phenomenon depends on the duration of the infusion as well as the dose. Moreover, the
dose effect is enhanced during low sodium intake. This warrants careful observation of
patients with essential hypertension who are given infusions of atrial natriuretic factor
over longer periods.
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To investigate whether atrial natriuretic factor (ANF) is involved in the long-term
regulation of sodium homeostasis and blood pressure control we infused ANF in a low
dose (0.2 µg/min) for 48-hours in two female patients with essential hypertension. Mean
arterial pressure did not decrease, but tended to increase in both patients during ANF-
infusion. No side-effects were observed, particularly no hypotensive periods occurred. In
both patients ANF-infusion induced a sustained natriuresis. The cumulative sodium
balance was 98 and 244 mmol negative after 2 days of ANF-infusion. These data suggest
a physiological role for ANF in the long-term regulation of urinary sodium excretion. It
can be hypothesized that an even longer infusion of ANF would (by its sustained
natriuretic effect) eventually decrease blood pressure.
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INTRODUCTION
Atrial natriuretic factor (ANF) has been shown to have an acute natriuretic effect
when administered in high (pharmacological) doses by bolus or short-term infusion.
Unfortunately, these doses may induce a sudden episode of symptomatic hypotension
after some time [1,2]. Only recently it has been shown that ANF has a natriuretic effect
at physiological levels in man [3,4]. However, whether ANF is involved in the long-term
regulation of sodium- and blood pressure homeostasis is yet unknown. We therefore
studied the natriuretic and hypotensive effect of a low dose (0.2 µg/min), 48-hour
infusion of ANF in man.
SUBJECTS AND METHODS
Two female patients with essential hypertension (age 52 and 61, diastolic blood
pressure > 95 mmHg), who for at least two weeks before the study did not take any
drugs and received a diet containing 200 mmol sodium daily, were admitted to hospital,
where they held absolute bedrest until the end of the study. After an equilibration period
of 3 days, the study was started at noon of the third day (day 1) with a 24 hour solvent
infusion, followed by 48 hours of infusion with synthetic α-human ANF(101-126, MSD-
RL, Rahway, New Jersey, USA) dissolved in 5 g mannitol/100 ml at a dose of 0.2
µg/min (days 2 and 3), and a one day recovery period with solvent infusion (day 4).
During the whole study the patients received a rhythm diet consisting of six portions of
equal amounts of sodium, potassium and fluid every 4 hours (total: 200 mmol, 80 mmol,
and 2500 ml per day, respectively). Mean arterial pressure (MAP) was recorded every
5 minutes with an automatic non-invasive device (Dinamap®, Criticon Inc, Tampa,
Florida, USA). Urine was collected every 4 hours by spontaneous voiding for
measurement of sodium excretion. Plasma samples for measurement of immunoreactive
ANF (irANF), plasma renin activity (PRA), and plasma aldosterone were taken at 4 PM,
midnight, and at 8 AM. Sodium, PRA, and aldosterone were determined using standard
techniques, irANF was measured as described previously [4].
RESULTS
ANF-infusion caused a 2-fold increase in irANF-levels (Table 1). MAP did not
decrease, but tended to increase in both patients during ANF-infusion. No side-effects
were observed, particularly no hypotensive periods occurred as has been reported
previously during short-term (30 min to 6 hour) high dose (0.5 to 3.5 µg/min) ANF-
infusions [1,2,5,6]. In both patients ANF-infusion induced a sustained natriuresis. Net
sodium balance was -56 and -42 mmol on the first and the second day of ANF-infusion
for patient 1, and -107 and -137 mmol for patient 2, resulting in a cumulative negative
sodium balance of 98 and 244 mmol after 2 days of ANF-infusion. During recovery all
values returned to baseline (Table 1).
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TABLE 1. Values of immunoreactive atrial natriuretic factor (irANF), mean arterial
pressure (MAP), urinary volume (UVol) and sodium excretion (UNaV), plasma renin activity
(PRA) and plasma aldosterone (Aldo) expressed as mean of the measurements during each
study day.
Parameters Patient Control ANF ANF Recovery
Day 1 Day 2 Day 3 Day 4
irANF (pg/ml) 1 56 75 98 33
2 54 131 93 42
MAP (mmHg) 1 94.1 97.7 97.1 87.2
2 102.3 104.0 107.0 99.8
UVol (ml/24 h) 1 1750 2110 1900 1490
2 1215 1635 2120 1685
UNaV (mmol/24 h) 1 182 238 224 129
2 119 226 256 156
PRA (nmol/l/h) 1 0.4 0.4 0.4 0.4
2 0.5 0.4 0.2 0.4
Aldo (nmol/l) 1 0.07 0.11 0.11 0.38
2 0.09 0.08 0.09 0.13
DISCUSSION
To date there are no data available on the long-term (that is over more than 6 hours)
effects of ANF on blood pressure and sodium excretion in man. Animal studies have
shown a marked decrease in MAP already after 2 days of ANF-infusion. Sodium
excretion did not change or even decreased during ANF-infusion, which was attributed
to the decrease in MAP [7,8]. The results of the present study in man therefore are in
contrast with those animal studies, since we found a sustained increase in sodium
excretion, which in both patients was similar on both days of the ANF-infusion. During
these days irANF-levels only increased 2-fold, thus staying within the physiological range
[3], while PRA- and plasma aldosterone-levels did not change. Together, these results
suggest a physiological role for ANF in the long-term regulation of urinary sodium
excretion. It can be concluded from these data that a low dose 48-hour ANF-infusion
causes firstly no symptomatic hypotension, and secondly a sustained natriuresis. It can
be hypothesized that an even longer infusion of ANF might by its sustained natriuretic
effect eventually decrease MAP. Further studies are needed to clarify the involvement
of ANF in the long-term regulation of sodium-homeostasis and blood pressure in man.
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ANTIHYPERTENSIVE EFFECT OF A 5-DAY INFUSION OF
ATRIAL NATRIURETIC FACTOR IN HUMANS





Atrial natriuretic factor was infused in a low dose (0.2 µg/min) during 5 days in six
patients with essential hypertension. Atrial natriuretic factor infusion caused plasma levels
of atrial natriuretic factor to increase from 49±10 to 106±19 pg/ml. Within 4 hours after
the start of the atrial natriuretic factor infusion, urinary sodium excretion increased in all
subjects. Sodium balance was regained after 24 hours with a net loss of 72.3±14.6 mmol.
However, systolic as well as diastolic blood pressure started to decrease gradually in all
subjects only after 12 hours of atrial natriuretic factor infusion, reaching a stable level
after 36 hours with a decrease of 11.5±1.5 % and 10.3±0.8 %, respectively. Heart rate
increased in parallel by 12.6±3.1 %. Hematocrit rose 7.1±2.3 %. After cessation of atrial
natriuretic factor infusion, plasma atrial natriuretic factor levels, sodium balance, and
hematocrit returned to baseline within 24 hours, whereas blood pressure slowly returned
toward baseline values over 3 days. These data show that chronic atrial natriuretic factor
infusion in patients with essential hypertension causes a negative sodium balance and a
rise in hematocrit, followed by a smooth decrease in blood pressure with a rise in heart
rate until a new equilibrium is reached after approximately 2 days. Thus, atrial natriuretic
factor in low doses appears intimately involved in the regulation of sodium balance and
blood pressure in humans. Moreover, these data suggest that atrial natriuretic factor-like
substances will eventually become useful antihypertensive drugs.
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INTRODUCTION
Atrial natriuretic factor (ANF) has been shown in many animal and human
investigations to have potent natriuretic and vasodepressor effects when administered in
high doses by bolus injection or short-term infusion [1,2]. However, whether ANF at
more physiological levels is involved in the chronic regulation of sodium balance and
blood pressure is still unknown. In most human studies, low-dose (<0.5 µg/min) infusion
of ANF during several hours has been shown to cause a clear natriuresis without
lowering blood pressure [3-5]. Animal data show that low doses of ANF may well cause
a decrease in blood pressure, especially in hypertensive rats [6,7]. This decrease,
however, was observed mainly after several days of ANF infusion [6-9]. We therefore,
investigated the effects of a 5-day low-dose (0.2 µg/min) ANF infusion on urinary
sodium excretion and blood pressure in patients with essential hypertension.
SUBJECTS AND METHODS
We studied six male patients with uncomplicated essential hypertension. Diagnostic
workup included careful history and physical examination. Rapid-sequence urography
was carried out in all patients; renal arteriography was performed when considered
appropriate. Patient age was 51±4 years (mean±SEM, range 35-65). Renal function, as
measured with 125I-iothalamate and 131I-hippuran [10], was characteristic for essential
hypertension [11] with a normal glomerular filtration rate (GFR) (93±3 ml/min/1.73m2),
a reduced effective renal plasma flow (ERPF) (355±8 ml/min/1.73m2), and an increased
filtration fraction (26±1 %). Normal values in our laboratory are 116±4, 508±28, and
23±1, respectively. None had signs of heart failure. Six weeks before hospitalization,
patients were instructed to adhere to a diet containing a constant amount of sodium (150
mmol/day). All antihypertensive medication had been withdrawn for 11±3 weeks (median
9, range 6-26 weeks) until diastolic blood pressure was stable. Blood pressure was
measured eight times after 15 minutes of supine rest with an automatic noninvasive
device (Dinamap®, Criticon Inc, Tampa, Florida, USA). This device measures blood
pressure and heart rate by oscillometric determination of cuff pressure and minute
pressure pulses within the incrementally deflated cuff. Mean systolic and diastolic blood
pressures were 160±5 and 101±1 mm Hg, respectively. The study was carried out in a
metabolic ward and lasted 14 days. During the whole study the patients had absolute bed
rest except for bathroom facilities (8:00 AM to 8:30 AM), weight measurement, and urine
voiding. During the 14 days, the patients received a rhythm diet consisting of equal
amounts of sodium, potassium, and fluid every 4 hours (total: 156 mmol, 90 mmol, and
1,800 ml/day, respectively), and in addition a continuous intravenous infusion of 32 ml/hr
5% dextrose and 2 ml/hr solvent (with or without ANF). After a 3-day equilibration
period, during which blood pressure and sodium excretion were allowed to stabilize, a
3-day baseline period was completed, followed by a 5-day ANF infusion period and a
3-day recovery period. Each of these days started at noon. During the 5-day ANF
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infusion period synthetic human ANF(101-126) (MSD-RL, Rahway, New Jersey, USA)
TABLE 1. 24-Hour data of the three separate baseline days.
Measurements Day 1 Day 2 Day 3
irANF (pg/ml) 51±10 48±10 49±10
Urinary volume excretion (ml/24 hr) 2102±192 2493±170 2241±98
Urinary sodium excretion (mmol/24 hr) 142±13 164±13 156±10
Systolic blood pressure (mm Hg) 136±4 136±5 134±5
Diastolic blood pressure (mm Hg) 89±3 89±3 88±3
Mean arterial pressure (mm Hg) 105±3 105±4 103±4
Heart rate (beats/min) 64±4 64±4 65±4
Hematocrit (%) 42.4±1.1 41.2±1.1 40.5±0.9
Weight (kg) 76.6±2.1 76.4±2.1 76.5±2.1
Values are the 24-hour mean±SEM. Hematocrit was measured at noon and weight at
8 AM. irANF, immunoreactive atrial natriuretic factor.
dissolved in 5 g mannitol/100 ml was infused at a dose of 0.2 µg/min. This is a
N-terminal-deleted form of the endogenous circulating peptide with probably similar or
identical bioactivity [5]. During the 11 days after equilibration, several measurements
were made every 4 hours: first, venous blood samples for the measurement of
immunoreactive ANF (irANF) were drawn while the patient was still in the supine
position. Thereafter urine was collected by spontaneous voiding for measurement of
volume, sodium, and creatinine excretion. Finally, the patients received their meal. Each
day at noon blood was also drawn for determination of serum biochemistry (sodium,
potassium, chloride, urea, creatinine, and transaminases) and hematocrit. The equivalent
amount of sodium was substituted intravenously each time blood was drawn. Blood
pressure was recorded continuously every 15 minutes with the Dinamap device. The
protocol was approved by the local medical ethical committee, and all patients gave their
informed consent.
Serum biochemistry and urinary sodium and creatinine concentration were measured
using standard autoanalyzer techniques (Technicon Instr Corp, Tarrytown, New York,
USA). Hematocrit was measured by the microcrit method. Immunoreactive ANF was
determined with a commercially available 125I-ANF tracer and a highly specific ANF
antibody (INCSTAR, Stillwater, Minnesota, USA). Blood samples for the measurement
of irANF were collected in prechilled EDTA tubes, immediately centrifuged (3,400g, 10
minutes) at 4° C, and the plasma (0.5 ml) was stored at -25° C until all samples of one
patient could be processed simultaneously. The plasma was then acidified with 1.5 ml
4% acetic acid and applied to a Sep-Pak C18 cartridge (Waters Assoc, Milford,
Massachusetts, USA), pretreated with 5 ml 4% acetic acid in 86% ethanol, 5 ml
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methanol, 5 ml distilled water, and 5 ml 4% acetic acid. After washing twice with 3 ml
distilled water, ANF was eluted three times with 1 ml 4% acetic acid in 86% ethanol,
evaporated to dryness, and dissolved in 250 µl radioimmunoassay (RIA) buffer. Then 100
µl plasma extract was mixed with 200 µl antibody and incubated (18 hours, 4° C).
Finally, 200 µl tracer was added. After a 22-hour incubation, free and bound ANF were
separated with horse anti-sheep precipitating reagent. Intra-assay and interassay variances
in our laboratory are 8.5% and 9.3%, respectively.
All results are expressed as mean±SEM. Statistical analysis was performed by
analysis of variance with repeated measurements, followed by Duncan’s multiple range
test. The changes during ANF infusion in the various parameters were calculated against
the mean of the three baseline data of the corresponding 4-hour time periods. Differences
were considered significant at p<0.05.
RESULTS
The first 3 days in the hospital were used to allow sodium balance and blood pressure
to equilibrate. Table 1 shows that all parameters were indeed stable. The 24-hour mean
of the urinary sodium excretion on the last baseline day was 156±10 mmol and thus
equaled the dietary intake of sodium. Twenty-four-hour blood pressure was significantly
lower compared with the outpatient clinic measurement, probably resulting from the
bedrest protocol and inclusion of the night values. There was a marked diurnal rhythm
in urinary sodium excretion and in systolic and diastolic blood pressure. The daily
variation in urinary sodium excretion was similar during these three baseline days, with
maximum values at noon (33.6±2.0 mmol/4 hr) and lowest values at midnight (19.4±0.6
mmol/4 hr). Figure 1 shows that systolic and diastolic blood pressure also followed a
diurnal rhythm with highest values at 4:00 PM (140.3±0.8 / 93.4±0.5 mmHg) and lowest
values at 4:00 AM (130.2±1.6 / 82.4±0.9 mmHg).
Infusion of synthetic ANF caused an immediate twofold increase in plasma levels of
irANF from 49±10 (range 27-88) to 106±19 (range 68-168) pg/ml (p<0.01), which
persisted during the whole infusion period of 5 days (Figure 1). Urinary volume excretion
increased immediately after the onset of the ANF infusion. In the first 4 hours of ANF
infusion, excess volume excretion as compared with baseline was 158.6±54.3 ml
(p<0.01). After 12 hours of ANF infusion, net volume balance was negative by
365.9±100.3 ml (p<0.05). For the following days of ANF infusion, volume excretion
matched baseline values again. Urinary sodium excretion also increased within 4 hours
in all patients (Figure 2). In the first 4 hours of ANF infusion, excess sodium excretion
was 15.6±2.9 mmol (p<0.01). After 12 hours of ANF infusion, net sodium balance was
- 51.8±8.3 mmol (p<0.01). Urinary sodium excretion continued to exceed baseline values
up to 24 hours, amounting to a net negative sodium balance of 72.3±14.6 mmol (range
32.2-138.9, p<0.01). Urinary creatinine excretion was 13.9±0.7 mmol/24 hr during
baseline and did not change during ANF infusion (13.7±0.9 mmol/24 hr, not significant
[NS]). Weight was reduced in five of the six patients, resulting in a decrease of
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systolic and diastolic blood pressure (4-hour mean±SEM) before, during, and after a 5-day, low-dose
(0.2 µg/min) atrial natriuretic factor infusion in six patients with essential hypertension.
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infusion in six patients with essential hypertension.
0.7±0.2 kg to 75.8±2.1 kg (NS). In the remaining patient, weight did not change. In
contrast to the immediate response of urinary volume and sodium excretion to ANF
infusion, neither systolic nor diastolic blood pressure decreased within the first 12 hours
of ANF infusion in any patient (Figures 1 and 2). However, after this delay both systolic
and diastolic blood pressure began to decrease gradually in all patients. Systolic blood
pressure was significantly lower than baseline values 16 hours after the start of the ANF
infusion (p<0.05), whereas diastolic blood pressure became significantly lower after 36
hours (p<0.01). Thereafter, systolic and diastolic pressure remained stable until the end
of the ANF infusion. The decrease in systolic blood pressure was 16.2±2.3 mmHg
(11.5±1.5%, range 7.8-17.2%, p<0.01) and, in diastolic blood pressure, 9.3±0.8 mmHg
(10.3±0.8%, range 7.2-12.3%, p<0.01). Heart rate was significantly elevated 24 hours
after the start of the ANF infusion by 8.4±1.9 beats/min (12.6±3.1%, p<0.05). Hematocrit
showed an increase in all patients of 7.1±2.3% (p<0.05), which was stable during the
whole ANF infusion period (Figure 3).
After cessation of ANF infusion, plasma levels of irANF returned to or below
baseline during the first recovery day, to stabilize thereafter at preinfusion values (Figure
1, NS). Urinary sodium excretion was significantly (p<0.01) decreased compared with
baseline values during the 24 hours after cessation of ANF infusion. Thereafter, sodium
excretion was similar to baseline values again. Thus, volume and sodium balance rapidly
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TABLE 2. Serum biochemistry before, during, and after a 5-day infusion of atrial
natriuretic factor.
Variables Baseline ANF Recovery
Sodium (mmol/l) 136.5±1.6 138.7±1.3 136.2±1.9
Potassium (mmol/l) 4.4±0.1 4.5±0.1 4.5±0.1
Chloride (mmol/l) 104.8±1.6 106.3±1.0 105.3±1.1
Urea (mmol/l) 3.5±0.4 3.7±0.3 3.3±0.4
Creatinine (µmol/l) 87.2±1.8 88.7±2.4 90.7±2.9
SGOT (units/l) 17.3±1.1 32.5±9.1* 32.2±7.5*
SGPT (units/l) 20.5±2.3 57.3±19.3** 57.3±19.2**
Values (mean±SEM) were measured at noon on the last day of each period. ANF, atrial
natriuretic factor; SGOT, serum glutamic-oxaloacetic transaminase; SGPT, serum glutamic-
pyruvic transaminase.
* p<0.05, ** p<0.01 versus baseline.
returned to baseline in 24 hours. In contrast, both systolic and diastolic blood pressure
and heart rate slowly returned toward baseline values, being statistically different
(p<0.05) from baseline values up to 44 hours after cessation of the ANF infusion.
Although these values were not statistically different from baseline values thereafter, they
did not show a complete return. On the last day of the recovery period, 24-hour mean
systolic and diastolic blood pressure were still 4.3±1.4 % (NS) and 5.6±1.9 % (NS)
below baseline, respectively (Figure 2). Hematocrit returned to or below baseline
(p<0.05), which may reflect the amount of blood sampling in this study (390 ml in 11
days).
No sudden hypotensive responses were observed. Also no adverse changes in serum
biochemistry were found, except for the serum transaminases (Table 2). In five of the six
patients a transient increase in transaminases was observed. Peak serum glutamic-
oxaloacetic transaminase (SGOT) levels in these patients varied from 27 to 75 units/l
(normal to 40 units/l), and peak serum glutamic-pyruvic transaminase (SGPT) levels from
36 to 119 units/l (normal to 30 units/l) during ANF infusion. In two patients normal
values were present again at the end of the ANF infusion. In the other three patients,
normal values were present 2 weeks after the study.
DISCUSSION
These data show that a chronic infusion of low-dose ANF in patients with essential
hypertension rapidly causes a negative sodium balance followed by a slower decrease in
blood pressure and a rise in heart rate.
ANF is now recognized to be a hormone of cardiac origin, whose circulating plasma
levels vary with different physiological stimuli [2]. It has thus been questioned whether
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ANF within this physiological range participates in the day-to-day regulation of sodium
excretion and blood pressure [2]. In the present study, we used a very low dose infusion
of ANF, increasing plasma levels only twofold. Other investigators have shown that
stimuli, for instance an increase in sodium intake [12] or, more acutely, volume loading
[12,13], may cause approximately threefold increases in plasma ANF levels. Therefore
we assume that the ANF effects on sodium excretion and blood pressure in the present
study can be assumed to represent effects of ANF levels within or close to the
physiological range.
The changes in urinary sodium excretion during ANF infusion were present within
4 hours of the start of the infusion period and leveled off after 24 hours. The immediate
natriuretic response to ANF even before a decrease in blood pressure coincides with
studies of Anderson et al [4] and Richards et al [5] in humans. These authors found that,
when infused during 2-3 hours, the same or a somewhat higher dose of ANF does indeed
cause natriuresis in humans without affecting blood pressure. The amount of
ANF-induced excess sodium excretion (approximately 4 mmol/hr) during the first 12
hours of ANF infusion is very close to the amounts observed by these authors. However,
the ANF-induced increase in urinary sodium excretion in the present study finally leveled
off. The reason is not clear from the present data, but it is conceivable that a new
balance between ANF and opposing sodium-retaining factors was reached. One of the
counterbalancing mechanisms involved might be the decrease in blood pressure, since
during the first 12 hours of ANF infusion the excess amount of sodium excreted per hour
was stable and started to diminish only when blood pressure began to decrease. After 2
days of ANF infusion, urinary sodium excretion equaled baseline values (and thus
sodium intake) again, while blood pressure now remained stable. In all animal and
human studies thus far, an evanescent natriuretic effect of ANF has always been
associated with a decline in blood pressure [14-16]. Moreover, there is extensive
evidence from animal studies that ANF-induced natriuresis depends on arterial blood
pressure [17-18]. Other sodium-retaining factors possibly involved in the discontinuation
of the natriuretic response to ANF might be an increase in sympathetic tone (as
suggested by the increase in heart rate) or an activation of the renin-angiotensin system.
Alternatively, tachyphylaxis, for instance through a down-regulation or occupancy of
renal tubular ANF receptors (induced by high ANF levels [19]), cannot be excluded as
a factor underlying the evanescent natriuretic effect of ANF in this study.
The most important observation of the present study is the ANF-induced gradual
decrease in blood pressure, starting after a delay of 12 hours and reaching a new, stable
level after 36 hours of ANF infusion. This observation is consistent with available
animal-study data showing that prolonged low dose infusion of ANF may indeed cause
a delayed or a more pronounced decrease in blood pressure after some days [6-9]. In
humans, however, such a gradual decrease during a long-term administration of a very
low dose of ANF has not yet been reported. In contrast, we and others have observed
that higher doses of ANF can cause a sudden symptomatic hypotensive response
[3,16,20]. The data of the present study thus suggest that doses of about 0.2 µg ANF/min
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(or maybe even lower) can be given safely and effectively over a longer period to
patients with essential hypertension. However, the level of sodium balance, which we
chose to be relatively high in the present study, could be of importance in this respect
[16,21]. The mechanism causing the decrease in blood pressure in the present study is
not clear. Data from animal studies have suggested that the decrease in blood pressure
induced by low-dose infusion of ANF is related to volume depletion, to a decrease in
cardiac output, or to vasodilation [6,7,22]. It has been suggested that the underlying
mechanism depends on the investigated animal model [6,7]. Parkes et al [22] suggested
from their study of sheep that the ANF-induced blood pressure reduction during the first
days of ANF infusion is related to a decrease in cardiac output associated with a fall in
blood volume and after 5 days is mediated in addition by peripheral vasodilation. In the
present study, the negative volume balance (although not impressive), the reduced weight,
and the stable increase in hematocrit during the 5 days of ANF infusion suggest that
volume depletion via urinary losses, the redistribution of extracellular fluid volume, or
both, contributes to the decrease in blood pressure. Moreover, these changes preceded the
decrease in blood pressure during ANF infusion. On the other hand, the increase in heart
rate during ANF infusion might suggest vasodilation. A vasodilatory action of ANF could
also explain the slow return toward baseline values of blood pressure and heart rate in
the recovery period in contrast to the quick return to baseline of volume balance and
hematocrit. Therefore, the time course of the changes in volume balance and blood
pressure in the present study could well be consistent with the suggestion of Parkes et
al [22] that volume depletion as well as vasodilation contribute in a time-dependent
fashion to the lowering of the blood pressure.
These observations raise the question as to whether ANF eventually will become
useful as an antihypertensive drug. The present data show that continuous intravenous
infusion of exogenous ANF lowers blood pressure in patients with essential hypertension
during continued bedrest and a rhythm diet. Therefore, a time-related effect on blood
pressure independent of ANF administration cannot be completely ruled out, nor can it
be concluded from the present data that ANF will lower blood pressure under typical
day-to-day circumstances. Moreover, to be convenient as a drug, effective oral or nasal
preparations must be available. To find another way of administration, one could think
of ANF-like analogues or drugs inhibiting the degradation of endogenous ANF. Whether
the long-term efficacy of such preparations is limited by an intermittent intake is still to
be demonstrated. In this respect, the observed slow return toward baseline of blood
pressure during recovery, consistent with the observations of others [3,20], certainly
could be a valuable property of ANF, despite its fast degradation. The increase in heart
rate and the possibly transient increase in transaminases may limit the usefulness of
ANF-like drugs. It is not clear from the present study whether heart rate would return to
normal values after a longer period of time, as has been observed in sheep [22]. The
reason for the increase in transaminases is unclear. Particularly no serological or
immunological evidence for the existence of one or the other form of hepatitis could be
obtained. Moreover, it should be noted, that the other liver enzymes were not affected
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during ANF infusion and that the rise was transient. Hypothetically, the rise could be
explained by the involvement of exogenous ANF in the metabolism of the transaminases.
Substances that inhibit the degradation of endogenous ANF [23] might not have this side
effect. Thus, studies showing the effects of ANF on blood pressure during more typical
day-to-day conditions must be conducted, and several difficulties have to be solved
before drugs interfering with ANF levels are considered suitable.
In conclusion, long-term, continuous infusion of very low doses of ANF, which
induces ANF levels within or close to the physiological range, causes a negative sodium
balance and lowers blood pressure in hypertensive humans. Moreover, ANF-like
analogues or substances inhibiting the degradation of endogenous ANF may eventually
become useful antihypertensive drugs.
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RENAL TUBULAR SENSITIVITY TO ATRIAL NATRIURETIC
FACTOR IN ESSENTIAL HYPERTENSION
Wilbert M T Janssen, Dick de Zeeuw, Gjalt K van der Hem, and Paul E de Jong




The objective of this study was to investigate the tubular site or sites of the natriuretic
action of atrial natriuretic factor (ANF) and possible differences between healthy subjects
and patients with essential hypertension. Nine healthy volunteers and six patients with
essential hypertension were studied on four test days under standard conditions, water
loading, and hydropenia with mannitol or saline loading. On each test day baseline, ANF
infusion (1 µg/min) and recovery measurements were performed after equilibrium had
been reached. The measurements included the ANF plasma levels, blood pressure,
glomerular filtration rate (GFR), effective renal plasma flow (ERPF), urinary osmolality,
and the (fractional) excretions of (free) water, sodium, and potassium. Fractional free
water excretion (CH2O/GFR) and free water reabsorption (TcH2O/GFR; as function of
osmolar clearance) were calculated during water loading and hydropenia with mannitol
or saline loading, respectively, using standard formulas. 125I-iothalamate and 131I-hippuran
were infused continuously for measurement of GFR and ERPF, respectively. The plasma
ANF concentration rose five- to eightfold during the infusion of ANF, which induced an
increase in urinary sodium excretion, a small increase in GFR, and a decrease in ERPF.
Moreover, ANF induced an increase in CH2O/GFR and a decrease in TcH2O/GFR. These
changes did not correlate with changes in GFR. Blood pressure and potassium excretion
were not affected. The effects of ANF on the plasma ANF levels, natriuresis, and renal
hemodynamics did not differ between the normotensives and the patients with essential
hypertension. However, the increase in CH2O/GFR was greater in patients with essential
hypertension (p<0.05), and correlated significantly with blood pressure (r=0.56, p<0.05).
These results indicate that the infusion of ANF at a low dose induces a similar
natriuretic response in normotensive subjects and in patients with essential hypertension.
This natriuresis is probably the result of both a glomerular and a tubular effect of ANF.
Proximal as well as distal tubular sites seem to be involved. In patients with essential





The renal natriuretic site of action of atrial natriuretic factor (ANF) has been the
subject of several studies in normotensive humans [1-6]. These studies have indicated
that at least the proximal and distal tubule are involved in ANF-induced natriuresis [1-3].
With regard to the distal tubule, Rabelink et al have provided evidence that ANF acts at
the inner medullary collecting duct (IMCD) in particular [4]. ANF has also been shown
to decrease urinary osmolality, which led us and others to suggest that ANF induces a
washout of the medullary interstitium [5,6]. Animal data have shown that ANF may
cause such a washout of the medullary interstitium by increasing the medullary blood
flow [7,8]. Because changes in medullary tonicity affect urinary sodium excretion,
probably through an effect at the loop of Henle [9], it can be hypothesized that medullary
tubular segments (i.c. Henle’s loop and the IMCD) are important for ANF-induced
natriuresis. In patients with essential hypertension (EH) the effects of ANF on these
medullary segments have not yet been studied, although several lines of evidence indicate
that ANF may act differently at these sites in EH. We and others have shown that the
natriuretic effect of ANF depends on the prevailing level of the systemic blood pressure
[10,11], and animal studies have shown that the ANF-induced increase in renal medullary
blood flow is enhanced at higher levels of renal perfusion pressure [8]. It could thus be
hypothesized that the higher perfusion pressure in EH [12] will enhance the effect of
ANF on Henle’s loop in EH. In contrast, the effect of ANF on the IMCD in Dahl salt-
sensitive rats has been shown to be impaired [13].
A method to evaluate the medullary tubular site of action of a natriuretic drug is to
study the effects on free water excretion (CH2O) and reabsorption (TcH2O) [14,15]. An
ANF-induced rise in CH2O (during water loading) is compatible with an effect at a tubular
segment proximal to the point of isotonicity in the medullary ascending limb of Henle’s
loop, whereas a decrease in CH2O suggests an action distal from this point. An ANF-
induced decrease in TcH2O (during hydropenia and mannitol or saline loading) suggests
a medullary tubular site of action, whereas an increase in TcH2O implies a more cortical
site of action, such as the proximal tubule.
To evaluate further the effect of ANF on renal tubular segments and to test the
possible different action of ANF at these segments in EH, we investigated the natriuretic
effect of ANF in relation to its effects on CH2O and TcH2O in normotensive subjects and
patients with essential hypertension.
SUBJECTS AND METHODS
Nine healthy volunteers (3 female, 6 male) were enrolled in the present study. Their
mean (±SEM) age was 31±5 yr (range 21-58). Systolic blood pressure (SBP) measured
123±3 mmHg (range 110-140), and diastolic blood pressure (DBP) 71±4 mmHg (range
58-86). Six patients (all male) with uncomplicated essential hypertension were also
enrolled. Their mean age was 44±2 yr (range 36-53), which was not significantly
different from the normotensive volunteers. SBP was 140±3 mmHg (range 134-150), and
DBP 97±1 mmHg (range 96-100) were enrolled. The protocol was approved by the local
Medical Ethical Committee, and all subjects gave their informed consent.
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From at least 2 weeks prior to the study until the end of the study they did not
receive any drug and adhered to a 200 mmol/day sodium diet. The dietary compliance
was good: 24-h urine collections contained 162 ± 12 mmol Na in the normotensives
(NT), and 185 ± 20 mmol Na in EH (NS). Normotensive and hypertensive subjects were
studied in random order. The study consisted of four test days, each separated by 1 week
and each characterized by different physiological conditions: standard conditions, water
loading, hydropenia with mannitol loading, and hydropenia with saline loading. All test
days started at 8 AM. The subjects assumed the supine position for the whole day, except
for urine voiding. Blood pressure was recorded every 2 min with an automated
non-invasive device (Dinamap®, Critikon Inc, Tampa, Florida, USA). On the first test day
all of the subjects were examined during standard conditions, consisting of an oral intake
of 150 ml water every hour and 17 mmol Na every 2 hours, and a continuous
intravenous infusion of 100 ml/h dextrose 5%. On the second test day a water loading
experiment was performed: a steady state of urinary dilution was induced and maintained
during the whole test day with an oral intake of 150 ml water every 20 min and a
continuous infusion of 1000 ml/h dextrose 5%. A subgroup of the normotensive and
hypertensive subjects were studied during urinary concentrating conditions; that is,
hydropenia with mannitol loading (NT n=7, EH n=5) and hydropenia with saline loading
(NT n=4, EH n=3): food and fluids were withheld for 14 hours before the start of the test
and no oral fluids were administered during the test day. At 8 AM lypressin (350 mU
vasopressin Sandoz®, Sandoz Pharma Ltd, Basle, Swiss) was injected intramuscularly,
followed by a continuous and simultaneous intravenous infusion of 350 mU lypressin/h
to induce supra-maximal vasopressin concentrations and 600 ml/h mannitol 10% in
100 mM NaCl or 600 ml/h saline 3% to ensure diuresis. On all of the test days
glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured
by continuous infusion of 125I-iothalamate and 131I-hippuran, respectively [16].
Urine was collected by spontaneous voiding. Collections were made every hour
during standard conditions and every 20 min during water loading and hydropenia.
Baseline data were obtained from 10 AM to 12 AM under standard conditions. During
water loading and hydropenia four consecutive baseline measurements were made after
a stable diuresis had been attained (difference in urinary volume less than 2 ml/min of
the mean). An intravenous infusion of 1 µg ANF/min (human ANF 101-126, MSD-RL,
New Jersey, USA) was then started for 2 hours under standard conditions and water
loading, and for 80 min under both hydropenia conditions. Meanwhile, the fluid infusions
mentioned above were maintained. Finally, after stopping the infusion of ANF, recovery
measurements were obtained for 2 hours under standard conditions and water loading,
and for 80 minutes under both hydropenia conditions. Blood for the measurement of
immunoreactive ANF (irANF) was drawn with the subjects in the supine position at the
end of each period in prechilled tubes containing EDTA. Blood for the measurement of
electrolytes, osmolality, 131I-hippuran, and 125I-iothalamate was sampled every hour under
standard conditions, and every 40-60 min during water loading and hydropenia.
Sodium, potassium, and chloride concentrations in urine and serum were measured
using standard autoanalyzer techniques (Technicon Instr Corp, Tarrytown, New York,
USA). Urinary and serum osmolality were measured using the method of freezing point
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depression (Osmomat-030, Gonotec GmbH, Berlin, Germany). Hippuran and iothalamate
radioactivities were measured in a gammacounter (1282 Compugamma, LKB-Wallac,
Turku, Finland). Immunoreactive ANF (irANF) was measured after extraction with a
commercially available radioimmunoassay (INCSTAR, Stillwater, Minnesota, USA), as
described previously [17].
Clearances were calculated using the extrapolated mid-collection serum value. Cosm,
CH2O, and TcH2O were calculated as: Cosm = (Uosm×V)/Posm, CH2O=V-Cosm, and TcH2O=Cosm-V,
where Uosm and Posm are osmolalities of urine and serum, respectively (mOsm/kg H2O),
and V is urinary flow (ml/h). Fractional free water excretion (CH2O/GFR) during maximal
water diuresis was taken as an index of sodium reabsorption in the diluting segment, i.e
distal of the point of isotonicity in the medullary ascending limb of Henle’s loop. The
changes in fractional free water plus chloride clearance ((CH2O+CCl)/GFR) were regarded
as an index of the changes in fractional solute delivery to the diluting segment, and
changes in the ratio (CH2O/(CH2O+CCl)) were regarded as an index of changes in the
diluting segment reabsorption [14,15]. The changes in these parameters were compared
to the mean of the four baseline values. However, changes in TcH2O can be interpreted
only in terms of their relationship to the changes in Cosm [14,15]. Since ANF increased
Cosm, changes in TcH2O needed a different evaluation. We therefore extrapolated the
curvilinear relationship between baseline TcH2O and Cosm values using a semilogarithmic
approximation [18]. The expected values for TcH2O during the infusion of ANF and
recovery could be calculated at the observed levels of Cosm. The ANF-induced changes
in TcH2O were interpreted as the difference between the measured and expected value at
the actual Cosm level. Recovery values returned to the extrapolated curve, justifying these
calculations. Nevertheless, this necessitates some caution in the interpretation of these
clearance data. ERPF was calculated using the continuous infusion method and GFR with
the standard method, corrected for incomplete collection of urine as described previously
[16]. For the calculation of fractional clearances, GFR as measured with the standard
method was used. Filtration fraction (FF) was calculated as the ratio of GFR to ERPF.
Statistical analysis was performed using two-way-analysis of variance with repeated
measurements followed by Student’s t-test for paired or unpaired samples. Data were
tested against the mean of the 2 or 4 baseline values. Pearson’s correlation coefficient
was used to calculate correlation between variables. Differences were considered
statistical significant when p<0.05.
RESULTS
Baseline (endogenous) plasma irANF was significantly lower in EH than in the
normotensives during standard conditions (p<0.05, Table 1) as well as during water
loading (p<0.05, Table 2). A similar difference tended to be present during both saline
and mannitol loading. Mean arterial pressure was higher in EH during all tests. The other
differences in baseline values were a lower ERPF in EH under all of the test conditions,
a higher plasma osmolality in EH during water loading, and a higher plasma osmolality,
and absolute urinary volume and sodium excretion in EH during hydropenia with
mannitol loading (all p<0.05, Table 3). Baseline sodium excretion in EH also tended to
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be higher during the other test days, but the difference was not statistically significant.
No further differences in the baseline data were present between the two groups.
Standard conditions
During standard conditions infusion of ANF induced an increase in urinary absolute
(UNaV) and fractional (CNa/GFR) sodium excretion in the normotensive and EH subjects
(p<0.05, Table 1). The magnitude of this ANF-induced natriuresis did not differ between
the two groups (Table 1, Figure 1). There was no increase in urinary potassium excretion
during ANF infusion. Urinary osmolality decreased upon ANF infusion, although this
decrease was significant only in the EH group. Interpretation of (a lack of) differences
Table 1. Effects of infusion of ANF (1 µg/min) during standard conditions in nine
normotensive and six hypertensive subjects.
NORMOTENSIVES HYPERTENSIVES
Variables Baseline ANF Recovery Baseline ANF Recovery
STANDARD CONDITIONS
Absolute and fractional urinary excretion
UVol (ml/h) 237±35 330±29 139±27 145±24 314±52* 150±17
UNaV (mmol/h) 8.9±1.1 14.3±1.2* 8.2±0.9 9.3±1.7 16.6±2.6* 11.8±2.3
UKV (mmol/h) 3.3±0.4 2.6±0.4 1.4±0.2* 3.8±0.7 2.5±0.3 2.0±0.3
V/GFR (%) 3.5±0.7 4.5±0.5 1.9±0.4 2.0±0.5 4.3±0.8* 1.7±0.2
CNa/GFR (%) 0.9±0.1 1.4±0.1* 0.8±0.1 0.9±0.2 1.7±0.4* 1.0±0.2
CK/GFR (%) 10.6±1.0 8.5±1.4 4.7±0.8* 11.0±1.1 8.0±0.9 5.9±0.8*
Urinary osmolality
Uosm (mOsm/kg H2O) 317±70 217±33 363±42 444±75 265±50* 439±48
Plasma sodium and osmolality
PNa (mmol/l) 140.1±0.2 140.4±0.3 139.6±0.5 139.5±0.
9
139.3±0.7 139.0±0.5
Posm (mOsm/kg H2O) 289±1 290±1 288±1 291±1 292±2 290±1
Immunoreactive ANF and blood pressure
irANF (pg/ml) 37±3 256±56* 43±8 21±4# 160±47* 31±5
MAP (mmHg) 87±3 87±4 88±3 111±3# 109±3 107±2
Renal hemodynamics
GFR (ml/min/1.73m2) 116±4 120±4* 112±4* 105±8 112±8* 108±8
ERPF (ml/min/1.73m2) 508±28 448±20* 490±20 404±39# 372±38* 420±41
FF (%) 23±1 27±1* 23±1 26±1 30±1* 26±1
Data are expressed as mean ± sem as measured for baseline over 2 hours, and for ANF
infusion and recovery over the last hour.
*=p<0.05 ANF vs baseline.
#=p<0.05 hypertensives vs normotensives, indicated only for the baseline values.
$=p<0.05 ANF response hypertensives vs normotensives.
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Figure 1. The mean and individual percentage changes in fractional sodium clearance (∆CNa/GFR) in













the last 40 or 60 minutes of infusion of ANF (1 µg/min) compared with the baseline values (=100 %)
in normotensive (open circles) and hypertensive subjects (closed circles) under standard conditions,
water loading, and hydropenia with mannitol loading.
in ANF-induced natriuresis between NT and EH should take into account possible
differences in the effects of the infusion of ANF on plasma composition, plasma irANF,
mean arterial pressure (MAP), or renal hemodynamics. However, the effects of ANF
infusion on plasma sodium and osmolality, plasma irANF and MAP were similar in both
groups. Plasma sodium and osmolality did not change. Plasma irANF level increased
approximately sevenfold in both groups during ANF infusion (Table 1), and MAP did
not change during these two hours of ANF infusion. The effects of ANF on renal
hemodynamics were also similar in both groups: ANF caused a small but significant
increase in GFR and a distinct decrease in ERPF in both groups (Table 1). FF thus rose
significantly in both groups. The ANF-induced effects on irANF, MAP, and renal
hemodynamics (Tables 2-4) in the other tests were similar to those during standard
conditions in both groups. During the recovery phase (in all test conditions) all of the
parameters returned towards their baseline levels in both groups.
Water loading
During water loading conditions the ANF-induced natriuresis again was found to be
similar in NT and EH subjects (Table 2, Figure 1). ANF infusion did not cause urinary
potassium excretion to change. Minimal urinary osmolality during maximal water loading
81
Chapter 6
Table 2. Effects of infusion of ANF (1 µg/min) during water loading conditions in nine
normotensive and six hypertensive subjects.
NORMOTENSIVES HYPERTENSIVES
Variables Baseline ANF Recovery Baseline ANF Recovery
WATER LOADING
Absolute and fractional urinary excretion
UVol (ml/h) 1130±58 1331±77* 1104±60 1178±68 1420±56* 1167±32
UNaV (mmol/h) 6.8±1.1 15.5±2.8* 7.1±1.1 9.5±1.7 18.9±3.7* 9.7±0.9
UKV (mmol/h) 2.1±0.3 1.9±0.1 1.6±0.1* 2.6±0.6 2.5±0.6 2.1±0.3
V/GFR (%) 14.4±0.7 16.3±1.0* 13.4±0.6 15.8±1.2 19.5±1.3* 15.8±1.1
CNa/GFR (%) 0.6±0.1 1.4±0.3* 0.6±0.1 1.0±0.2 2.0±0.5* 1.0±0.1
CK/GFR (%) 5.9±0.9 6.5±0.7 5.2±0.8 7.8±1.1 7.6±1.7 6.1±1.0
Urinary osmolality
Uosm (mOsm/kg H2O) 48±2 52±3 45±1 55±3 61±6 57±5
Plasma sodium and osmolality
PNa (mmol/l) 135.4±0.9 135.7±1.4 135.1±1.5 136.3±0.8 135.5±0.9 135.2±1.1
Posm (mOsm/kg H2O) 280±1 277±2 275±2* 285±2# 285±3 280±2
Renal hemodynamics
GFR (ml/min/1.73m2) 123±4 130±6* 129±5* 114±6 120±6 115±7
Parameters of proximal and distal tubular sodium handling
CH2O (ml/min) 15.7±0.8 18.1±1.1* 15.8±1.0 15.8±1.0 18.6±0.7* 15.5±0.6
CH2O/GFR (%) 12.0±0.6 13.3±0.8* 11.3±0.5 12.8±0.9 15.3±1.0*$ 12.5±0.8
(CH2O+CCl)/GFR (%) 12.7±0.6 14.6±0.9* 11.9±0.6 13.7±0.9 17.3±1.1*$ 13.3±0.7
CH2O/(CH2O+CCl) (%) 94.3±0.8 91.5±1.3* 95.5±0.7 93.6±1.1 88.6±2.6* 93.9±1.0
Data are expressed as mean ± sem as measured for baseline over 4 periods, and for ANF
infusion and recovery over the last hour.
*=p<0.05 ANF vs baseline.
#=p<0.05 hypertensives vs normotensives, indicated only for the baseline values.
$=p<0.05 ANF response hypertensives vs normotensives.
tended to increase in both groups, with the ANF-induced change being statistically
significant only for the combined data from both groups. Filtered load, being the product
of plasma osmolality and GFR may affect parameters of free water clearance. Baseline
plasma osmolality was higher in EH, whereas plasma sodium was similar in both groups.
Neither was affected by ANF infusion. GFR values did not differ between both groups,
nor did the response to ANF infusion. This infusion caused filtered load to increase
similarly in both groups, although the increase reached statistical significance only in the
normotensives. Free water clearance (CH2O) increased after ANF infusion to a similar
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(open circles) and six hypertensive subjects (closed circles) during water loading. Mean baseline value
is given as 100 %; * denotes p<0.05 ANF effect versus mean baseline value in each group; $ denotes
p<0.05 ANF response between both groups.
extent in both groups. The (absolute) increase in CH2O correlated with the increase in
GFR (r=0.61, p<0.05), but not with mean arterial pressure in the second hour of ANF
infusion (r=0.07, NS). In contrast, the data on fractional free water excretion (CH2O/GFR)
showed clear differences between NT and EH subjects (Table 2, Figure 2). Fractional
free water excretion (CH2O/GFR) rose significantly after the infusion of ANF in both
groups (NT p<0.02, EH p<0.002, Table 2), the increase being significantly greater in EH
(p<0.05, Figure 2). Similarly, (CH2O+CCl)/GFR, indicating distal delivery, rose
significantly after the infusion of ANF in both groups (NT p<0.02, EH p<0.002,
Table 2). Again, this increase was significantly greater in EH (p<0.05). Analysis of the
combined data for both groups showed a significant correlation between mean arterial
pressure and the ANF-induced changes in CH2O/GFR (r=0.56, p<0.05, Figure 3) and in
(CH2O+CCl)/GFR (r=0.55, p<0.05). There were no correlations with the increase in GFR
(r=0.04, NS, and r=0.11, NS, respectively). Thus, the proximal tubular natriuretic effect
of ANF in EH appears to be enhanced, which may be related to the level of blood
pressure. CH2O/(CH2O+CCl), indicating distal reabsorption, decreased in both groups (both
p<0.05). The ANF-induced change in this parameter was not statistically different
between the two groups.
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Figure 3. The relationship between mean arterial pressure and the absolute change in fractional free
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water clearance (∆CH2O/GFR) during water loading conditions in nine normotensive volunteers (open
circles) and six patients with essential hypertension (closed circles)(r=0.56, p=0.029).
Hydropenia
During both hydropenia conditions (with mannitol and saline loading, respectively),
the ANF-induced natriuresis was again similar in both groups, and the urinary potassium
excretion was not affected (Tables 3 and 4, Figure 1). The ANF-induced (absolute)
increase in CNa/GFR was higher during the hydropenia tests than during the tests under
standard conditions or water loading in both groups (p<0.05). Analysis of the data for
all four test days combined showed that this could be related to a significant correlation
between baseline CNa/GFR and its (absolute) increase. These parameters correlated
significantly and similarly both in NT-subjects (r=0.52, p<0.05), and in EH-patients
(r=0.55, p<0.05). Urinary osmolality was significantly decreased by the infusion of ANF
in both groups, without a significant difference between the two groups. During ANF
infusion plasma osmolality increased similarly in both groups. GFR values and the ANF-
induced increase in GFR were similar in both groups. Since ANF caused fractional
osmolar clearance (Cosm/GFR) to increase (by approximately 30 per cent in both groups;
(Tables 3 and 4)), the changes in fractional free water reabsorption (TcH2O/GFR) were
corrected for Cosm/GFR (see subjects and methods). The infusion of ANF induced a
similar decrease in TcH2O/GFR (p<0.05) in both groups (Tables 3 and 4), indicating an
effect of ANF on renal medullary tubular segments. The (absolute) decrease in TcH2O/GFR
did not correlate with the increase in GFR (r=0.46, NS).
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Table 3. Effects of ANF infusion (1 µg/min) during hydropenia with mannitol loading in
seven normotensive and five hypertensive subjects.
NORMOTENSIVES HYPERTENSIVES
Variables Baseline ANF Recovery Baseline ANF Recovery
HYDROPENIA WITH MANNITOL LOADING
Absolute and fractional urinary excretion
UVol (ml/h) 773±36 1228±76* 1061±52* 928±42# 1212±72* 1100±50*
UNaV (mmol/h) 52±6 98±8* 74±7* 71±5# 94±6* 70±2
UKV (mmol/h) 11.3±1.4 14.3±1.4 13.3±1.4 13.9±1.0 13.7±1.3 12.8±1.2
V/GFR (%) 11.6±0.6 17.4±1.3* 15.0±0.7* 13.7±1.4 19.0±1.9* 15.7±1.5*
CNa/GFR (%) 5.9±0.6 10.7±1.0* 8.1±0.6* 8.0±0.9 11.4±1.3* 7.7±0.6
CK/GFR (%) 32.2±3.4 37.1±3.6 35.5±3.8 39.7±2.9 42.9±2.7 37.1±2.8
Urinary osmolality
Uosm (mOsm/kg H2O) 466±15 430±14* 456±10 455±17 428±15* 468±9
Plasma sodium and osmolality
PNa (mmol/l) 129.4±0.3 129.1±0.5 129.4±0.6 129.2±1.2 129.0±1.2 130.0±1.2
Posm (mOsm/kg H2O) 307±2 313±2* 318±2* 315±2# 321±4* 327±3*
Renal hemodynamics
GFR (ml/min/1.73m2) 108±3 115±3* 109±4 104±5 110±6* 98±5*
Osmolar clearance and fractional free water reabsorption
Cosm/GFR (%) 17.6±0.5 23.7±1.0* 21.7±0.7* 19.5±1.3 25.0±1.8* 22.4±1.6*
TcH2O/GFR (%) -0.1±0.1 -10.3±3.7* 0.4±1.3 -1.3±0.5 -9.3±3.0* 6.4±0.6
Data are expressed as mean ± sem as measured for baseline over 4 periods, and for ANF
infusion and recovery over the last 40 minutes.
*=p<0.05 ANF vs baseline.
#=p<0.05 hypertensives vs normotensives, indicated only for the baseline values.
$=p<0.05 ANF response hypertensives vs normotensives.
DISCUSSION
In the present study we found that low dose ANF infusion induces a similar
natriuretic effect in normotensive and EH subjects. Moreover, the present data show that
the ANF-induced increase in CH2O/GFR correlates with blood pressure and is enhanced
in EH compared with NT.
Our observation of a similar ANF-induced (overall) natriuretic effect in normotensive
and EH subjects (under all of the present test conditions) is in good agreement with other
recent studies that have used low doses of ANF [19]. However, for several reasons
ANF-induced natriuresis would be expected to be enhanced in EH. First, considerable
evidence exists from animal experiments that the ANF-induced rise in urinary sodium
excretion depends rather strongly on blood pressure [20]. Similarly, in patients with
secondary hypertension a dose of ANF comparable with that used in the present study
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Table 4. Effects of ANF infusion (1 µg/min) during hydropenia with saline loading in four
normotensive and three hypertensive subjects.
NORMOTENSIVES HYPERTENSIVES
Variables Baseline ANF Recovery Baseline ANF Recovery
HYDROPENIA WITH SALINE LOADING
Absolute and fractional urinary excretion
UVol (ml/h) 596±200 985±61 884±50 739±175 1275±144 962±146
UNaV (mmol/h) 120±35 230±24 198±16 152±31 257±20 210±25
V/GFR (%) 6.2±2.0 11.2±0.7 9.6±0.6 8.7±3.0 13.5±1.9 10.7±2.4
CNa/GFR (%) 8.1±2.3 16.1±0.8 13.4±0.9 12.0±4.0 17.5±3.0 13.5±2.5
Urinary osmolality
Uosm (mOsm/kg H2O) 573±51 481±16 513±11 537±71 463±28 533±39
Plasma sodium and osmolality
PNa (mmol/l) 155.5±1.3 158.3±0.9 161.0±1.1 153.0±0.9 158.0±0.9 159.3±1.9
Posm (mOsm/kg H2O) 317±3 325±3 328±3 319±1 326±3 330±4
Renal hemodynamics
GFR (ml/min/1.73m2) 130±6 139±5 140±7 123±8 132±11 128±11
Osmolar clearance and fractional free water reabsorption
Cosm/GFR (%) 10.1±2.2 15.9±0.8 15.0±0.7 13.4±3.9 19.2±2.8 16.0±2.1
TcH2O/GFR (%) 0.5±0.4 -4.8±2.6 -2.5±2.4 -0.1±0.1 -6.8±2.2 2.8±4.3
Data are expressed as mean ± sem as measured for baseline over 4 periods, and for ANF
infusion and recovery over the last 40 minutes. Statistical analysis was not performed for
the test with hydropenia and saline loading since too few subjects were involved.
has been shown to induce a greater natriuretic response than in normotensive controls.
Moreover, the natriuretic effect of ANF was shown to correlate with blood pressure [21].
The first studies in EH used higher doses of ANF and showed an enhanced ANF-induced
natriuretic response in EH [11]. In that study ANF-induced natriuresis also was found to
correlate with the prevailing blood pressure level. We have found that the ANF-induced
natriuresis in EH is positively influenced by the blood pressure level even during the
infusion of very low doses of ANF [10]. Secondly, differences in sodium or volume
status may change the overall ANF-induced natriuresis. This possibility is supported by
our observation that ANF-induced natriuresis is enhanced at higher baseline levels of
urinary sodium excretion, in agreement with the literature on this topic [22,23]. Since
baseline urinary sodium excretion tended to be higher in EH under all four test
conditions, our observation of a similar natriuretic response in both groups again suggests
a relative hyposensitivity in EH to ANF. Therefore, in our opinion, as has been
hypothesized by others [19], the absence of an enhanced natriuretic effect in the presence
of a higher blood pressure suggests a relative hyporesponsiveness of EH to ANF. The
discrepancies between studies on the natriuretic effect of ANF in EH can be explained
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in terms of the clear differences in the dose of ANF, if it is hypothesized that a subtle
hyporesponsiveness of EH to ANF is overcome at higher doses.
As far as the natriuretic mechanism of action of ANF is concerned, this mechanism
appears to be complex, and glomerular as well as proximal and distal tubular effects of
ANF have been suggested [1-4,6,24]. In the present study we observed a small but
significant ANF-induced increase in GFR, which was similar in both groups under all
four test conditions. Other studies using low doses of ANF did not find that ANF
increased GFR [3,19,25], whereas in some studies using higher doses the ANF-induced
increases in GFR were not statistically significant [1,2,4]. An increase in GFR certainly
contributes to an increase in urinary sodium excretion and may even effect the
parameters of tubular sodium handling. For instance, we observed the ANF-induced
increase in CH2O correlated with the increase in GFR. However, in the low dose human
ANF studies, which showed no change in GFR, tubular effects of ANF are held to be
responsible for the observed urinary changes. The present study also supports the
possibility of there being tubular sites of action of ANF.
From the present study proximal as well as distal tubular actions of ANF may be
suggested to be involved in both NT and EH subjects. In favour of a distal tubular action
of ANF are the absence of an increase in urinary potassium excretion under all of the test
conditions, and the ANF-induced decrease in CH2O/(CH2O+CCl), an index of diluting
segment reabsorption and the increase in the minimal urinary osmolality during water
loading [14,15]. These findings are consistent with previous studies [4]. Both the absence
of an ANF-induced increase in urinary potassium excretion and the increase in minimal
urinary osmolality cannot be attributed to an increase in GFR. A distal tubular effect of
ANF is further supported by studies showing distal ANF receptors in animals as well as
in humans and animal micropuncture studies showing distal ANF effects [26-28]. The
absence of a kaliuretic effect may suggest an action at the inner medullary collecting duct
as suggested by Rabelink et al [4]. The main argument in favour of a proximal tubular
action of ANF is the observed increase in CH2O/GFR. This increase in CH2O/GFR
correlated with blood pressure and not with GFR, which suggests at least a
hemodynamically mediated ANF effect at a tubular site before the point of isotonicity.
Blood pressure related renal effects are shown to be mediated by changes in sodium
reabsorption in the proximal convoluted tubule [29,30] or the thin descending limb of
Henle [29,31], or both. Moreover, pressure-related natriuresis is associated with increases
in the medullary blood flow, and ANF has been shown in animal experiments to increase
the medullary blood flow. Our observation that ANF decreases urinary osmolality may
be in agreement with such an effect. Finally, we found that ANF decreased TcH2O/GFR.
Within the limits of this test, this suggests a medullary tubular site of action [14,15]. This
decrease in TcH2O/GFR did not correlate with the increase in GFR. Therefore, although
it remains hard to assess the significance of the possible effect of the observed increase
in GFR on the parameters of fractional free water clearance or reabsorption, we suggest
that the ANF-induced natriuresis is due to the combined effects of a small increase in
GFR and (direct or hemodynamically mediated) distal and proximal tubular sites of
action in humans.
The enhanced ANF-induced rise in CH2O/GFR in EH and the correlation with blood
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pressure suggest an enhanced delivery of sodium to the diluting segments in EH, which
is not, however, accompanied by an enhanced natriuresis. In addition, this enhanced
increase in CH2O/GFR in EH could be explained by an attenuated ANF effect at a distal
tubular site. Such an additional diminished distal action of ANF may then also explain
its similar natriuretic effect in EH. Interestingly, in Dahl salt-sensitive rats a
hyposensitivity to ANF has been found in the IMCD [13]. Moreover, a diminished ANF
immunoreactivity at distal tubular segments has been reported in hypertensive
patients [27], similar to that found in spontaneously hypertensive rats [26]. Such a distal
hyporesponsiveness to ANF could be a primary defect underlying the development of
hypertension, or an adaptive process to prevent sodium loss from (ANF-related) pressure
natriuresis. This cannot be concluded from the present study. Alternatively, other
mechanisms may be operative. For instance, the interpretation of the changes in
CH2O/GFR is based on the assumption that secretion of antidiuretic hormone is suppressed
[14]. If this was not achieved, then the results can be explained by an enhanced
inhibition of the action of antidiuretic hormone by ANF in EH. However, the water load
used in the present study was large. Moreover, we did not replace the voided urinary
volume. Since in EH the ANF-induced increase in urinary volume excretion tended to
be larger than in the normotensives, the enhanced increase in CH2O/GFR in EH is
probably underestimated. We therefore hypothesize that both the observed similar
natriuretic action of ANF in EH and the associated enhanced change in CH2O/GFR could
be explained by an enhanced (blood pressure related) delivery of sodium to the diluting
segments together with an impaired natriuretic response at more-distal tubular segments.
In conclusion, the present data show that the overall natriuretic response to ANF in
EH is similar to that in normotensive subjects during different states of volume loading.
The data suggest glomerular as well as proximal and distal tubular effects of action of
ANF. From these data an enhanced proximal and an impaired distal tubular action of
ANF in EH can be hypothesized.
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CHAPTER 7
ATRIAL NATRIURETIC FACTOR INFLUENCES
RENAL DIURNAL RHYTHM
IN ESSENTIAL HYPERTENSION





We investigated in six patients with essential hypertension the effect of a low dose
atrial natriuretic factor infusion for 5 days on the diurnal rhythm of renal electrolyte
excretion. Atrial natriuretic factor infusion increased the net excretion of sodium and
caused a delay in its time of maximal diurnal urinary excretion. Similarly, atrial
natriuretic factor caused an increase in the net excretion of chloride, calcium, and
magnesium and also changed the diurnal rhythms of these electrolytes. In contrast, atrial
natriuretic factor did not change the net excretion of potassium, phosphate, and uric acid,
nor did atrial natriuretic factor change the diurnal rhythms of these solutes. During
baseline, the time points of maximal urinary excretion of sodium and potassium
overlapped, whereas atrial natriuretic factor infusion caused sodium excretion to peak
2.2±0.3 hours (P<0.02) after the potassium excretion peak. During baseline, the time of
maximal urinary excretion of sodium did not correlate with the time of highest blood
pressure, whereas it correlated negatively with mean plasma aldosterone concentration.
In contrast, during atrial natriuretic factor infusion the time of maximal urinary excretion
of sodium correlated positively with the time of highest blood pressure, whereas it did
not correlate with mean plasma aldosterone concentration. These data suggest that atrial
natriuretic factor is involved with the diurnal rhythm of the urinary excretion of sodium





Renal sodium handling has been found to be abnormal in patients with essential
hypertension (EH). One example is the exaggerated natriuresis in EH after volume
loading [1]. Also the diurnal time of maximal urinary sodium excretion has been reported
to be different in patients with EH compared with normotensive subjects [2]. In
normotensive subjects maximal urinary sodium excretion occurs later than maximal
potassium excretion [3]. In patients with EH this relation has not yet been investigated.
Since atrial natriuretic factor (ANF) is known to be released during volume expansion
[4] and may give rise to an enhanced natriuresis in EH [5], we investigated in patients
with EH the relation between the time of maximal diurnal urinary sodium and potassium
excretion as well as the effects of low (physiological) dose ANF infusion on this relation.
SUBJECTS AND METHODS
Six male patients (mean age, 51±4 years) with uncomplicated EH (blood pressure,
160±5/101±1 mmHg; mean±SEM) were enrolled in the study. The study protocol was
approved by the hospital’s Medical Ethical Committee, and all patients gave informed
consent. Patients were placed on a diet that contained 150 mmol sodium per day and
were asked to discontinue any medication for at least 6 weeks before the study. The
patients were then admitted to our metabolic ward for a 14-day period, where they held
absolute bed rest except for urine voiding and bathroom facilities (8 to 8:30 AM). They
received a rhythm diet consisting of equal amounts of sodium (156 mmol/day), potassium
(90 mmol/day), and fluids (1,800 ml/day) every 4 hours during the whole study. In
addition, they were continuously infused with 32 ml/hour dextrose 5% (to ensure
adequate diuresis) and 2 ml/hour solvent (with or without ANF). The first 3 days were
used for equilibration. The next 3 days were used to measure baseline values. Baseline
sodium excretion was 154±10 mmol/24 hour, equal to the daily sodium intake. The
baseline period was followed by a 5-day ANF infusion period, during which synthetic
human ANF (101-126, MSD-RL, Rahway, New Jersey, USA) dissolved in 5 g mannitol
per 100 ml was infused at a dose of 0.2 µg/min. Recovery measurements were performed
during the last 3 days. During all periods blood pressure was recorded every 15 minutes
with an automatic noninvasive device (Dinamap®, Critikon Inc, Tampa, Florida, USA).
Mean arterial pressure (MAP) was calculated as two thirds diastolic plus one third
systolic blood pressure. Urine collection was performed every 4 hours for analysis of the
urinary excretion of sodium (UNaV), chloride (UClV), potassium (UKV), calcium (UCaV),
phosphate (UPhosV), magnesium (UMgV), and uric acid (UuaV). Blood was sampled every
4 hours during all study days before urine voiding for measurement of immunoreactive
ANF (irANF). To minimize the amount of blood withdrawal, blood samples for
determination of the diurnal rhythms of glomerular filtration rate (GFR), plasma renin
activity (PRA), and plasma aldosterone concentration (PAC) were only taken every 4
hours during the last 24 hours of each period. Each time that blood was drawn, an
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equivalent amount of sodium and chloride was administered intravenously.
Urinary electrolyte concentrations were measured using standard autoanalyzer
techniques (Technicon Instr Corp, Tarrytown, New York, USA). Blood samples for
measurement of irANF, PRA, and PAC were collected in prechilled EDTA tubes and
immediately centrifuged, and the plasma was stored at -25° C to process all samples of
one patient simultaneously. irANF was determined after extraction on a Sep-Pak C18
cartridge (Waters, Milford, Massachusetts, USA) using a commercially available 125I-ANF
tracer and a highly specific ANF antibody (INCSTAR, Stillwater, Minnesota, USA) [6].
PRA and PAC were measured by radioimmunoassay [7,8]. GFR was measured using
continuously infused 125I-iothalamate [9].
The rhythm characteristics for plasma irANF, all urinary parameters, MAP, GFR,
PRA, and PAC of each patient were determined by a computer program fitting the best
sinusoidal graph with a 24-hour periodicity and a linear component to the data using the
method of least squares, as described by Koopman et al [10]. The sinusoid was fitted to
the data of the 3 baseline days, the last 3 days of the ANF infusion period, and the last
2 days of the recovery period. With respect to GFR, PRA, and PAC, the sinusoid was
fitted to the data measured at the last day of each period. The rhythm was considered
significant if the sinusoid fitted the data better than a straight line (variance ratio F test;
p<0.05). From the fitted sinusoid two typical parameters were derived describing the
rhythm characteristics: the acrophase as the time of the maximum value of the sinusoid
and the amplitude of the sinusoid as percentage of the mean (A/M). To study the effects
of ANF infusion on these parameters, a significant rhythm had to be present in all
patients before, during, and after ANF infusion. All data are given as mean±SEM.
Statistical analysis for the effects of ANF infusion was done by analysis of variance with
a repeated measurement design followed by Duncan’s multiple range test and by
Pearson’s correlation coefficient for correlation between variables. Differences were
considered statistically significant at p<0.05.
RESULTS
ANF infusion resulted in an immediate increase in plasma irANF from 49±10 to
110±20 pg/ml (Table 1). Within 4 hours after the start of ANF infusion UNaV, UClV,
UCaV, and UMgV increased compared with baseline. Net cumulative negative balances for
these urinary electrolytes after 48 hours of ANF infusion were: 72±15 mmol for sodium
(p<0.01), 60±12 mmol for chloride (p<0.01), 1.42±0.39 mmol for calcium (p<0.01), and
0.42±0.17 mmol for magnesium (p<0.05). The increase in absolute amounts of UNaV
during the first 4 hours of ANF infusion tended to correlate with preinfusion values of
MAP (r=0.67, p<0.1). In contrast, ANF infusion did not induce changes in UKV, UPhosV,
and UuaV compared with baseline. MAP started to decrease gradually 12 hours after the
onset of the ANF infusion. After 40 hours, MAP had decreased by 11.8±1.4 mmHg
(p<0.01) and did not decrease any further [6]. At that time, the urinary excretion of all
solutes matched baseline values again. No changes were observed in the mean values of
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TABLE 1. Immunoreactive atrial natriuretic factor, urinary solute excretion, and mean
arterial pressure calculated from data of three baseline days, first two and last three days
of atrial natriuretic factor infusion, and the last two recovery days.
Parameter Baseline ANF (0-48 hr) ANF(48-120 hr) Recovery
irANF (pg/ml) 49±10 110±20*** 106±19*** 41±11
Sodium (mmol/4 hr) 26.2±1.6 31.6±1.4*** 25.3±1.2 26.2±2.4
Chloride (mmol/4 hr) 25.0±1.4 29.5±1.0** 24.2±1.1 25.2±1.9
Potassium (mmol/4 hr) 11.8±0.6 10.5±0.4 11.0±0.4 12.3±0.3
Calcium (mmol/4 hr) 0.97±0.18 1.09±0.19* 0.98±0.17 0.93±0.17
Phosphate (mmol/4 hr) 3.78±0.20 3.64±0.17 3.62±0.10 3.83±0.11
Magnesium (mmol/4 hr) 0.68±0.05 0.72±0.05* 0.67±0.08 0.63±0.07
Uric acid (mmol/4 hr) 0.70±0.03 0.70±0.01 0.74±0.02 0.77±0.02
MAP (mmHg) 105±3 98±3** 93±2*** 97±4**
GFR (ml/min/1.73 m2) 90±3 ... 89±2 87±3
PRA (nmol/l/hr) 0.52±0.07 ... 0.64±0.08 0.63±0.11
PAC (nmol/l) 0.21±0.02 ... 0.23±0.03 0.23±0.02
Values are mean±SEM. Mean of glomerular filtration rate (GFR), plasma renin activity
(PRA), and plasma aldosterone concentration (PAC) were each calculated over the last day
of each period. ANF, atrial natriuretic factor; irANF, immunoreactive ANF; MAP, mean
arterial pressure.
* P<0.05, ** P<0.025, *** P<0.01 versus baseline.
GFR, PRA, or PAC during ANF infusion. Thus, during the last 3 days of ANF infusion
all variables except plasma irANF and MAP equaled baseline values again. After
cessation of ANF infusion, plasma irANF returned to preinfusion values, whereas the
negative cumulative balances for all electrolytes were compensated for by retention of
these electrolytes. MAP only recovered slowly [6].
Significant circadian rhythms were found for the urinary excretion of sodium (at least
p<0.025, p<0.005, and p<0.025 in each individual during baseline, ANF infusion, and
recovery, respectively), chloride (p<0.025, p<0.025, and p<0.01), potassium (p<0.001,
p<0.001, and p<0.025), calcium (p<0.01, p<0.05, and p<0.05), phosphate (p<0.05,
p<0.05, and p<0.05), magnesium (p<0.025, p<0.05, and p<0.05), and uric acid (p<0.01,
p<0.05, and p<0.025). Figure 1 shows a "typical" example of the fitting of the sinusoid
for diurnal UNaV and UKV. MAP was also found to have a significant circadian rhythm
(at least p<0.025, p<0.005, and p<0.05 in each individual during baseline, ANF infusion,
and recovery, respectively). A significant circadian rhythm of plasma irANF in the
individual patients was present in only two of the six patients during baseline and in one
(other) patient during ANF infusion. A significant rhythm for GFR was found in all
individual patients (at least p<0.05 in each individual during baseline, ANF infusion, and
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ANF
sodium (UNaV) and potassium (UKV) in a patient with essential hypertension before, during, and after
a 5-day infusion of 0.2 µg/min atrial natriuretic factor (ANF) (solid lines). Data and sinus curves are
plotted only for the last 3 days of the ANF period and the last 2 recovery days. Dotted line is
extrapolated from the sinusoid of the baseline days.
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TABLE 2. Time of maximum value and amplitude as percentage of the mean of urinary
solute excretion and mean arterial pressure.
Parameter Baseline ANF Recovery
Acrophase (hour)
Sodium 11.9±1.3 14.6±0.6** 10.9±1.2
Chloride 11.5±1.1 13.3±0.8** 11.0±1.0
Potassium 12.1±0.7 12.4±0.6 11.4±0.8
Calcium 8.8±0.7 10.5±0.7*** 10.2±1.1
Phosphate 20.3±0.8 19.5±0.4 19.4±1.2
Magnesium 7.3±0.9 7.5±0.6 8.1±0.8
Uric acid 11.3±0.8 11.3±0.5 10.8±0.9
MAP 16.3±0.5 16.4±0.8 15.8±0.5
GFR 12.5±0.7 12.5±1.8 11.8±0.8
A/M (%)
Sodium 33.1±5.9 33.9±6.8 31.2±6.2
Chloride 40.5±6.5 39.7±7.0 41.4±7.2
Potassium 51.1±8.8 48.0±6.7 45.8±6.8
Calcium 32.3±5.4 26.6±6.5 34.9±6.6
Phosphate 21.3±4.5 19.8±3.2 15.5±3.9
Magnesium 23.2±3.1 16.0±4.2* 22.6±3.6
Uric acid 19.4±3.1 15.9±3.0 17.5±1.9
MAP 5.8±0.7 7.8±0.4 5.3±1.0
GFR 5.2±0.6 4.5±0.7 4.2±0.2
Values are mean±SEM as derived from a significant sinusoid fit over the data of the 3
baseline days, the last 3 atrial natriuretic factor infusion days, and the last 2 recovery days
and for glomerular filtration rate over the last day of each period.
ANF, atrial natriuretic factor; MAP, mean arterial pressure; GFR, glomerular filtration
rate; A/M, amplitude as percentage of the mean.
* P<0.05, ** P<0.025, *** P<0.01 versus baseline.
recovery), whereas no rhythm was found for individual values of PRA and PAC.
Interestingly, during ANF infusion only the rhythm characteristics were changed
significantly in those electrolytes in which the excretion had increased during the first
days of ANF infusion, i.e., sodium, chloride, calcium, and magnesium (Table 2). During
ANF infusion a time shift was found in the acrophases of UNaV (p<0.025), UClV
(p<0.025), and UCaV (p<0.01) and a decrease in the amplitude of UMgV (p<0.05) in all
individual patients. In contrast, the rhythm characteristics of UKV, UPhosV, and UuaV did
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Figure 2. Individual data of the differences
between the time points of maximal diurnal
urinary sodium and potassium excretion
derived from a significant sinusoid fit
(acrophase UNaV-UKV) before, during, and
after a 5-day infusion of 0.2 µg/min atrial
natriuretic factor (ANF).
relation between the acrophases of UNaV and UKV; during baseline the acrophases of
UNaV and UKV coincided, but during ANF infusion the acrophase of UKV preceded that
of UNaV in all individual patients (Figure 2, p<0.02). Remarkably, the shift was greatest
in those patients in whom baseline acrophase was earliest (r=-0.91, p<0.02). The shift
in the difference between the acrophases of UNaV and UKV correlated with mean plasma
irANF reached during ANF infusion (Figure 3, r=+0.92, p<0.01). Omitting the subject
with the highest irANF level during ANF infusion, the correlation persisted (r=+0.79,
p<0.05). For UClV a similar correlation was found (r=+0.87, p<0.02). During ANF
infusion the acrophase of UNaV correlated with the acrophase of MAP (r=+0.83, p<0.05),
whereas such a relation was absent during baseline (r=0.42, p>0.1). Thus, MAP may
have had a greater influence on urinary sodium excretion during ANF infusion than
during baseline. In contrast, mean PAC correlated negatively with the acrophase of UNaV
before ANF infusion (r=-0.82, p<0.05), whereas this relation was absent during ANF
infusion (r=-0.65, p>0.1). During recovery, the acrophases of UNaV and UClV, and the
amplitude of UMgV returned to baseline (Table 2, Figure 2).
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Figure 3. Scatterplot shows relation between plasma immunoreactive atrial natriuretic factor (PirANF)

























induced by ANF infusion and the change in the difference between the time points of maximal diurnal
urinary sodium and potassium excretion (acrophase UNaV-UKV). Solid line represents the correlation for
all individuals (r=+0.92, p<0.01) and dashed line that for all individuals except the one with the highest
plasma irANF level (r=+0.79, p<0.05).
DISCUSSION
The present baseline data show that in our EH subjects, the acrophases of UNaV and
UKV coincide, whereas during low dose ANF infusion these acrophases dissociate. Data
in the literature on diurnal rhythms are scarce. However, it is known that in normotensive
subjects, the acrophase of UKV precedes that of UNaV [3]. Moreover, Kawasaki et al [2]
showed that the acrophase of UNaV rhythm in patients with EH occurs earlier than in
normotensive subjects, whereas the acrophase of UKV is similar in these groups. As such,
our baseline data are comparable with those in the literature. We observed a wide
variation in these diurnal rhythms despite careful standardization. We found that the
ANF-induced shift was greatest when baseline acrophase was earliest. Thus, an
underlying difference in individual diurnal rhythm may contribute to the reported wide
variation in effects of ANF between individuals [11].
The intriguing result of the present study is that we found that the acrophase of
sodium rhythm shifted during continuous low dose ANF infusion (which only doubled
irANF levels), whereas potassium rhythm was unaffected. Thus, during ANF infusion
UKV acrophase preceded that of UNaV in all EH patients, whereas it did not during
baseline. Although this study was not placebo controlled, we interpret the shift in sodium
acrophase to be due to the effect of ANF infusion. We observed changes in the rhythm
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characteristics of other electrolytes besides sodium (chloride, calcium, and magnesium).
All of these parameters were affected in their net cumulative excretion during the first
48 hours of ANF infusion. In contrast, no rhythm changes were observed in those solutes
that were unaffected in their excretion by ANF infusion, such as UKV. Our results on net
cumulative excretion are in agreement with studies showing that short-term ANF infusion
also enhances the absolute urinary excretion of sodium, chloride, calcium, and
magnesium, whereas the excretion of potassium is not affected [12]. Moreover, all the
changes in rhythms were reversed during the recovery period, and the changes in irANF
levels and the shifts in the acrophases of UNaV and UClV correlated.
It is difficult to explain how ANF shifted the acrophase of UNaV in our patients with
EH. Although the effect of ANF on the many mechanisms suggested to underlie diurnal
excretory rhythms cannot be evaluated from this study, the present data are compatible
with an important role for the influence of blood pressure and aldosterone (PAC) on
ANF-induced sodium excretion. Richards et al [5] showed the influence of blood pressure
on the short-term natriuretic effect of ANF. Although in the present study this relation
only reached borderline significance, the present data on rhythmic parameters show this
influence of blood pressure on ANF-induced changes in UNaV in another way: during
ANF infusion the acrophases of blood pressure and UNaV correlated significantly,
whereas this relation was absent during baseline. Moreover, we showed that net sodium
excretion returned to baseline levels during ANF infusion as blood pressure decreased.
This is in agreement with data on short-term ANF infusion showing a decrease in
ANF-induced sodium excretion as blood pressure decreases [13,14]. Animal studies have
shown that ANF may decrease preglomerular vessel tone [15]. ANF infusion thus could
render the (vasoconstricted) hypertensive kidney more sensitive to systemic blood
pressure rhythm through preglomerular vasodilation, thereby shifting the acrophase of
UNaV toward that of blood pressure. However, this hypothesized mechanism cannot
explain the absence of a shift in the rhythm of UKV. The observed negative correlation
between UNaV and PAC during baseline and the absence of this relation during ANF
infusion conditions is in favor of a role for PAC in the modulation of ANF-induced
natriuresis, as suggested by others [16], and may contribute to the dissociation of the
effects of ANF on UNaV and UKV. Also a direct (tubular) effect of ANF may underlie
the observed correlation of irANF levels and shift in the acrophase of sodium excretion.
The present data do not support a significant role for changes in GFR in ANF-induced
natriuresis.
In summary, we showed that low dose ANF infusion significantly changes the
absolute amounts and diurnal rhythms of the UNaV, UClV, UCaV, and UMgV in patients
with essential hypertension. Moreover, the present data suggest that ANF-induced
natriuresis in humans is mediated in part by blood pressure and aldosterone. ANF may
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CHAPTER 8
ATRIAL NATRIURETIC FACTOR-INDUCED DECREASES
IN RENAL BLOOD FLOW IN MAN:
Implications for the natriuretic mechanism
Wilbert MT Janssen, Dick de Zeeuw, Gjalt K van der Hem, and Paul E de Jong




We studied the effect of a low-dose infusion of atrial natriuretic factor (ANF) on
renal blood flow in healthy volunteers. We additionally investigated the effect of ANF
on renal hemodynamic function and on urinary sodium excretion. ANF induced a rise in
hematocrit and a slight increase (but no decrease) in the renal extraction of hippuran.
These changes did not offset the observed fall in effective renal plasma flow. Renal
blood flow thus truly decreased and renal vascular resistance increased. Atrial natriuretic
factor induced an increase in glomerular filtration rate and a decrease in urinary
osmolality in the first hour of ANF infusion, whereas absolute and fractional sodium
excretion increased significantly only in the second hour of ANF infusion. The decrease
in urinary osmolality in the first hour of ANF infusion correlated with the induced
natriuresis. The changes in urinary osmolality and sodium excretion both correlated with
the changes in plasma immunoreactive ANF levels. These data indicate that ANF may
cause a decrease in renal blood flow and an increase of renal vascular resistance in man.
Our results suggest a role for ANF-induced (intra)renal hemodynamic changes in ANF-





The renal effects of atrial natriuretic factor (ANF) have been studied extensively since
the discovery of this hormone (for review see [1]). Although most studies agree on the
distinct natriuretic properties of ANF, the renal hemodynamic effects and the mechanism
of the natriuretic response are still debated. Increases in glomerular filtration rate (GFR)
are frequently observed, although GFR is also reported to remain unchanged [1]. ANF-
induced alterations in renal blood flow (RBF) are most inconsistent [1]. Experiments in
vitro have shown that ANF relaxes vascular smooth muscle (for review see [2]). The
renal artery seems to be particularly sensitive to the vasodilatory action of ANF [2].
Experiments in vivo in different animal species have also demonstrated the vasodilatory
action of ANF on the renal artery [3-5]. Some investigators, however, found no change
or even a decrease in RBF [6]. Interestingly, in man several studies have consistently
shown that ANF decreases effective renal plasma flow (ERPF) estimated from the renal
clearance of continuously infused hippuran [7-10]. However, ERPF does not directly
reflect true RBF, since the transformation of ERPF to RBF involves correction for
hematocrit and for the renal extraction of hippuran (Ehip). ANF has been shown to
increase hematocrit [7]. Moreover, many vasoactive drugs have been demonstrated to
interact with Ehip [11,12], and it is not yet known what effect ANF may have on this
renal extraction. We and others therefore suggested that the observed decrease in ERPF
may not represent a decrease in true RBF [7-9]. As far as the mechanism by which ANF
induces natriuresis is concerned, many investigators suggested that this is largely
accounted for by the ANF-induced renal hemodynamic changes [5,7,9,13,14].
We therefore investigated, first, the effect of a low-dose infusion of ANF on RBF by
studying the ANF-induced changes in hematocrit and Ehip, and secondly, the effect of a
2 hour low-dose infusion of ANF on the relation between ANF-induced changes in renal
hemodynamic function and urinary sodium excretion.
SUBJECTS AND METHODS
Seven normotensive volunteers (five female and two male, age 22±1 years, systolic
blood pressure 122±3 mmHg and diastolic blood pressure 74±2 mmHg) were enrolled
in the study on RBF and Ehip (study 1), and nine normotensive subjects (four female and
five male, age 22±1 years, systolic blood pressure 120±3 mmHg and diastolic blood
pressure 68±3 mmHg) in the study on renal function and urinary sodium excretion (study
2). None of the subjects used medication. For at least 2 weeks before the studies the
subjects adhered to a 200 mmol sodium diet (24-hour urine collection: 175±18 and
192±15 mmol of sodium, respectively). The protocols were approved by the local
Medical Ethical Committee, and all subjects gave their informed consent.
Study 1
The study was started at 8 AM with an intravenous infusion of 131I-hippuran. Then the
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right renal vein was catheterized. The position of the catheter was checked radiologically
as well as with So2 measurements each time before taking blood samples. Finally, a
catheter was introduced into the right ulnar artery. Intra-arterial pressure was
continuously recorded with a pressure transducer and amplifier (HP1280C and HP8805B;
Hewlett Packard, Waltham, Massachusetts, USA). After a 2 hour run-in period,
measurements were started: at an interval of 15 minutes arterial and renal venous blood
samples were taken simultaneously for measurement of hippuran, hematocrit, and
immunoreactive ANF (irANF). Blood samples for measurement of hippuran (and irANF)
were taken in pre-chilled ethylenediaminetetra-acetate tubes and immediately centrifuged.
After three baseline measurements an intravenous infusion of 1 µg of ANF/min (human
ANF (101-126), MSD-RL, Rahway, New Jersey, USA) was started for 1 hour, followed
by a 1 hour recovery period.
Study 2
The study was started at 8 AM with an intravenous infusion of dextrose 5% at a rate
of 100 ml/hour. Simultaneously, a continuous infusion of 125I-iothalamate and
131I-hippuran was started for measurement of GFR and ERPF, respectively. The subjects
held absolute bedrest until the end of the study, except that they stood to void every
hour. All adhered to a diet, consisting of an oral fluid intake of 125 ml every hour and
a sodium intake of 17 mmol of NaCl every 2 hours. Mean arterial pressure (MAP) was
recorded every 2 minutes with an automatic non-invasive device (Dinamap®, Criticon Inc,
Tampa, Florida, USA). From 10 AM until noon baseline values were measured, followed
by measurements during an intravenous infusion of 1 µg of ANF/min for 2 hours and a
2 hour recovery period. Blood samples for measurement of sodium, 131I-hippuran, and
125I-iothalamate were drawn from the cubital vein every hour, and for measurement of
irANF at the end of each period.
Analysis
Sodium in urine and plasma was measured using standard autoanalyzer techniques
(Technicon Instruments Corp, Tarrytown, New York, USA), and urinary osmolality by
depression of the freezing point (Osmomat-030; Gonotec GmbH, West Berlin, FRG).
Hematocrit was measured with a Coulter Counter S-plus (Coulter Electronics Inc,
Hialeah, Florida, USA). 131I-hippuran and 125I-iothalamate radioactivities in urine and
plasma were determined in duplicate by photopeak selection in an universal gamma-
counter (1282 Compugamma; LKB-Wallac, Turku, Finland). IrANF in plasma was
measured as previously described [9].
Renal clearances were calculated using standard formulae. Plasma concentrations used
for the clearance calculations were the average of the values obtained at the beginning
and the end of each clearance period. ERPF was calculated in both studies with the
continuous infusion method and GFR with the standard method, corrected for incomplete
collection of urine as previously described [15]. Ehip and renal extraction of irANF (EANF)
were calculated as (A-V)×A-1, where A and V are plasma concentrations of hippuran or
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Figure 1. Effective renal plasma flow (ERPF,
panel A), hematocrit (panel B), and renal
extraction of hippuran (Ehip, panel C) before,
during, and after infusion of ANF (1 µg/min).











































Figure 2. Renal blood flow (RBF, panel A), and
renal vascular resistance (RVR, panel B) before,
during, and after infusion of ANF (1 µg/min).
Data are expressed as mean±SEM, *=p<0.05 vs
baseline.
ERPF×(Ehip×(1-hematocrit))-1, and renal vascular resistance (RVR) as MAP×RBF-1.
All results are expressed as mean±SEM. Statistical analysis was performed by analysis
of variance with repeated measurements followed by Student’s paired t-test and by
Pearson’s correlation coefficient for correlation between variables. Differences were
considered significant when p<0.05.
RESULTS
Study 1
In this study we estimated the effect of ANF on RBF from the simultaneous
measurement of ERPF, hematocrit, and Ehip, before, during, and after infusion of 1 µg of
ANF/min for 1 hour. Arterial plasma levels of irANF showed a significant five-fold
increase during ANF infusion from 56.2±5.2 to 263.5±44.4 pg/ml (p<0.002) and returned
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to baseline during recovery (52.9±5.2 pg/ml). MAP did not change during ANF infusion
(90.7±3.1 mmHg vs 91.0±2.4 mmHg during baseline and ANF infusion, respectively).
Figure 1 shows the ANF-induced changes in ERPF, hematocrit, and Ehip. ERPF decreased
significantly from 490±25 to 429±19 ml/min/1.73m2 (p<0.005, mean of the
measurements at 30, 45, and 60 min). Hematocrit rose significantly from 38.5±1.5 to
40.6±1.5 % (p<0.001). Interestingly, Ehip did not decrease, but increased slightly from
77.8±1.1 to 79.1±1.1 % (p<0.02). The changes in hematocrit and Ehip did not offset the
observed fall in ERPF. RBF thus decreased significantly, from 1038±81 to 926±73
ml/min/1.73m2 (p<0.02, Figure 2A). Since MAP did not change, RVR increased during
ANF infusion, from 0.092±0.010 to 0.102±0.008 mmHg.ml-1.min-1.1.73m-2 (p<0.02,
Figure 2B). All these changes were already 15 present minutes after the beginning of the
ANF infusion and were maximal after 30 minutes. The absolute as well as percentage
change in Ehip correlated significantly with the changes in ERPF (r=-0.82 and r=-0.86,
respectively, p<0.01) or RBF(r=-0.91 and r=-0.92, respectively, p<0.01). No correlation
was found between 24-hour sodium excretion and changes in ERPF or RBF. Plasma
irANF levels in the renal vein were 33.8±1.2 pg/ml and increased during ANF infusion
to 78.8±7.6 pg/ml (p<0.001). EANF was therefore 37±6 %, similar to values reported
before [16]. Interestingly, but unexpectedly, EANF was higher (61±10%) during ANF
infusion (p<0.01). This may be explained by the fact that exogenous synthetic ANF is
handled differently by the kidney compared with the endogenous protein. During
recovery all parameters returned towards baseline.
Study 2
Table 1 summarizes the results of this study on the relation between ANF-induced
changes in renal function and urinary sodium excretion. MAP did not change. Plasma
levels of irANF increased significantly during ANF infusion (p<0.002) and returned to
baseline during recovery. The ANF-induced changes in renal function were already
present in the first hour of ANF infusion: ERPF decreased (p<0.02) and GFR increased
(p<0.01) significantly. ERPF decreased to a level similar to that observed in the first
study. Urinary osmolality showed a significant (p<0.02) decrease, particularly in the first
hour of ANF infusion, and returned to baseline during the recovery period. Absolute and
fractional sodium excretion, in contrast, increased significantly only in the second hour
of ANF infusion (p<0.02). The percentage increase in plasma levels of irANF correlated
significantly with the decrease in urinary osmolality in the first hour of ANF infusion
(r=-0.78, p<0.05, Figure 3A). Interestingly, a significant correlation (r=-0.71, p<0.05)
was also observed between the change in urinary osmolality in the first hour of ANF
infusion and the induced natriuresis during the 2 hours of ANF infusion: the more
osmolality decreased the more sodium was excreted (Figure 3B). Figure 3C shows the
correlation between the percentage changes in irANF and the increase in sodium
excretion (r=+0.90, p<0.01). None of these changes correlated significantly with the 24-
hour sodium excretion. During recovery all parameters returned to baseline.
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TABLE 1. MAP, plasma levels of immunoreactive atrial natriuretic factor (irANF), renal
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function, diuresis (UVol), urinary osmolality (Uosm), urinary sodium excretion (UNaV), and
fractional sodium excretion (CNa/GFR), during baseline and in the first and second hour
during and after a 2 hour infusion of ANF (1µg/min).
Baseline ANF Recovery
Time (min)... -120-0 0-60 60-120 120-180 180-240
MAP (mmHg) 84.5±2.2 83.1±1.7 82.2±2.0 82.3±1.6 82.9±2.2
Plasma irANF (pg/ml) 38±4 - 248±54* - 47±8
ERPF (ml/min/1.73m2) 507±27 464±21* 445±22* 461±20* 491±19
GFR (ml/min/1.73m2) 117±3 120±3* 121±3* 116±4 115±3
Filtration fraction (%) 23±1 26±1* 28±1* 26±1* 24±1
UVol (ml/hour) 230±35 330±34* 307±37 137±14 156±32
Uosm(mosmol/kg H2O) 311±70 179±32* 237±42 387±48 370±43
UNaV (mmol/hour) 8.7±1.4 10.1±1.0 13.3±1.6* 11.4±0.9* 9.1±0.9
CNa/GFR (%) 0.83±0.11 0.98±0.10 1.28±0.17* 1.12±0.08* 0.86±0.08
Values are given as mean±SEM. Statistical significance: * p<0.05 compared with
baseline values.
Figure 3. Relation between the percentage change in plasma levels of irANF (∆ANF) and the percentage
change in urinary osmolality (∆Uosm) in the first hour of ANF infusion compared with baseline (panel
A; r=-0.78, p<0.05). Relation between the percentage change in urinary osmolality (∆Uosm) in the first
hour of ANF infusion and the percentage change in urinary sodium excretion (∆UNaV) during ANF
infusion (panel B; r=-0.71, p<0.05). Relation between the percentage change in plasma levels of irANF




The present study shows that the observed decrease in ERPF during a low-dose
infusion of ANF (1 µg/min) in normotensive subjects indicates a true decrease in RBF.
It is further shown that the renal hemodynamic responses, consisting of a decrease in
RBF and an increase in GFR and filtration fraction, coincide with a decrease in urinary
osmolality and precede the increment in urinary sodium excretion.
Animal data on the effects of ANF on renal vasculature in vivo are conflicting.
Although many investigators have found that ANF induces increases in RBF and/or
decreases in RVR [3-5], some workers reported that after an initial increase ANF causes
RBF to decrease [14]. Thus far, most studies in man found a decrease in ERPF estimated
from the continuous infusion of hippuran [7-10]. We and others thus hypothesized that
the renal extraction of hippuran during ANF infusion may be decreased, thus influencing
the accuracy of the measurement [7-9]. However, the renal extraction of hippuran during
ANF infusion did not decrease but rather increased, in agreement with data on ANF-
induced changes in hippuran extraction in anaesthetized dogs [14]. Thus, we found RBF
to be truly decreased, and RVR to be increased already at 15 minutes of ANF infusion,
while the maximum response was present at 30 minutes. However, we cannot exclude
a transient increase in RBF within the first 15 minutes of ANF infusion. The mechanism
of this renal vasoconstrictor response to ANF in humans is as yet unknown. Sosa et al
[5] suggested that ANF exerts a partial agonist action, causing constriction in dilated
vessels and dilatation in constricted vessels. The present study was performed using a
relatively high sodium intake, which may have induced some renal vasodilation.
However, we found that ANF induced a decrease in ERPF also in hypertensive patients
with a low initial ERPF, both during a 200 and a 50 mmol sodium intake [10,17]. In the
present study, moreover, no correlation was found between the 24-hour sodium excretion
and changes in ERPF. Also the increase in hematocrit as observed in this and other
[7,18] studies in man may lead to an indirect decrease in RBF because of the induced
higher viscosity [19]. Finally, the combination of an afferent vasodilator and efferent
constrictor effect [3] can explain the observed decrease in ERPF together with the
increase in GFR.
The observed changes in GFR, ERPF and urinary osmolality preceded the increase
in urinary sodium excretion. As such this has not been reported to date. The finding of
a delayed onset of ANF-induced natriuresis is in agreement with the studies of Richards
et al [18], Anderson et al [20] and Biollaz et al [21]. The mechanism of the ANF-
induced natriuresis is still unknown. The observed time-courses of the different factors
which may underlie the ANF-induced increase in sodium excretion, could have some
implications in this respect. GFR rose about 3% and had nearly reached its maximum in
the first hour. Although sodium excretion did increase somewhat in the first hour, the
major rise was observed in the second hour. Thus, the small rise in GFR may have
contributed in part to the ANF-induced natriuresis; however, it does not seem to explain
sufficiently the distinct rise in sodium excretion in the second hour of ANF infusion.
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Moreover, an ANF-induced natriuresis is not always accompanied by a rise in GFR
[18,20,21]. Others have suggested that a washout of the medullary interstitium, possibly
through changes in (intra)renal hemodynamics, underlies the ANF-induced natriuresis
[5,14,22]. Particularly, the combination of a medullary washout with a (small) increase
in GFR is known to increase sodium excretion [23]. Therefore, it may be of interest that
the changes in renal hemodynamics during ANF infusion in the present study coincided
with a decrease in urinary osmolality. Such a fall in urinary osmolality has also been
observed by others [5,7,9,14,24] and could well support the idea of a washout. In
addition, we found that the decrease in urinary osmolality induced in the first hour of
ANF infusion correlated with the degree of natriuresis. This may support the view that
the natriuresis is (in part) secondary to a hemodynamically mediated washout of the
medullary interstitium. However, a dissipation of the medullary gradient through losses
of solute through the urinary space [24] cannot be excluded by the present data.
Alternatively, or additionally, ANF has been suggested to have proximal as well as distal
tubular sites of action in man [25], and the delayed increase in urinary sodium excretion
may be explained by the time needed for ANF to penetrate to these tubular sites of
action or for the formation of second messengers.
In conclusion, the present data show that ANF, unlike other natriuretic substances,
may induce directly and/or indirectly a decrease in RBF and an increase in RVR in man.
The induced changes in renal hemodynamics coincide with a decrease in urinary
osmolality and precede the increase in urinary sodium excretion. These data therefore
suggest a role for ANF-induced (intra)renal hemodynamic changes in ANF-induced
natriuresis.
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OF INTRARENAL BLOOD FLOW DISTRIBUTION USING A
KINETIC MODEL OF RENAL 123I-HIPPURAN HANDLING
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A new technique for non-invasive measurement of intrarenal blood flow
distribution over cortex and medulla is proposed. The technique involves analysis of
123I-hippuran renography according to a kinetic model, which describes the flow of
123I-hippuran from the heart (input) through the renal cortex and medulla to the
bladder (output). The method is validated and compared to the standard microsphere
injection technique in anesthetized dogs. Changes in intrarenal blood flow distribution
were induced by infusion of placebo (n=6), angiotensin-I (n=5), or atrial natriuretic
factor (n=5). Baseline percentage medullary blood flow in the left kidney was 12±1 %
of total renal blood flow measured with microspheres, and 15±1 % with renography.
During infusion of placebo medullary blood flow decreased slightly as compared to
baseline as measured with both methods by 2±6 % (mean difference of paired
measurements, microspheres) and 1±8 % (renography). Infusion of angiotensin-I
caused a marked fall in medullary blood flow by 42±11 % (microspheres) and
57±8 % (renography). In contrast, infusion of atrial natriuretic factor caused a small
rise in medullary blood flow as measured with both methods (9±3 % and 12±11 %,
respectively). The absolute and percent changes in medullary blood flow measured
with renography correlated with those measured with microspheres (left kidney:
r=0.67, p=0.005, and r=0.71, p=0.003, respectively; right kidney r=0.62, p=0.01, and
r=0.68, p=0.004, respectively).
We conclude that the results of our pilot study suggest that the proposed kinetic
model of renal 123I-hippuran handling probably can be used to measure changes in
intrarenal blood flow distribution, and because of its non-invasive character, may be
of use in clinical studies.
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INTRODUCTION
Total renal blood flow (RBF) is considered to consist of a cortical and a
(complementary) medullary part. The cortical flow (CBF) and medullary flow (MBF)
each supply another nephron population with different functional characteristics.
Measurement of (changes in) the relative contribution of CBF and MBF to total RBF
is therefore considered to be important [1]. Several techniques are available to date,
such as radiolabeled xenon-washout, medullary albumin accumulation, and the
microspheres technique [2]. However, these are all invasive techniques, and some
even require kidney extirpation. Britton et al introduced a new non-invasive technique
for measurement of RBF distribution using hippuran renography and subsequent
deconvolution of the curves of an outer and middle zone of the kidney with the help
of the heart curve [3-5]. However, we conclude that this technique poses several
practical (and theoretical) difficulties, which cause the measurement to depend on and
to vary markedly with several maneuvers of this technique. Firstly, the technique
requires the definition of a pelvico-calyceal area. It is hard to define such an area
consistently. Secondly, after deconvolution of the data, an impulse retention function
is obtained which needs to be differentiated after the "exclusion of the early vascular
phase". In practice, this procedure appears hazardous, and theoretically it is
inconsistent with the deconvolution procedure, which is meant to simulate a peak
injection at time zero. Moreover, with this deconvolution technique transit times are
determined, which are reported to depend on urinary volume excretion [6]. To avoid
these potential problems, we developed and tested a new method based on a kinetic
model, describing the flow of 123I-hippuran through the contributing compartments as
a set of coherent mathematical equations. This model was validated by comparing the
changes in intrarenal blood flow distribution induced by placebo and vasoactive drugs
(angiotensin-I, and atrial natriuretic factor (ANF)) with those measured with the
standard microsphere technique in dogs.
MATERIALS AND METHODS
Dogs, instrumentation and infusions
Experiments were carried out in 13 adult mongrel dogs of both sexes, weighing
18-32 kg. The animals had been maintained on laboratory chow containing 4.5 gram
NaCl per day for two weeks. The study protocol was approved by the local ethical
committee on animal experiments.
The actual experiments were performed under anesthesia with continuous infusion
of 6-12 mg.kg-1.h-1 sodium pentobarbital dissolved in dextrose 5%. An additional
infusion of dextrose 5% was adjusted to a total of 12-14 ml.kg-1.h-1 to ensure adequate
diuresis. Infusion of para-amino-hippuric acid (PAH 3.0 g per 100 ml NaCl 0.9% at
Ph 7.4, Sigma, St Louis, Missouri, USA) was started at a rate of 22.5 ml/hour after a
bolus of 15 ml for measurement of effective renal plasma flow (ERPF). Catheters
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were inserted in the left ventricle for injection of microspheres, in the abdominal aorta
at the aorta-iliacal bifurcation for microsphere sampling (for determination of RBF),
and in the abdominal aorta suprarenally for administration of ANF. Two catheters
were inserted in a brachial vein; one for injection of 123I-hippuran for renography and
another for infusion of angiotensin-I or placebo. Finally, a bladder catheter was
inserted and connected to a three-way valve for bladder occlusion during hippuran
renography and measurement of urinary volume. After instrumentation, the dogs were
positioned on their back on the gammacamera and equilibration was allowed for one
hour. Then 123I-hippuran and microspheres were injected simultaneously for
measurement of baseline intrarenal blood flow distribution at approximately 11:30 AM
during the infusion of placebo (dextrose 5%, the solvent for angiotensin-I and ANF).
After two hours (at approximately 1:30 PM) 123I-hippuran was injected again together
with differently labelled microspheres during placebo (n=6), human Angiotensin-I
(Sigma, St Louis, Missouri, USA, 2 µg bolus followed by 20 µg/min, n=5), or ANF
(MSD, Rahway, New Jersey, USA, 0.3 µg.kg-1.min-1, n=2). Angiotensin-I infusion
started 5 seconds before injection of 123I-hippuran and microspheres, whereas ANF
infusion started 10 min before injection of these tracers. The doses and timing were
chosen to simulate previous experiments [7-9]. In three dogs who had received
placebo twice, the experiments were repeated again after another two hours (at
approximately 3:30 PM) with ANF in an identical dosis. For these experiments the
second placebo renogram is considered to be the baseline. Blood for measurement of
ERPF and hematocrit was drawn before and after renography. The mean value of the
two blood samples was taken to calculate ERPF by the UV/P formula. Urinary
volume was measured during each renography to exclude an effect of changes in
urinary volume on the measurement of MBF, as has been reported for the
determination of transit times with deconvolution techniques [6].
Microspheres method
Microspheres were 11.3±0.1 µm in size and labeled with 141Ce, 113Sn, or 46Sc
(DuPont-New England Nuclear, Wilmington, Delaware, USA). The sequence of
nuclide injection was randomized. The stock solution of microspheres was suspended
in 10% dextran with 0.01% polysorbate 80 (Tween 80) surfactant added to prevent
aggregation of spheres. Before injection the stock solution of spheres was
mechanically agitated and ultrasonicated. Spheres were withdrawn from the stock
solution to yield approximately a total of 185 kBq (5 µCi). Before injection, the
microspheres were suspended in 2 ml 0.1% Tween 80 in saline warmed to 37 °C in
special glass vials chambers as described by Heymann et al [10], and again
mechanically agitated and ultrasonicated. After starting automatic blood withdrawal
with a Harvard pump model 906 (Harvard Apparatus Inc, South Natick,
Massachusetts, USA) at a rate of 6.46 ml/min during 75 seconds for determination of
RBF, the microspheres were immediately flushed into the left ventricle with 10 ml
saline in 30 sec during continuous agitation. The left ventricular catheter was flushed
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with 10 ml saline after injection of each nuclide species to minimize retention of
microspheres in the injection system. At the end of the experiment, the kidneys were
removed and dissolved in formalin 8%. After one week the renal cortices were
divided in four equal zones. The medullary and renal poles, which could not be
divided accurately, were treated as separate zones so that total RBF could be
evaluated. The tissue for each zone was weighed and placed in identical 60 ml
bottles. To minimize errors due to differences in geometry the tissues were dissolved
in NaOH at 80 °C at identical fluid volumes. The sampled blood was diluted similarly
to an identical fluid volume. Radioactivity of each vial was measured during one hour
using a Germanium Lithium counter (EG&G ORTEC, Oak Ridge, Tennessee, USA).
Count rates of individual radionuclides were determined by spectrum peak analysis. It
was assumed that the changes in inner fourth cortical microsphere content reflect the
changes in MBF [2], and both terms are used as synonyms. Percent MBF was
calculated by taking the count rate in the inner fourth zone divided by total count rate
for the four zones per gram tissue weight multiplied by 100. Percent CBF was taken
to be the complementary part. RBF was calculated as the product of the blood
sampling rate with the ratio of measured radioactivity in total kidney tissue and
sampled blood [10]. Absolute MBF then can be calculated from the product of
percentage MBF and RBF, and is expressed in ml/min.
Renography data acquisition and processing
Renography was performed with a large-field-of-view gammacamera (Siemens
Gammasonics Inc, Hoffman Estates, Illinois, USA) with a low energy all-purpose
parallel-hole collimator. The data were recorded with a 64x64 resolution starting with
1-second frames for the first 8 minutes, followed by 10-second frames for 10 minutes,
using on-line computer data acquisition (Gamma 11, Digital Equipment Corporation,
Maynard, Massachusetts, USA). Approximately 30 seconds after starting data acquisi-
tion 40 MBq of [123I]o-iodohippurate (Cygne, Eindhoven, The Netherlands) was
injected intravenously.
After completion of the experiment the renograms were processed. First, a region
of interest (ROI) was generated over the heart. The first 1-second frame with clear
activity in the heart region was determined. One or two more frames were added to
obtain the best heart configuration. The left rim was chosen as ROI since this
corresponds best with the left ventricle. To standardize the relation between the time
of starting data acquisition and actual appearance of 123I-hippuran in the kidney, an
"initial time" was defined as follows: to the first 1-second frame that contained clear
radioactivity in the kidneys, 150 subsequent frames were added and a kidney ROI was
drawn; a time-activity curve of this ROI was generated and the intersection of the
initial slope of this curve with the time-axis was defined as "initial time". Starting at
this initial time, all subsequent 1-second frames (first eight minutes) were added to
obtain 10-second frames. Thereafter, ROI’s were generated for the kidneys, tissues,
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Figure 1. A typical example of a 123I-hippuran renogram to illustrate schematically the fitting to
renogram data of analytical functions derived from a kinetic model that describes the intrarenal
distribution of 123I-hippuran flow in a cortical and medullary part. Panel A shows the regions of
interest, which were used for time-activity curve generation. Panel B shows these time-activity curves
of 123I-hippuran measured (in 10-second frames) over the heart (squares), outer kidney region (cros-
ses), inner kidney region (diamonds), and bladder (triangles). Tissue data have been omitted since it
interferes with the data of the outer kidney region. Panel C shows the fitting of the analytical
functions to the data. Panel D shows the estimated relative contributions of cortical and medullary
flow to the inner kidney region: the shaded area represents the medullary part, the remainder the
cortical part.
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estimated kidney area and the frame with highest activity was sought. Then, frames
were added from the initial time till this frame, and the best total kidney configuration
was determined with this sum frame. The kidney was separated in an outer and an
inner kidney ROI (Figure 1A). The outer ROI was chosen such that it only contained
one or two layers of pixels at the periphery of the kidney, excluding the pelvic area.
The amount of pixels in the outer ROI was chosen to be between 25 % and 35 % of
the amount of pixels in the total kidney. The tissue ROI’s were chosen lateral to each
outer kidney ROI leaving at least 2 pixels in between. The ROI of the bladder was
chosen from the picture that was generated by adding the last sixty 10-second frames.
Finally, a background ROI for the heart was chosen lateral to the left rim of the heart
ROI and for the bladder half circular above the bladder ROI, both with a width of 2
pixels and separated from the heart or bladder ROI by at least 2 pixels, similarly as
for the tissue ROI.
After optimizing the selection of these ROI’s, time-activity curves were generated
using these ROI’s and the 10-second frames. The time-activity curves of background
ROI’s for heart and bladder were subtracted from the heart curve and bladder curve,
respectively. The outer and inner kidney curves were corrected for overlying tissue
("background") radioactivity using the best fit over the time-activity curve of the
tissue ROI as obtained with the kinetic model. The mean activity in the 10-second
frames before the initial time was assumed to represent the zero line (thus correcting
for the possible presence of radioactivity due to previous 123I-hippuran injection) and
was subtracted from the subsequent data points. Finally, as part of normalization the
time-activity curves for heart and tissues were multiplied with the ratio of the number
of pixels of total kidney area and heart or tissue area, respectively. Thus, the
following time-activity curves were obtained for analysis with the kinetic model: a
background corrected and normalized heart curve (representing the blood flow to the
kidney) Nblood, a curve over the outer kidney region Nouter (25-35 % of total kidney
area), a curve over the remaining inner region of the kidney Ninner, a normalized tissue
curve (representing the flow vice versa from blood to tissues) Ntissue, and a background
corrected bladder curve Nbladder (Figure 1B). The activities were assumed to be
measured at the middle of the 10-second interval.
Kinetic model
The proposed kinetic model is given in detail in the appendix. In short, the kinetic
model defines rate constants by means of a set of differential equations, which
describes the flow of 123I-hippuran from the heart through a cortical and a
(complementary) medullary kidney compartment to the bladder. Solution of these
differential equations gives a set of analytical functions, and with the aid of a
constrained non-linear least square method the rate constants are found that give the
best fit of these functions to the original renography data. Medullary blood flow (as
percentage of total RBF) simply follows from the rate constants. The fitting of these
analytical functions to the original data is shown in figure 1C.
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The kinetic model was based on some known characteristics of renal hippuran
handling. About 20 % of the renal hippuran load is handled by glomerular filtration,
which depends on intraglomerular hemodynamics and glomerular membrane
characteristics. After glomerular filtration, the remaining 80 % of hippuran enters
peritubular capillary structures and most of it is secreted by means of the organic
anion system through proximal tubular cells into the intraluminal space [11]. Efferent
arterioles from cortical glomeruli supply the adjacent proximal tubules. Efferent
arterioles from juxtamedullary nephrons in contrast, first traverse the outer stripe of
the outer medulla before forming a capillary plexus and vasa recta [12]. The cortical
and medullary capillary plexus therefore are reasonably well separated. Tubular
hippuran secretion from these capillary plexus into the intraluminal space is
characterized by a first rapid rate and a second slow proces leading to appreciable
accumulation in the proximal tubule [13]. Using 123I-hippuran renography, it is
impossible to assign the measured radioactivity-time curve over a certain renal area to
originate from vascular, intracellular or urinary (intraluminal) space. The current
model therefore describes the percentage cortical blood flow as the percentage of
hippuran that is handled in the cortex by both glomerular filtration and proximal
tubular secretion, and was chosen to be described as the combination of a fast and a
slow diffusion compartment. The former presumably depicts the glomerular filtration
of hippuran together with the fast tubular secretion phase, whereas the latter
corresponds to the slow tubular accumulation phase [13]. The main feature of
medullary structures (tubuli and vasa recta) is that they are much longer as compared
to cortical structures. Accordingly, hippuran handling in these structures together was
described mathematically as if hippuran enters a (long) tube and leaves this tube some
time later (delay time δ1). The purpose of describing cortical and medullary handling
mathematically different was to allow the model to give an unequivocal result. Total
cortical blood flow can then be calculated as the sum of the blood flow measured
over the outer kidney ROI and the estimated cortical part of the blood flow in the
inner kidney ROI. The CBF in the inner kidney ROI for this purpose was assumed to
have the same mathematical description as CBF in the outer kidney ROI. This
assumption neglects the flow of hippuran through the medullary collecting ducts: after
entering the urinary space from the cortical glomeruli, hippuran is transported with
urinary flow through the short loops of Henle, reenters the cortical area in the distal
tubule and finally passes the medulla through the collecting ducts before leaving the
kidney (and entering the bladder after delay time δ2). The main difference between
the descriptions of cortical and medullary blood flow is that in the cortical (diffusion)
compartments large amounts of hippuran may pass so fast that the measured
radioactivity at any time is low, whereas in the medullary (tube-like) compartment
small amounts of hippuran may accumulate to yield relatively high amounts of
measured radioactivity. This explains the relatively great area under the curve for the
medullary part of blood flow in the inner kidney ROI despite MBF only being about
15 percent of total renal blood flow (Figure 1D).
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To evaluate whether the renography method could non-invasively measure changes
in absolute MBF, absolute MBF was calculated by multiplying percentage MBF of a
single kidney as measured with the renography method with half of effective renal
blood flow (ERBF) as measured with PAH infusion. ERBF was calculated as
ERPF × (1-hematocrit)-1. This was compared to the absolute MBF measured with the
microsphere method, which was calculated as percentage MBF multiplied with RBF.
The PAH concentration in blood and urine was determined in duplicate with the
method described by Waugh et al [14]. Hematocrit was measured in duplicate with
the microcrit method.
Statistical analysis
All data are given as mean±SEM. Since only 5 experiments were done with
angiotensin-I as well as with ANF, the effects of these hormones were not tested for
statistical significance. It is indicated however, in how many of the 5 experiments the
effects of these hormones confirmed to literature. This expected effect is described as




The mean (±SEM) baseline values and the effects of placebo, angiotensin-I, and
ANF on percentage MBF for all 16 experiments are given in table 1 and shown in
figure 2. Baseline percentage MBF as measured with the renography method was
slightly higher compared to the measurement with the microsphere method, although
the results were comparable in left and right kidney. The mean baseline MBF of all
first baseline experiments in the 13 dogs combined (i.e. in the experiments at 11:30
AM) measured with the microsphere method was 12±1 % of RBF in the left kidney,
and 12±1 % in the right kidney, and measured with the renography method 15±1 %
of RBF in the left kidney, and 17±1 % in the right kidney. Placebo caused a decrease
in percentage MBF in 4 (out of 6) experiments in both kidneys as measured with the
microsphere method, and in 4 experiments for the left kidney and 6 experiments for
the right kidney as measured with the renography method. The mean placebo-induced
percent change as measured with the microsphere method was -2±6 % in the left
kidney, and -3±7 % in the right kidney, and as measured with the renography method
-1±8 % in the left kidney, and -26±8 % in the right kidney. A marked decrease in
percentage MBF was seen during angiotensin-I infusion in all five experiments in
both kidneys as measured both with the microsphere method (percent change: left
kidney -42±11%, and right kidney -50±12 %), as well as with the renography method
(percent change: left kidney -57±8%, and right kidney -62±8 %). During ANF
infusion, a small increase in percentage MBF was measured in 4 (out of 5)
experiments in the left kidney and in 3 (out of 5) experiments in the right kidney with
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TABLE 1. Renal hemodynamic parameters before (baseline) and during infusion of
placebo, A-I, and ANF




left kidney (%) 12.9±1.5 12.3±1.1 10.0±0.5 5.7±1.0 11.5±0.8 12.5±0.8
right kidney (%) 12.9±1.5 12.0±1.1 10.0±0.4 5.0±1.2 12.2±1.6 12.9±1.5
Renography method:
left kidney (%) 14±1 13±1 18±3 8±2 12±1 14±2
right kidney (%) 16±1 11±2 18±3 6±1 13±2 12±1
RBF:
Microsphere method:
left kidney (ml/min) 223±28 196±20 255±35 164±56 198±25 237±25
right kidney (ml/min) 213±24 188±15 262±38 162±49 192±21 230±20
Hematocrit, ERPF, and
ERBF:
hematocrit (%) 45.2±2.3 44.6±2.4 44.9±0.6 45.4±1.1 42.2±1.7 42.6±1.7
ERPF (ml/min) 170±24 135±20 210±30 190±43 173±42 175±41
ERBF (ml/min) 315±46 250±41 383±54 343±77 309±81 316±81
Absolute MBF:
Microsphere method:
left kidney (ml/min) 29±5 24±3 25±3 11±5 23±3 30±4
right kidney (ml/min) 29±5 23±3 26±3 11±4 25±6 31±6
Renography method:
left kidney (ml/min) 23±5 17±3 35±7 16±5 20±5 23±7
right kidney (ml/min) 26±5 15±3 34±8 13±4 23±8 20±5
Values are means ± SEM. A-I, angiotensin-I; ANF, atrial natriuretic factor; ERPF,
effective renal plasma flow; ERBF, effective renal blood flow; MBF, medullary blood flow;
RBF, renal blood flow. ERBF = ERPF × (1-hematocrit)-1. Absolute MBF = percentage
MBF × RBF, microsphere method; or absolute MBF = percentage MBF × (0.5 × ERBF),
renography method.
the microsphere method and in 2 experiments in the left kidney and in only 1
experiment in the right kidney with the renography method. During ANF infusion
there was a mean increase in percentage MBF, in particular when one considers the
decrease during placebo, as measured with both methods in both kidneys. The mean
percent change during ANF infusion as measured with the microsphere method was
9±3 % in the left kidney, and 6±5 % in the right kidney, and as measured with the
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Figure 2. Absolute change in (percentage) medullary blood flow induced by placebo (squares),
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angiotensin-I (discs), and atrial natriuretic factor (triangles) measured with the standard microsphere
technique (∆MBFmic), and the proposed kinetic model based on renography (∆MBFren): left kidney
(r=0.67, p=0.005; left panel), and right kidney (r=0.62, p=0.010; right panel). The dashed line
indicates the line of identity.
renography method 12±11 % in the left kidney, and 2±18 % in the right kidney. The
individual absolute as well as percent changes in percentage MBF induced by
placebo, angiotensin-I and atrial natriuretic factor as measured with both methods
correlated significantly (left kidney: r=0.67, p=0.005 (Figure 2, left panel), and
r=0.71, p=0.003, respectively; and right kidney: r=0.62, p=0.010 (Figure 2, right
panel), and r=0.68, p=0.004, respectively). The correlation between both methods in
the left kidney was closer to the line of identity than in the right kidney, which may
be due to overlying liver tissue over the right kidney.
To investigate the importance of the bladder data as output function for the
measurement of percent change in MBF with the renogram method, the calculations
were repeated with exclusion of the bladder data. The absolute and percent changes in
MBF calculated with the renogram method without the bladder data also correlated
with the microsphere data (left kidney: r=0.62, p=0.010, and r=0.65, p=0.006; and
right kidney: r=0.71, p=0.003, and r=0.60, p=0.012, respectively).
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Figure 3. Medullary blood flow (as percentage of total renal blood flow) measured with the
Urinary flow (ml.min   )-1
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proposed renography method (MBFren) as function of urinary flow: left kidney (r=0.17, p=0.39; left
panel), and right kidney (r=0.10, p=0.62; right panel).
RBF and urinary flow
Data on renal blood flow are shown in table 1. ERBF was calculated from ERPF
and hematocrit. Except for the angiotensin-I experiments, the sum of left and right
kidney RBF measured with the microsphere method tended to be greater than ERBF.
This may be due to the fact that intrarenal hematocrit is smaller then systemic
hematocrit, which was used to calculate ERBF [15], or by a not complete renal
extraction of PAH. Total renal blood flow as measured with the microsphere method
and ERBF as measured with ERPF and hematocrit correlated significantly (r=0.87,
p=0.0001). Similarly, the absolute and percent changes in total RBF as measured with
both methods correlated significantly.
Mean urinary volume flows during each renography experiment were: 4.3±1.4
(range 0.77-8.83) and 5.5±0.9 (range 2.73-8.63) ml/min before and during placebo;
2.9±1.0 (range 0.71-6.27) and 4.6±1.4 (range 0.38-10.0) ml/min before and during
angiotensin-I infusion; and 2.6±0.8 (range 0.39-4.88) and 5.2±1.2 (range 1.09-8.38)
ml/min before and during ANF infusion, respectively. No significant correlation was
found between urinary flow and (percentage) MBF as measured with the renography
method: r=0.17, p=0.39 for the left kidney, and r=0.10, p=0.62 for the right kidney
(Figure 3). Similarly, no correlation was found between the absolute changes in
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urinary flow and absolute changes in percentage MBF: r=0.16, p=0.57 (left kidney),
and r=0.11, p=0.69 (right kidney), nor for the percent changes: r=0.05, p=0.84, and
r=0.12, p=0.64, respectively.
Absolute MBF
The absolute MBF can be calculated by multiplying percentage MBF and renal
blood flow. For the microsphere technique renal blood flow in this study was
measured for each kidney separately. The mean baseline absolute MBF of all first
baseline experiments in the 13 dogs combined (i.e. in the experiments at 11:30 AM)
was 28±3 ml/min in the left kidney, and 29±3 ml/min in the right kidney as measured
with the microsphere technique. To evaluate whether the renography method could
non-invasively measure (changes in) absolute MBF, percentage MBF as measured
with the renography method was multiplied with (half of) ERBF as measured with
PAH infusion and hematocrit. The mean baseline absolute MBF of all first baseline
experiments in the 13 dogs combined was 29±4 ml/min in the left kidney, and 32±4
ml/min in the right kidney as measured with the renography method. The effects of
infusion of placebo, angiotensin-I, and ANF on absolute MBF are shown in table 1.
The absolute changes in (absolute) MBF as measured with the microsphere method or
the renography method with ERBF correlated significantly (r=0.62, p=0.009 (left
kidney), and r=0.59, p=0.016 (right kidney)). The percent changes in MBF as
measured with the microsphere method or the renography method with ERBF also
correlated significantly (r=0.73, p=0.002 (left kidney), and r=0.71, p=0.002 (right
kidney)).
DISCUSSION
Our renography analysis technique studied in a pilot study seems to be an usable
tool for the measurement of (changes in) renal medullary blood flow. The technique
compares well with the standard microsphere technique, as baseline values and
changes for MBF measured with both methods were similar. We thus suggest that the
proposed method using 123I-hippuran renography may be useful as a non-invasive
method for the determination of (changes in) intrarenal blood flow distribution.
Baseline MBF with the microsphere method in this study was found to average
12% of RBF. This is in good agreement with other studies using this method [7-9].
Angiotensin-I induced a 40 % decrease and ANF a 10 % increase in MBF. Previous
studies have shown similar results, albeit quantitatively different. Intrarenal
angiotensin-I has been shown to induce a 10 % decrease in MBF (calculated as
percent decrease in MBF as percentage of RBF) [8], whereas others found intrarenal
ANF to increase MBF by 20 % [7,9]. Differences in study design may explain why
we observed a larger decrease in MBF elicited by angiotensin-I and a smaller ANF-
induced increase in MBF. We infused angiotensin-I systemically, whereas others
infused angiotensin-I intrarenally [8]. Systemic effects of angiotensin-I (such as an
increase in blood pressure) may have had an additional effect on MBF decrease [16].
As far as ANF is concerned, we infused a relatively high dose which may have had
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not such increasing effects on percentage MBF as lower doses of ANF [7]. An
alternative explanation could be that we used 11 µm microspheres whereas others
used 15 µm microspheres. Compared to smaller microspheres, a decrease in MBF
measured with larger microspheres is found to be attenuated and an increase in MBF
measured with larger microspheres is found to be enhanced, probably due to
skimming artefacts [17]. We thus conclude that the present results with the
microsphere technique are comparable to those reported previously in literature.
Our model for the measurement of MBF is based on the kinetic modelling of renal
hippuran handling. Limitations of this model therefore may be related to the
mathematical description of renal hippuran handling, which involves as well
glomerular filtration, tubular secretion, and more or less delay caused by transport
through the tubuli. The accuracy of the method therefore will be affected when the
relation between CBF and cortical (glomerular and/or tubular) handling of hippuran
by some intervention is changed differently than the relation between MBF and
medullary hippuran handling. Although to our knowledge such data are not available,
it is theoretically conceivable for instance that some intervention increases MBF and
decreases CBF with a concurrent increase in the cortical extraction of hippuran. Such
an increase in extraction of hippuran causes urinary hippuran concentration to rise,
which by the proposed renography method is interpreted to be (cortical) blood flow.
The actual induced decrease in CBF (and thus the actual increase in MBF) then will
be underestimated by the proposed method. Similarly, any other change in the cortical
handling of hippuran (see methods) that is not parallelled by a similar change in the
medullary handling of hippuran might affect the accuracy of the method. Moreover,
the current proposed analysis might not be the ideal model yet. As is illustrated in
figure 1C, the current model sometimes slightly underestimates the initial cortical
slope. This probably may have two explanations. First, the model assumes the
analytical function of cortical blood flow to be similar in the outer and inner kidney
ROI. This assumption however, neglects the passage of hippuran from the cortex
through the medulla (via the collecting ducts). Thus, the contribution of CBF to the
inner kidney ROI in fact will have a slightly greater "late" flow. Therefore, this
assumption might contribute to this underestimation of the initial cortical slope.
Alternatively, and in our opinion more likely, this underestimation is caused by the
underestimation of the initial slope of the background data, which in this figure are
not subtracted. In the current model the background is described by a simple diffusion
compartment, which in practice appeared not optimal. Finally, some parameters were
fixed or defined by ratio’s of number of pixels in ROI’s to simplify the model (see
appendix). The effect however, of these possibly confounding factors appear to be
limited, since the results of the renography method correlated well with those of the
standard microsphere technique. Future investigations may clarify the limitations of
the current model and may possibly yield better mathematical functions to describe
renal hippuran handling.
Another limitation of the proposed method may be that the results are dependent
on the prevailing urinary flow as in the measurement of MBF with the use of transit
times [6]. In the present study the range of urinary flows was quite large (23 to 600
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ml per hour) and no relation was found between MBF and urinary flow, nor between
simultaneous changes in these parameters. However, whether the model is valid
beyond this range or in cases with renal artery stenosis or pyelo-urethral emptying
dysfunction cannot be concluded from the present data.
Several improvements of the proposed model may be suggested. Firstly, using dual
head acquisition on both sides of the investigated subject, would allow geometrically
corrected data collection. Particularly the input function (heart) will be improved with
such a design. Secondly, the time resolution of several parameters of the kinetic
model may be improved by using 2-second, 4-second, etcetera frames instead of 10-
second frames as in the present study. Such a higher time resolution might need more
radioactive material to be injected, which may be achieved by high doses of 99mTc-
MAG3 instead of 123I-hippuran. Both radiopharmaceuticals behave similarly [18], and
Britton et al found similar results with both radiopharmaceuticals with their method of
transit time renography [19]. Thirdly, radioactive albumin or labeled erythrocytes may
be used in a similar way, although they behave differently. Since particularly
erythrocytes do not enter the urine compartment, the application of labeled
erythrocytes would have the advantage of studying blood flow more directly.
Obviously however, an output function then cannot be defined. Finally, mathematical
modelling of the kind described in the present study offers the interesting opportunity
to investigate dynamically the clearance of other renal interesting substances such as
iothalamate, EDTA (as glomerular markers) or radioactive urea (as medullary
marker).
We conclude from the present study that the proposed kinetic model is accurately
capable of registering changes in renal MBF induced by vasoactive substances. This
offers the opportunity to non-invasively measure changes in MBF. The method may
therefore also be applicable in man.
APPENDIX
The proposed kinetic model consists of 7 compartments, representing the
intravenous bolus injection (0), the blood (1), the fast cortical component (2), the slow
cortical component (3), the medulla (4), tissues (5), and the bladder (6) (Figure A1).
The function that describes the hippuran concentration in the blood (C1), i.e. the blood
concentration curve, is taken to be three-exponential with one exponential correcting
for the initial upward slope of the heart curve that was found after adding the frames
starting from the initial time (see also reference 13). This probably reflects the initial
injection and mixing of hippuran in the blood. Therefore, the blood curve is given by
a three-exponential curve:
C1(t)=Aexp(-Bt)+Cexp(-Dt)+Eexp(-Ft), A,B,C,D,F>0, E<0 (1)
The analytical functions describing the hippuran concentration in the other
compartments i (Ci) then follow from the following system of ordinary differential
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Figure A1. Flow diagram of the proposed kinetic model of renal 123I-hippuran handling for the
5: Tissues
























measurement of intrarenal blood flow distribution in a cortical and medullary part. Compartments 0
to 6 represent the intravenous bolus injection (0), the blood (1), renal cortex (fast compartment (2),
slow compartment (3)), renal medulla (4), tissues (5), and bladder (6), respectively. Straight lines
and parameters kij indicate diffusion to compartment i from compartment j. Dotted lines and
parameters δ indicate delay in time.
equations, in which kij stands for diffusion to compartment i from compartment j, and
δ for a delay in time:
dC2(t)/dt = k21C1(t)-k62C2(t) C2(0)=0 (2a)
dC3(t)/dt = k31C1(t)-k63C3(t) C3(0)=0 (2b)
dC4(t)/dt = k41C1(t), t<δ1 C4(0)=0 (2c)
= k41C1(t)-k41C1(t-δ1) t>δ1 (2d)
dC5(t)/dt = k51C1(t)-k5C5(t) C5(0)=0 (2e)
dC6(t)/dt = k62C2(t-δ2)+k63C3(t-δ2)+k41C1(t-δ1-δ2) C6(δ2)=0 (2f)
Normalization is achieved by k21+k31+k41=1 (per 10 seconds), i.e. total input in each
kidney is 1 per chosen frame time, since the aim of the model is to measure MBF as
percentage of total RBF. Solution of this system of ordinary differential equations
gives the analytical functions describing the flow of hippuran through the separate
compartments. The cortical function was assumed to be described by a function with
diffusion characteristics (equations (2a) and (2b)). The medullary function was taken
to be described by a function with tube characteristics (equations (2c) and (2d)),
because the main discriminating characteristic of medullary stuctures in comparison to
cortical stuctures is that their tubuli (and vasa recta) are much longer. Moreover, since
a considerable amount of hippuran was found to be retained in the cortical region, the
cortical function was split in a fast and a slow component (both with diffusion
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characteristics). Thus, in compartments 2, 3 and 5 (Figure A1) diffusion is assumed to
be the predominant factor determining flow. The solution of equation (2a) for







Similarly, equations (2b) and (2e) can be resolved for compartments 3 and 5.
The medullary compartment (4) is described to be represented by a tube, in which







The solution for compartment 6 (bladder) can be calculated by integrating the
solutions for compartments 2, 3 and 4 and compensating for the delay in time δ2 that























In contrast to the analytical functions, the count rate data (blood: Nblood, outer
kidney region: Nouter, inner kidney region: Ninner, tissues: Ntissue, bladder: Nbladder) are
generated from ROI’s which in case of the kidney represent (mixtures of) fractions (f)
of these compartments. Thus, the analytical function that is taken to fit the count rate
data of the outer kidney region is a fraction f1 of the function representing total CBF
(C2+C3). The function that is taken to fit the count rate data of the inner kidney region
then is the remaining fraction (1-f1) of the function representing total CBF plus the
function representing MBF (C4). Moreover, the count rate data of both kidney regions
should be corrected for overlying tissue activity. This is realized by adding fractions
f2 and f3 of the tissue function (C5) to the functions fitting the count rate data of the
outer and inner kidney region. Finally, one should correct the count rate data for
relative differences in gammacamera count efficiency of measurement (E). The
relation between count rate data N and functions describing flow through the separate
compartments (Ci) are then:
Nblood (t) = Eblood C1(t) (6a)
Nouter (t) = Eouter f1(C2(t)+C3(t))+Etissuef2C5(t) (6b)
Ninner (t) = Einner ((1-f1)(C2(t)+C3(t))+C4(t))+Etissuef3C5(t) (6c)
Ntissue(t) = EtissueC5(t) (6d)
Nbladder(t) = EbladderC6(t) (6e)
To simplify the mathematical model some parameters were defined by the ratio of
number of pixels in ROI’s or were taken fixed. Fraction f1 was taken to be equal to
the number of pixels of the outer kidney ROI divided by the number of pixels of the
total kidney ROI. Fractions f2 and f3 were taken to be the ratio of the number of
pixels in outer and inner kidney region to the number of pixels in renal background
region, respectively. However, since the renal background curve was normalized to
total kidney area f2=f1, and f3=1-f1. Moreover, one only has to correct for relative
differences in efficiencies of measurement. Therefore, the efficiencies for cortex,
medulla, and renal background ROI were set to be equal, since the curves over these
ROI’s represent organ activities at about the same depths in the body, and were
expressed relative to the efficiencies of heart and bladder. In case of the heart ROI,
this parameter (E/blood) also corrects for the fact that it is impossible to measure total
cardiac activity, since the outer rim of the heart is only part of the left ventricle.
Similarly, the efficiency parameter for the bladder (E/bladder) also corrects for the fact
that the bladder input from one kidney may be more or less than 50 percent from
total input due to differences in functional activity between both kidneys. With these
simplifications equations (6) can be rewritten:
Nblood (t) = E/bloodC1(t) (7a)
Nouter (t) = f1(C2(t)+C3(t)+C5(t)) (7b)
Ninner (t) = (1-f1)(C2(t)+C3(t)+C5(t))+C4(t) (7c)
Ntissue(t) = C5(t) (7d)
Nbladder(t) = E/bladderC6(t) (7e)
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TABLE A1. Mean±SEM for parameters of the kinetic model measured in the first
experiments in the 13 dogs
left kidney right kidney
Diffusion parameters
(as percentage of k21+k31+k41):
k21 (%) 73.5±2.3 72.6±1.9
k31 (%) 11.1±1.0 10.8±0.9
k41 (%) 15.4±1.5 16.6±1.5
k51 (%) 11.2±0.8 13.0±0.7
k63 (%) 1.9±0.1 1.8±0.1
k5 (%) 4.3±0.5 4.1±0.3
Delay parameters (sec):
δ1 (delay in medullary tubular structures) 15.1±2.6 18.8±0.9
δ2 (delay between kidney and bladder) 180±11 178±10
To simplify the model further, the rate constant of the tissues k15 was taken not to
flow back to the blood, which is based on the (realistic) assumption that this rate
constant is very low. Moreover, parameters F and k62 were fixed at preset levels, since
they were found to be relatively constant in the first experiments (10 sec-1, and 0.15
sec-1, respectively). The analytical functions (right hand side of equation (7)) were
fitted simultaneously using a weighed constrained non-linear least squares method
(E04JAF, NAG, Oxford, 1990) to the experimental data (left hand side of equation
(7)). To guide the proces of fitting, weighing factors were chosen such that the count
rate data of the initial slopes of the heart and bladder function and the tops of both
cortical and medullary function were given a higher weight. The time points with
highest radioactivity in the curves were defined in the curves of the outer kidney
(ITOP1), inner kidney (ITOP2), and renal background (ITOP3). The weighing of the
count rate data was done with the following general formula (with T the actual time
point and NT the total number of time points):
(T-1)×(N-O)/(ITOP-1)+O for T<ITOP (8a)
((ITOP-T)×U)/(NT-ITOP)+N for T>ITOP (8b)
Parameters ITOP, N, O, and U arbitrarily being: ITOP1, 1, 4, and 0.75 for the heart
curve; ITOP1, 7, 2, and 6.5 for the outer kidney curve; ITOP2, 5, 2, and 4.5 for the
inner kidney curve; ITOP3, 2, 2, and 1.5 for the renal background curve; and ITOP2,
6, 0.25, and 5.5 for the bladder curve, respectively. Similarly, to guide the medullary
function (described as a tube), the frame time with the maximum counts in the inner
kidney ROI was used as initial value of the delay in time for hippuran in this tube, on
which the variable parameter δ1 was superposed.
The mean of the values of the most important parameters calculated in the
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simultaneous fit of all count rates shown in equations (7) to the data of the first
experiments in the 13 dogs (i.e. in the experiments at 11:30 AM) for the left and right
kidney are given in table A1. The diffusion parameters are expressed as percentage of
k21+k31+k41 (=1 per 10 seconds by normalization). Thus, MBF as percentage of total
RBF is given by k41, and is given extensively in the text. On request the program is
available from the authors.
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THE EFFECT OF ATRIAL NATRIURETIC FACTOR
ON INTRARENAL BLOOD FLOW DISTRIBUTION IN MAN
Wilbert M T Janssen, Paul E de Jong, Henk Beekhuis, Dick de Zeeuw




We evaluated the effect of atrial natriuretic factor (ANF) on intrarenal blood flow
distribution in 5 volunteers using of a recently developed renographic (123I-hippuran)
technique. Baseline percentage renal medullary blood flow (MBF) in the left kidney
averaged 14 % (as percentage of total renal blood flow) on two (placebo or ANF
infusion) test days. Conversely, baseline percentage renal cortical blood flow (CBF),
as complementary to MBF, averaged 86 %. During placebo, percentage MBF of the
left kidney decreased (and CBF increased) in 4 subjects. During ANF, percentage
MBF increased (and CBF decreased) in 4 subjects, and after correction for placebo in
all subjects (p<0.05). ANF induced a decrease in effective renal plasma flow
(131I-hippuran clearance, p<0.05) and an increase in hematocrit (p<0.05). As a result,
ANF induced a decrease in absolute CBF in all volunteers (p<0.05, compared to
placebo), and an increase in absolute MBF in 4 of the 5 subjects (non significant).
The results for the right kidney were similar.
These data suggest that the proposed renographic method to measure (changes in)
MBF is applicable in man. Thus measured, an ANF-induced decrease in total renal
blood flow in man is due to a decrease in CBF, while MBF remains stable or even
increases.
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INTRODUCTION
Evidence is growing that changes in the intrarenal distribution of total renal blood
flow in a cortical and (complementary) medullary part are an important mechanism by
which drugs and hormones may affect renal function [1,2]. Recently, atrial natriuretic
factor (ANF) was observed in animal experiments to increase total renal blood flow
with a preferential increase in renal medullary blood flow (MBF) over renal cortical
blood flow (CBF) [3,4]. However, in contrast to these animal studies, we and others
showed that ANF decreases effective renal plasma flow (ERPF) in humans [5,6].
Since we also performed renal extraction measurements to correct these renal
hippuran clearance data, we concluded that renal blood flow is truly decreased by
ANF in humans [5]. However, ANF was also found to decrease urinary osmolality
and fractional free water reabsorption [5-7]. Therefore, notwithstanding this decrease
in total renal blood flow, we and others had hypothesized that ANF still may increase
MBF in humans [5-7]. Recently, we developed a new renographic analysis method
using 123I-hippuran for the measurement of (changes in) intrarenal blood flow distribu-
tion. This method was evaluated in dogs [8]. To assess the clinical applicability of
this method and to test the hypothesis that the ANF-induced decrease in total renal
blood flow in humans is primarily due to a decrease in CBF, we performed
123I-hippuran renography in five human volunteers before and during ANF or placebo.
SUBJECTS AND METHODS
Subjects were 5 healthy male volunteers aged 23-30 years (median: 27), weighing
68-83 kg (median: 75). The purpose of the study had been explained and an informed
consent had been previously obtained. Each volunteer had a medical history taken and
underwent a physical examination. Routine laboratory tests were normal. Subjects
adhered to a 200 mmol sodium diet, and compliance was tested with 24 hour urine
collection. Urinary sodium output ranged from 125 to 260 mmol/day (median: 187).
The protocol had been approved by the Medical Ethical Committee of our hospital.
Study design
Each subject was examined on two test days, separated by one or two days. Each
test day started at 8:00 AM and experiments lasted until 2:10 PM. The supine position
was assumed for the whole day, except for urine voiding. During each test day the
subjects adhered to a rhythm diet consisting of 150 ml tap water every hour and 17
mmol sodium every two hours. A bolus of 0.4 MBq 131I-hippuran was given at 8 AM
and followed by continuous infusion of 131I-hippuran (2.0 MBq in 100 ml dextrose
5%) at a rate of 12 ml/h for the measurement of effective renal plasma flow (ERPF)
and 200 ml/h dextrose 5% to ensure adequate diuresis. The period from 8:00 AM till
10:00 AM served as an equilibration period. From 10:00 AM till 11:20 AM urine was
voided and blood was sampled at two intervals of 40 minutes for the baseline
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measurement of ERPF and hematocrit. At 11:40 AM 40 MBq 123I-hippuran (Cygne,
Eindhoven, The Netherlands) was injected in a cubital vein for the baseline
measurement of 123I-renography. The experimental period lasted from 12:10 PM till
2:10 PM. At 12:10 PM placebo (vehicle) or synthetic human ANF(101-126) (L-346,670,
MSD-RL, Rahway, New Jersey, USA) infusion was started at a dose of 1 µg/min.
ANF and placebo were infused double blind and in random order on the different test
days. After 40 and 80 minutes of infusion, urine was voided and blood was drawn
again for the measurement of ERPF and hematocrit. Finally, 100 minutes after the
start of the infusion with ANF or placebo, a second 123I-hippuran renography was
performed using the same amount of radioactivity.
Renography data acquisition and processing
Renography data were recorded from posterior with a large-field-of-view
gammacamera (Siemens Gammasonics Inc, Hoffman Estates, Illinois, USA) with a
64x64 resolution using on-line computer data acquisition (Gamma 11, Digital
Equipment Corporation, Maynard, Massachusetts, USA). Data were recorded in
1-second frames for the first 8 minutes, followed by 10-second frames for the
following 10 minutes.
After completion of the experiments the renograms were blindly processed. In
short, to standardize the relation between the start of data acquisition and actual
appearance of 123I-hippuran in the kidney, an "initial time" was defined: to the first 1-
second frame that contained clear radioactivity in the kidneys, 150 subsequent frames
were added and a kidney region of interest (ROI) was drawn; a time-activity curve of
this ROI was generated and the intersection of the initial slope of this curve with the
time-axis was defined as "initial time" [8]. Starting at this initial time, all subsequent
1-second frames (first eight minutes) were added to obtain 10-second frames.
Thereafter, ROI’s were generated for the heart, both kidneys, and their background
areas. The kidney was separated in an outer and an inner kidney ROI. The amount of
pixels in the outer kidney ROI was chosen to be between 25 % and 35 % of the
amount of pixels in the total kidney. Finally, time-activity curves starting at the initial
time were generated using these ROI’s and the 10-second frames. These curves were
used for calculation of medullary blood flow with the kinetic model.
Kinetic model
The kinetic model has previously been described and evaluated in comparison with
the microsphere technique in dogs [8]. In short, the kinetic model defines rate
constants by means of a set of differential equations, which describes the flow of 123I-
hippuran from the heart (blood compartment) through a cortical and a
(complementary) medullary kidney compartment to the bladder. Solution of these
differential equations gives a set of analytical functions, and with the aid of a
constrained non-linear least square method (E04JAF, NAG, Oxford 1990) rate
constants can be found that give the best fit of these functions to the measured
138
ANF and intrarenal blood flow distribution in man
renography data. Renal medullary blood flow (as percentage of total renal blood flow)
follows from the rate constants.
Laboratory and Mathematical analysis
131I-Hippuran radioactivity in plasma and urine was determined in duplicate in an
universal gammacounter (1282 Compugamma, LKB-Wallac, Turku, Finland) after a
24 hours delay to avoid contamination with 123I-hippuran used for renography.
Hematocrit was measured with a Coulter counter S-plus (Coulter Electronics Inc,
Hialeah, Florida, USA).
ERPF was calculated using the standard method (UV/P) [9]. The plasma
concentration used for the clearance calculation was the average of the plasma values
obtained during baseline or ANF or placebo infusion period. Absolute medullary
blood flow was calculated as the product of ERPF with the mean of the percentages
medullary blood flow of left and right kidney, divided by (1-hematocrit). Cortical
blood flow was calculated as the complementary part of MBF to total renal blood
flow. The blood flow data were corrected for body surface area (1.73 m2).
All results are expressed as median and range. Data for ERPF and hematocrit are
the mean of the two collection periods during either baseline or placebo or ANF
infusion. Statistical analysis was performed by Wilcoxon’s matched pairs test to
investigate the effect of ANF in comparison to placebo. Regression analysis was
performed with Pearson’s coefficient for correlation between variables. Differences
were considered significant when p<0.05.
RESULTS
All individual data for the measured parameters (ERPF, hematocrit, and percentage
MBF) as well as calculated parameters (absolute CBF and MBF) on the placebo and
ANF test day are given in Table 1. Measured percentage CBF is not given, but
simply follows from the assumption that it is complementary to MBF. Thus, baseline
percentage MBF averaged 14 % on both test days, and conversely, baseline
percentage CBF 86 %. During placebo, (mean) values of ERPF and hematocrit
remained similar to baseline. Percentage MBF decreased (and CBF increased) during
placebo infusion in 4 out of 5 subjects in the left kidney, and in 3 out of 5 subjects in
the right kidney. As a result, during placebo infusion calculated absolute MBF
decreased in 3 out of 5 subjects (median -14 ml/min, range -54 to 18) and absolute
CBF increased in 3 out of the 5 volunteers (median +12 ml/min, range -109 to 112).
Infusion of 1.0 µg/min ANF induced a decrease in ERPF and a rise in hematocrit
in all 5 volunteers, as expected (both p<0.05, compared to placebo). Interestingly,
ANF infusion caused an increase in percentage MBF (and thus a decrease in
percentage CBF) in 4 out of the 5 subjects in both kidneys. Corrected for placebo,
percentage MBF in the left kidney increased in all five volunteers during infusion of
ANF (p<0.05). As a result, calculated absolute MBF corrected for placebo increased
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Table 1. Individual data on effective renal plasma flow (ERPF (ml/min)), hematocrit (%),
percentage medullary blood flow (%MBF) in left and right kidney, and absolute
medullary (absMBF) and cortical (absCBF) blood flow on two test days before and during
either placebo or atrial natriuretic factor (ANF).
parameter ERPF Hematocrit %MBF left %MBF right absMBF absCBF
case (ml/min) (%) (%) (%) (ml/min) (ml/min)
PLACEBO BASELINE
1 544 43.1 9.1 12.8 105 851
2 690 39.3 15.0 16.7 180 955
3 549 42.0 17.6 16.3 160 786
4 394 42.1 13.0 10.2 79 600
5 606 36.6 13.7 11.3 119 836
mean 556 41 14 14 129 806
PLACEBO
1 552 44.0 10.9 14.1 123 863
2 696 40.0 13.2 12.9 155 1009
3 507 41.7 13.4 10.9 106 763
4 457 42.6 12.0 9.2 84 712
5 533 35.6 12.6 11.7 105 727
mean 549 41 12 12 113 815
ANF BASELINE
1 569 44.5 11.6 12.7 124 900
2 634 38.9 19.7 18.8 200 839
3 500 42.4 12.2 10.9 100 766
4 445 42.2 12.9 8.9 84 685
5 679 38.5 11.9 7.6 108 996
mean 565 41 14 12 123 837
ANF
1 462 49.0 14.2 11.0 114 793
2 594 41.6 18.2 19.0 189 828
3 430 46.4 16.4 17.6 136 665
4 400 45.5 17.5 15.2 120 614
5 430 41.2 18.0 15.0 121 611
mean 463 45 17 16 136 702
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Figure 1. Upper panel: relation between the
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absolute difference in percentage renal
medullary blood flow (∆MBF) of 2 baseline
experiments on the first minus the second test
day in left and right kidney. Lower panel: the
relation between the (placebo corrected) effect
of infusion of 1.0 µg/min atrial natriuretic
factor on percentage renal medullary blood
flow in left and right kidney (r=0.85, p=0.07).
The dashed line indicates the line of identity.
in 4 of the 5 subjects during ANF
infusion (median +27 ml/min, range
-28 to 90) (non significant). Vice versa,
absolute CBF decreased during ANF
infusion in all volunteers (median
-119 ml/min, range -65 to -276) (p<0.05,
compared to placebo).
Since percentage MBF as all
biological parameters may fluctuate from
day to day and even over the same day,
it is not possible to calculate an
interassay coefficient of variance to
assess the reproducibility of the
renography method in clinical use. We
therefore used both kidneys as controls
of each other. Firstly, we compared the
combined data of all measurements of percentage MBF in left and right kidney. These
combined data showed a significant correlation (n=20, r=0.73, p<0.05). The
percentage MBF of all combined data in the right kidney tended to be slightly lower
by 1.0% (p=0.07). This may indicate a physiological difference between both kidneys
or a systemic detection error of the method. Secondly, we compared the baseline data
of each kidney on the two test days. Variation in percentage MBF between the first
and second test day in the left and right kidney appeared to be distributed
symmetrically around the line of identity (Figure 1A, r=0.76, p=0.14). This suggests
that these were true variations in stead of detection errors. The median difference of
right minus left kidney in the difference in the two baseline percentages MBF was 0%
(range -2.6 to 2.6%). Finally, we compared the (placebo corrected) ANF-induced
change in percentage MBF between both kidneys. The ANF-induced change in
percentage MBF differed between individuals, and this difference was comparable in
both kidneys (Figure 1B, r=0.85, p=0.07). This indicates that these changes are due to
the effect of ANF, rather than detection errors. The median difference of right minus




In the present study we firstly demonstrate that the recently developed method for
measurement of intrarenal blood flow distribution seems to be applicable in man.
Secondly, we have indications that ANF induces a significant decrease in renal
cortical blood flow with a small rise in renal medullary blood flow in man.
The proposed method for the non-invasive measurement of (changes in) intrarenal
blood flow distribution was developed and evaluated in dogs [8], and this is our first
study in man. The present data therefore offer the first possibility to asses the clinical
practice of this method. Its usefulness in man is supported by several observations.
We did not encounter significant problems in the application of the animal model to
human data. Moreover, the baseline percentage MBF as measured with the kinetic
model in man are very similar to animal data [1-4]. Lastly, the ANF-induced changes
in the intrarenal distribution of blood flow as measured with our technique are similar
to animal observations and consistent with our hypothesis from previous data [5-7].
To assess the reproducibility of the renography method we used both kidneys as
controls of each other in order to avoid differences due to day-to-day variation or due
to diurnal rhythm of percentage MBF. The differences between the baseline
measurements of percentage MBF on the two tests days were comparable in both
kidneys. Similarly, the variation in ANF-induced increase in percentage MBF between
the subjects tended to correlate between both kidneys. Moreover, there was a good
correlation between the combined data of all measured percentages MBF in left and
right kidney. Thus, the measurement of percentage MBF with this method appears to
be reproducible in man. Therefore, we interpret the present data to indicate that our
method may be applied to human renography data to measure (changes in) MBF.
However, we cannot exclude a systemic detection error due to background
radioactivity. For instance, percentage MBF in the right kidney tended to be slightly
(1%) lower. Although this might indicate a physiological difference between both
kidneys, an alternative explanation is that this is due to overlying liver tissue over the
right kidney. Indeed, the validation of the present method in dogs [8] showed the
correlation between the changes in percentage MBF as simultaneously measured with
the present renography method and with the standard microsphere technique to
correspond better with the line of identity in the left kidney than in the right kidney.
Similarly, the decrease in percentage MBF during placebo can be explained by a
physiological diurnal rhythm in MBF or alternatively, by an effect of enhanced
background radioactivity due to former renography on MBF measurement. This would
imply that the measurement of percentage MBF with the proposed model are more
reliable in the left kidney. Future studies are necessary to clarify this issue.
The present data show a distinct dissociation in the ANF-induced effects on
cortical and medullary renal blood flow. Whereas absolute CBF was found to
decrease significantly upon ANF infusion, absolute MBF tended to increase compared
to placebo. We previously showed that ANF induces a decrease in total renal blood
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flow (renal hippuran clearance corrected for hematocrit and renal hippuran extraction)
in man [5]. The present data suggest that this is due to an ANF-induced decrease in
CBF, whereas ANF even may increase MBF like in animal experiments [3,4]. It is
possible that the present study underestimated the effects of ANF on intrarenal blood
flow distribution. Firstly, one should take into account possible changes in the renal
extraction of hippuran. We have found previously that ANF induces an increase in
renal hippuran extraction in man, which correlates negatively with changes in ERPF
[5]. Thus, it is possible that ANF decreases CBF with a concurrent increase in the
renal extraction of hippuran in the cortical area. With renography it is impossible to
distinct whether measured radioactivity over a certain area originates from the blood
or from the urinary pool. An enhanced renal extraction of 123I-hippuran will cause the
contribution of the urinary pool to the measured radioactivity to rise in excess of the
contribution of the blood pool. This will lead to an overestimation of the blood flow
in this area. By this mechanism the ANF-induced decrease in CBF in the present
study may be underestimated, and the actual rise in ANF-induced MBF (as
complementary part of CBF) may be larger than indicated. Secondly, animal
experiments have shown that the effect of ANF on MBF vanishes after half an hour
of infusion [10]. In the present study the effect of ANF on MBF was measured after
nearly two hours. Therefore, we suggest the present results to indicate that ANF
decreases CBF and increases MBF in man.
The dissociation of the ANF-induced effects on cortical and medullary blood flow
suggests a different effect of ANF on cortical and medullary pre- or post-glomerular
vessels. Animal and human data have suggested ANF to induce a preglomerular
vasodilation and a postglomerular vasoconstriction [11,12]. The increase in MBF
suggests that in the juxtamedullary nephrons ANF preferentially has a vasodilatory
action. The observed decrease in CBF (together with the well-known ANF-induced
increase in filtration fraction) in contrast, is compatible with a (post-glomerular)
vasoconstriction most likely located in cortical nephrons. This could be in line with
the animal experimental findings of Veldkamp et al and Aalkjaer et al [13,14], who
showed a selective preglomerular vasodilation in juxtamedullary nephrons without an
effect of ANF on postglomerular arterioles. Such a juxtamedullary vasodilation in turn
is associated with an increase in renal interstitial pressure and a washout of the
medullary interstitium [15]. Moreover, the observed variation between the subjects in
the MBF response to ANF is in agreement with data in literature showing
interindividual variations in ANF-induced natriuresis. The present data therefore
support the hypothesis of an important contribution of an increase in medullary blood
flow to ANF-induced natriuresis also in man.
In conclusion, the present study shows that the ANF-induced decrease in total
renal blood flow is due to a decrease in CBF with a stable or increased MBF in man.
The latter may contribute to ANF-induced natriuresis. The present data justify further
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SUMMARY
The studies of the present thesis are focused on the systemic and renal effects of
low (physiological) doses of ANF, and describe a few of the first studies in man. In
chapter 1 an introduction to the subject is given, reviewing the many animal studies
demonstrating that ANF lowers blood pressure, inhibits the renin-angiotensin-
aldosterone system, and affects renal function. These renal actions of ANF
encompassed increases in urinary sodium excretion, glomerular filtration rate, renal
blood flow, and renal medullary blood flow, whereas ANF decreased renal tubular
sodium reabsorption. In chapter 2 a review of the literature on the effects of ANF in
man including many of the studies of this thesis is given. It is argued that most of the
reviewed studies are in favor of a (patho)physiological role of ANF in humans. It is
concluded that lowering intravascular volume by increasing renal sodium excretion
and inducing a redistribution of extracellular fluid volume are the primary functions
of ANF.
Section I of this thesis encloses three studies, that focus first on the effects of
different doses during different states of sodium balance and second on the effects of
duration of ANF infusion on systemic blood pressure and urinary sodium excretion in
patients with essential hypertension. During a 4 hour infusion of 0.5 µg ANF/min no
decrease in blood pressure or even a pressure response occurred when the patients
adhered to a 200 mmol sodium intake daily, whereas the same infusion of 0.5 µg
ANF/min caused a marked fall in blood pressure when the patients had switched to a
50 mmol sodium intake. Lower doses of ANF (0.125 and 0.25 µg/min) did not change
blood pressure. Natriuresis was induced by all doses of ANF during both high and
low sodium intake, whereas ANF-induced natriuresis vanished when blood pressure
decreased. However, a sudden symptomatic hypotensive drop was observed after two
to three hours of ANF infusion at the higher doses, which forced us to stop
enrollment of patients in this study. Thus, the sensitivity of the blood pressure
lowering effect of ANF appeared to be enhanced during low sodium intake.
Moreover, the sensitivity of the systemic and the renal vasculature to exogenous ANF
appeared to be different, since one could observed a natriuresis during (low) doses of
ANF without any blood pressure response.
In the next two studies in Section I (chapters 4 and 5) we continued our
research on the (physiological) systemic and natriuretic effects of ANF by attempting
to lower blood pressure by prolonging the infusion duration of a low dose of ANF
(0.2 µg/min). It was hypothesized that a low dose of ANF had to be infused during a
longer period to induce a continuous urinary excretion of sodium in excess of sodium
intake, which would finally result in a decline in blood pressure. Indeed, ANF
induced a net negative sodium balance during 48 hours of low-dose infusion in two
patients with essential hypertension (chapter 4). Blood pressure however, did not
decrease during these 48 hours, although it tended to decline towards the end of the
study period. A sudden hypotensive effect fortunately did not occur. In the next study
(chapter 5) therefore, ANF was infused during an even longer period of 5 days again
at 0.2 µg/min in 6 patients with essential hypertension. In the first 12 hours of this 5-
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day ANF infusion urinary sodium excretion increased, whereas blood pressure did not
change. Thereafter, blood pressure began to fall gradually to stabilize at a level
approximately 10 % below baseline and urinary sodium excretion reached a new
equilibrium. The mechanism of this decrease in blood pressure could be explained by
the combined effects of volume depletion as well as vasodilation in a time-dependent
fashion. Thus, ANF in low doses appears intimately involved in the long-term
regulation of sodium balance and blood pressure in (hypertensive) humans.
The studies in section II focus on the mechanism of the natriuretic effect of ANF
First, the renal tubular sites of action of ANF (1 µg/min for 2 hours) were studied in
9 normotensive subjects and 6 patients with essential hypertension (chapter 6). ANF
induced an increase in urinary sodium excretion, a small increase in glomerular
filtration rate, and a decrease in effective renal plasma flow. Blood pressure and
potassium excretion were not affected. Furthermore, ANF induced an increase in
CH2O/GFR and a decrease in TcH2O/GFR. The ANF-induced increases in urinary
sodium excretion correlated with the changes in these parameters. These data suggest
glomerular as well as (direct or hemodynamically mediated) proximal and distal
tubular effects of ANF in humans. The effects of ANF on urinary sodium excretion
and renal hemodynamics did not differ between normotensive and hypertensive
subjects. However, the increase in CH2O/GFR was greater in the patients with essential
hypertension, and correlated significantly with blood pressure. Thus, the proximal
tubular effects were interpreted to be in part related to a contribution of (transmitted)
systemic blood pressure to ANF-induced natriuresis. Moreover, from these data a
(blood pressure related) enhanced delivery of sodium to the diluting segments together
with an impaired natriuretic response at more distal tubular segments of ANF in
patients with essential hypertension can be hypothesized.
The importance of blood pressure for ANF-induced sodium excretion was further
emphasized in diurnal rhythm studies in chapter 7. Infusion of ANF caused a ± 2
hour delay in the time of maximal diurnal urinary sodium excretion, whereas in
contrast, ANF did not change the net excretion of potassium. During baseline the time
of maximal urinary excretion of sodium did not correlate with the time of highest
blood pressure, whereas there was a correlation between these parameters during ANF
infusion. Conversely, during baseline mean plasma aldosterone concentration and the
time of maximal urinary excretion of sodium correlated negatively, whereas these
parameters did not correlate during ANF infusion. Thus, these data again stress the
important influence of blood pressure on ANF-induced natriuresis, and support the
hypothesis of an interaction between the natriuretic effects of ANF and components of
the renin-angiotensin-aldosterone system.
To date evidence is accumulating that the mechanism of the relation between
blood pressure and sodium excretion is related to simultaneous changes in renal
medullary blood flow. The following studies of section II of this thesis therefore,
address the effects of ANF on total renal blood flow and intrarenal blood flow
distribution in man. Since we had observed that ANF decreases effective renal plasma
147
Chapter 11
flow in humans, whereas animal studies had suggested a renal vasodilatory action of
ANF, first the effect of ANF on true total renal blood flow was established (chapter
8). ANF-induced changes in true total renal blood flow were calculated from effective
renal plasma flow, which was corrected for ANF-induced effects on hematocrit and
renal extraction of hippuran. ANF caused hematocrit to rise, and renal extraction of
hippuran to increase slightly. These changes did not offset the decrease in effective
renal plasma flow. Renal blood flow thus truly decreased and renal vascular resistance
increased during ANF infusion. In addition, the relation between the effects of ANF
on renal hemodynamic function and urinary sodium excretion was investigated. In the
first hour of ANF infusion, glomerular filtration rate increased, and urinary osmolality
decreased. In contrast, urinary sodium excretion increased significantly only in the
second hour of ANF infusion. The decrease in urinary osmolality in the first hour of
ANF infusion correlated with the induced natriuresis. Moreover, the changes in
urinary osmolality and sodium excretion both correlated with the changes in plasma
irANF. Thus, it was concluded from these data that ANF may cause a true decrease
in renal blood flow in man. A contributory role for ANF-induced (intra)renal
hemodynamic changes in ANF-induced natriuresis was suggested: the results are
compatible with an ANF-induced increase in the filtered load of sodium into a
washed-out medullary interstitium. From animal experiments one might speculate that
an ANF-induced increase in renal medullary blood flow is involved with such a
washout of the medullary interstitium. However, in humans changes in renal
medullary blood flow could not be measured.
A new method to measure non-invasively changes in the intrarenal distribution of
blood flow in humans was developed, evaluated in animals, and applied to a human
study on the effects of ANF on this distribution (chapters 9 and 10). The technique is
based on the kinetic modeling of 123I-hippuran renography. The changes in intrarenal
blood flow distribution as induced by placebo, angiotensin-I, or ANF were
simultaneously measured with this new technique and the standard microsphere
injection technique in anesthetized dogs. Baseline percentage medullary blood flow as
measured with both methods were similar. The absolute and percent changes in
medullary blood flow measured with renography correlated with those measured with
microspheres in both kidneys. These results thus suggest that this new method can be
used to measure changes in intrarenal blood flow distribution non-invasively in
humans. Therefore, we performed 123I-hippuran renography in 5 healthy volunteers to
test the clinical applicability of this method in man and to test our hypothesis that
ANF may increase medullary blood flow despite its decreasing effects on total renal
blood flow. Renographic studies were performed before and after infusion of ANF
(1.0 µg/min) or placebo. Significant problems in the application of the model to
human data were not encountered. The measurement of percentage medullary blood
flow with this method appeared to be reproducible and accurate in man in both left
and right kidney. During ANF infusion percentage medullary blood flow increased.
Since during ANF infusion effective renal plasma flow decreased and hematocrit
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increased, ANF caused absolute cortical blood flow to decrease, and absolute
medullary blood flow to increase. Thus, these data support the hypothesis that the
ANF-induced decrease in total renal blood flow in man is due to a decrease in
cortical blood flow, while ANF does not decrease (or even increases) medullary blood
flow. The latter may contribute to ANF-induced natriuresis.
In conclusion, the studies of the present thesis suggest that ANF is involved in the
physiological regulation of blood pressure and/or sodium homeostasis in man. Long-
term low-dose ANF infusion was shown to increase urinary sodium excretion (an
effect that may depend on the blood pressure level) and to decrease blood pressure
(an effect that may depend on sodium balance). In man, ANF-induced natriuresis
probably is due to glomerular as well as (direct or hemodynamically mediated)
proximal and distal tubular effects of ANF. Moreover, it is suggested that ANF
increases renal medullary blood flow in man. However, the original idea that only one
cardiac hormone regulates the feedback mechanism between cardiac pre- and afterload
and renal function appears to be too simple.
LOOK TO THE FUTURE
A family of natriuretic factors
During the years of the studies of this thesis a hugh amount of knowledge on ANF
became available, and it appears that one may speak of an "ANF-family" (for
reviews, see [1-3]). To date, at least 4 ANF-like peptides with autocrine, paracrine or
endocrine functions are discovered. These peptides have similar chemical structures
and share a similar spectrum of hemodynamic, renal, and RAAS-suppressing effects.
Apart from ANF, BNF (brain natriuretic factor), CNF (C-type ANF), and urodilatin
("renal natriuretic factor" or "RNF") are characterized. Urodilatin is identical to ANF
except for four additional residues at the amino terminus. The other peptides are
derived from separate precursor molecules, but they all share a similar 17-amino acid
ring structure with a disulfide binding between 2 cysteines. BNF (32-amino acids) has
its main production site in the atria, rather than in the brain where it was discovered,
and circulates in healthy volunteers at plasma concentrations of about 20 % of that of
ANF. CNF (22-amino acids and lacking the carboxy-terminal extension beyond the
ring structure) is confined mainly to the central nervous system, while concentrations
in plasma and kidney are small. CNF has been shown to have very potent venodilator
actions [4]. Finally, two peptide segments derived from the NH2-terminus and the
mid-portion of the ANF-prohormone (ANF(1-30) and ANF(31-67)) appear to circulate
in human plasma and to have vasodilatory and natriuretic effects of their own [5].
Moreover, at least 3 ANF-receptors are discovered [6]. The so-called type A and B
ANF-receptor both are coupled to guanylate cyclase and are supposed to have
identical biological activities. However, their tissue distribution and the affinities of
the various natriuretic factors for these receptors are different. The main function of
the ubiquiteous type C receptor is hypothesized to be elimination ("clearance") of
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these peptides from the circulation by endocytosis. Alternative functions of this
receptor are suggested to be inhibition of cyclic AMP formation or effects on growth
regulation [7,8].
The magnitude and the duration of the biological actions differ between the
various natriuretic peptides. This is probably explained by the difference between the
peptides in their affinity for the three recognized types of ANF-receptors in
connection with the different tissue distribution of these ANF-receptors. Moreover, the
production sites of the peptides are different, which provides an anatomical basis for
different regulation of release and paracrine action. For instance, BNF has a longer
half-life than ANF, which may be explained by the lower affinity of BNF for the type
C receptor [6]. Moreover, BNF release appears to be differently regulated than ANF
release [9]. Another example is the lower natriuretic activity of CNF at comparable
doses as ANF [10]. This may in part be explained by the lower affinity of CNF for
the type A receptor, which is found in endothelial cells and in renal epithelial cells, in
particular at or near the glomerulus and IMCD. In contrast, CNF has by far the
highest affinity for the type B receptor (for review see [1-3]). This type B receptor is
found primarily in heart, vascular smooth muscle and brain. The kidney however, is
relatively deficient of the type B receptor. These differences in receptor affinity
together with the difference in the tissue distribution of the receptors suggest that
ANF is predominantly involved with volume- and sodium homeostasis, whereas the
main action of CNF may be at the cardiovascular level. However, reality might even
be more complicated, since the receptors are shown to be (down)regulated via an
action of the natriuretic factors on the other receptors rather than on the receptor itself
[11]. In contrast, the natriuretic action of urodilatin has been found to be higher than
ANF at comparable plasma levels [12]. Urodilatin (or ANF(95-129) is postulated to
be synthetized in the kidney itself, probably at a distal cortical site [13], and is found
to be relatively resistant to the breakdown by endopeptidase 24.11 in contrast to the
circulating natriuretic peptides (for review see [14]). Urodilatin synthesis is enhanced
with higher sodium intake. These charactistics suggest that the action of urodilatin is
local, presumably at the IMCD. Finally, ANF(1-30) and ANF(31-67) are observed to
have a longer half-life than ANF(99-126), indicating that these peptides are involved
in the long-term regulation of sodium balance and/or blood pressure, whereas the
classic form of ANF has a shorter duration of action [5]. Thus, it appears that within
the ANF system the diverse natriuretic factors may have highly specialized functions,
which all together make the ANF system a flexible and probably powerful system that
contributes elegantly to the physiological regulation of blood pressure and sodium
homeostasis.
Pathophysiological significance
The role of ANF or of one of the other natriuretic factors in the pathogenesis or
maintenance of various disease states remains to be determined. To date it is
hypothesized and investigated for edematous and/or hypertensive states that the newly
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discovered natriuretic factors play a pathophysiological role rather than ANF itself. In
essential hypertension, BNF is suggested to be elevated, which contrasts with the
current view that ANF concentrations are not [15]. In cardiac failure sodium retention
has been associated with the finding that βANF (which has reduced biological
activity) is the principal form of circulating ANF [16], or with receptor
downregulation [17]. BNF increases only in severe congestive heart failure, in
contrast to the well-known rise in plasma ANF concentrations [18]. In liver cirrhosis
peritoneo-venous-shunting has been suggested to restore the renal hyposensitivity to
ANF, indicating that this hyposensitivity was mainly due to an impaired distal
delivery of sodium [19]. In animal models of the nephrotic syndrome an improper
processing of renal derived proANF has been suggested to underly the frequently
observed renal hyporesponsiveness to ANF [13]. Alternatively, a renal natriuretic
hyporesponsiveness together with an enhanced proteinuric action of BNF has been
suggested to contribute to the pathogenesis of this disorder [20].
Therapeutic perspectives
The therapeutic potential of interference in the ANF system has become enlarged
with the growing knowledge of more and distinct natriuretic factors. Interference in
the ANF system can be imagined to include development of specific analogues with
exclusively renal natriuretic effects or blood pressure lowering effects, or specific
blockers of one of the ANF receptors. During the last few years clinical expertise has
been build up with the use of various inhibitors of endopeptidase 24.11, a widely
occuring ectoenzyme that hydrolyzes many natural and synthetic substrates (for
review see [14]). These compounds have been shown to initially have a natriuretic
effect, which turns into a slight antinatriuresis upon continued endopeptidase
inhibition over several days. Blood pressure effects are absent or very modest [21,22].
However, it is possible that it takes more than a few days for these compounds to
decrease blood pressure [23]. Theoretically, these compounds may have several
advances over the use of classic diuretics [14]. The diuretic and natriuretic effects of
these substances are enhanced at hypervolemic states [24], which conversely may
prevent the development of volume depletion upon continued use. Moreover, these
substances are potassium sparing and do not affect uric acid metabolism like low
doses of ANF. Currently, in animal models diverse strategies have been tried to
enhance the usefulness of the endopeptidase inhibitors. Combination with angiotensin
converting enzyme inhibitors may result in a synergistic suppression of the renin-
angiotensin-aldosterone system [25]. Alternatively, endopeptidase inhibitors can be
combined with blockers of the clearance (type C) receptor in order to prevent the
induced rise in plasma concentrations of natriuretic factors to be opposed by the
action of this receptor [26]. However, currently there is no report on the clinical use
of such a compound. An attractive way of interfering with the ANF system may be to
synthetize chimera of the natural natriuretic peptides, such as the recently described
vasonatrin [27]. Vasonatrin is in fact CNF with the addition of the carboxy terminus
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of ANF. It was shown to have the venodilating actions of CNF, the natriuretic actions
of ANF and to possess arterial vasodilating actions as well. All these therapeutic
options are aimed at raising the ANF levels. However, ANF infusion has also been
shown to cause proteinuria, and has been associated with the hyperfiltration of
diabetes mellitus [28]. Thus, in some clinical states it may turn out to be useful to
oppose the ANF actions. In this regard, compounds such as the recently described
non-specific (type A and B) receptor blocker HS-142-1 [29], which is mainly used to
study the physiological actions of ANF, may have clinical implications as well.
The use of our new method to measure changes in the intrarenal distribution of
blood flow can now be applied in various human studies. Not only will it be
interesting to measure the effects of physiological maneuvers and of various kinds of
renal vasoactive drugs on the intrarenal blood flow distribution, the model may also
be used to study differences in the intrarenal blood flow distribution between healthy
subjects and patients with various diseases such as essential hypertension, congestive
heart failure, nephrotic syndrome, liver cirrhosis, and others. In animal models of
these diseases abnormalities in the intrarenal blood flow distribution have been
suggested [30].
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Korte samenvatting van het proefschrift
In dit proefschrift zijn enkele studies gebundeld die in de periode van 1986 tot
1993 in het Academisch Ziekenhuis Groningen werden verricht. Het doel van de
studies was uit te zoeken wat voor effect het atriaal natriuretisch factor (ANF, een
eiwit dat in het hart voorkomt) had op bloeddruk, zoutuitscheiding in de urine en de
(verdeling van de) doorbloeding van de nier. Dit naar aanleiding van de bevindingen
van De Bold, die in 1981 na een experiment bij ratten als eerste aantoonde dat er in
het hart een stof voorkomt die de nieren aanzet tot het uitscheiden van meer zout en
die de bloeddruk kan verlagen. Naarstig speurwerk van vele onderzoekers leidde tot
de ontdekking dat er in het hart een eiwit wordt gemaakt dat die hogere
zoutuitscheiding en bloeddrukdaling zou kunnen veroorzaken. Dit eiwit wordt ANF
genoemd omdat het vooral in de boezem (=atrium) van het hart blijkt voor te komen
en omdat het een hogere zoutuitscheiding in de urine (=natriurese) veroorzaakt. Sinds
een paar jaar zijn er nog drie andere eiwitten bekend die min of meer dezelfde
scheikundige structuur en vergelijkbare eigenschappen hebben als het ANF. Ten tijde
van de studies van dit proefschrift ging men er echter van uit dat er maar één eiwit
bestond (het ANF) dat de link vormde tussen uitzetting van het hart enerzijds (zoals
kan voorkomen bij achteruitgang van hart- of nierfunctie) en de hogere
zoutuitscheiding van de nier anderzijds. Het hart gaat ANF aanmaken en afgeven aan
de bloedbaan als het hart uitzet. Dit kan het geval zijn als er door een afnemende
hart- of nierfunctie te veel vocht in de bloedbaan komt. Er wordt ANF aangemaakt en
het teveel aan vocht wordt dan via de urine uitgescheiden. Uitzetting van het hart kan
eveneens voorkomen als men in bad gaat: het water duwt het bloed dan uit de
ledematen naar de romp, en dus naar het hart. Het aangemaakte ANF komt via de
bloedbaan in de nier terecht, waar het een toename van de zoutuitscheiding in de
urine veroorzaakt. Na het baden neemt de urineproduktie dan vaak toe. Er was nog
weinig bekend over de concentraties van ANF in het bloed en hoe het bij de mens
werkt. Dat werd onder andere in deze studies uitgezocht.
De effecten van continue, langdurige toediening van ANF werden bestudeerd bij
zowel gezonde vrijwilligers als bij patiënten met hoge bloeddruk. In ons eerste
onderzoek werd ANF gedurende vier uur en in verschillende hoeveelheden langzaam
in de bloedbaan ingespoten. Met name de nieren bleken zeer gevoelig te reageren op
het ANF. Bij de hogere doseringen ANF die in deze studie werden gebruikt, nam
eerst de zoutuitscheiding in de urine toe en daalde daarna de bloeddruk pas. Helaas
bleken deze hogere doseringen soms een te abrupt en te sterk verlagend effect op de
bloeddruk te hebben. De lagere doseringen ANF veroorzaakten wel een toename van
de zoutuitscheiding in de urine, maar de bloeddruk daalde niet. In onze tweede studie
werd ANF daarom in een vergelijkbare lage dosering toegediend, maar nu gedurende
48 uur. Wederom bleek de zoutuitscheiding in de urine wel toe te nemen, maar de
bloeddruk niet te dalen. Opvallend was wel, dat de toename van de zoutuitscheiding
aanhield en niet afvlakte. Daarom zetten we een soortgelijke, derde studie op, met als
voornaamste verschil dat ANF nu gedurende vijf dagen werd toegediend. Uit deze
studie bleek dat wanneer ANF gedurende langere tijd (meerdere dagen dus) wordt
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toegediend, de bloeddruk wel daalt. Dit komt waarschijnlijk doordat er steeds meer
zout wordt uitgescheiden. We maten in deze studie niet alleen de bloeddruk, maar ook
de hoeveelheid ANF in het bloed. Het bleek dat de lage doseringen ANF, zoals die in
deze studies werden gebruikt, de hoeveelheid ANF in het bloed deden toenemen tot
waarden zoals die ook optreden bij een teveel aan vocht in de bloedbaan, of zelfs na
het baden. Op grond van deze studies concludeerden wij daarom dat ANF in
hoeveelheden die ook in ’normale’ situaties voorkomen, betrokken is bij de regulering
van de zoutuitscheiding door de nier en ook bij de regeling van de bloeddruk.
We onderzochten ook hoe ANF de toename van de zoutuitscheiding in de urine
bewerkstelligt. In het algemeen regelt de nier de uiteindelijke hoeveelheid zout in de
urine op twee manieren. Ten eerste kan de nier meer of minder ’primaire urine’ (= de
allereerste urine die wordt gevormd door filtratie van het bloed dat door de nier
stroomt) maken. Ten tweede kan de nier vervolgens in de nierbuisjes meer of minder
zout terugwinnen uit deze primaire urine. ANF bleek de zoutuitscheiding op beide
manieren te beïnvloeden: het bevorderde de vorming van de primaire urine en het
remde waarschijnlijk tevens de terugwinning van zout door de nierbuisjes. Maar ook
de verdeling van het bloed tussen de nierbuisjes in de schors (= aan de buitenkant van
de nier gelegen) en het merg (= in het binnenste van de nier gelegen) kon een rol
spelen bij de zoutuitscheiding. Men vermoedde dat ANF veranderingen in die
verdeling kon bewerkstelligen. Met bestaande technieken kon dit echter niet bij de
mens gemeten worden. Daarom werd binnen dit onderzoek een nieuwe methode
ontworpen die het wel mogelijk maakte om de verdeling van de bloeddoorstroming in
de nier bij de mens te bestuderen. Met deze methode werd de hypothese getoetst dat
ANF de doorbloeding van het niermerg bij de mens zou kunnen doen toenemen, wat
de toename in zoutuitscheiding mede zou kunnen verklaren. Dit lijkt inderdaad het
geval te zijn, hoewel de studie nog wel uitgebreider zal moeten worden uitgevoerd om
dit te bewijzen.
Of ANF van betekenis is voor het ontstaan van bepaalde ziektebeelden (zoals
essentiële hypertensie (= bloeddruk met onbegrepen oorzaak)), is op dit moment nog
vooral speculatie. Uit het onderzoek naar de manier waarop ANF de toename van de
zoutuitscheiding in de nier bewerkstelligde, bleek dat ANF de terugwinning van zout
uit de primaire urine door de nierbuisjes waarschijnlijk remt. Dit laatste zou voor een
deel verband kunnen houden met de hoogte van de bloeddruk: een hogere bloeddruk
zou dan een hogere zoutuitscheiding veroorzaken. Bij patiënten met essentiële
hypertensie echter was dit niet het geval, wat zou kunnen wijzen op een relatieve
ongevoeligheid van de nier voor ANF bij deze patiënten. Het onderzoek naar
therapeutische mogelijkheden door in te grijpen in het ANF-systeem gaat gestaag
voort. De aanvankelijke hoop dat hier de mogelijkheden voor het ontwikkelen van
nieuwe middelen met urinevormende en bloeddrukverlagende eigenschappen voor het
oprapen lagen, is nog geen werkelijkheid geworden. De eerste resultaten zijn
bemoedigend voor de volhouders, maar de meeste onderzoekers hebben hun heil
inmiddels elders gezocht. Enerzijds heeft ANF theoretische voordelen. Met name
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omdat het de vorming van de primaire urine verhoogt en omdat de veroorzaakte
zoutuitscheiding waarschijnlijk weer afneemt als er voldoende effect is geweest, zodat
er geen gevaar is voor te veel zoutverlies. Anderzijds verhoogt ANF de druk in de
nieren en veroorzaakt het mogelijk eiwituitscheiding in de urine, wat allebei waar-
schijnlijk schadelijke effecten zijn. In bepaalde gevallen zou het dan in de toekomst





ANF: Atrial natriuretic factor
AVP: Arginine vasopressin
bpm: Beats per minute
cAMP: Cyclic adenosine mono phosphate
CBF: Cortical blood flow
cGMP: Cyclic guanosine mono phosphate
CHF: Congestive heart failure
CH2O: Free water excretion
CH2O/GFR: Fractional free water excretion
(CH2O+CCl)/GFR: Distal delivery term
CH2O/(CH2O+CCl): Distal segment reabsorption term
CK/GFR: Fractional urinary potassium excretion
CNa/GFR: Fractional urinary sodium excretion
Cosm: Osmolar clearance
Cosm/GFR: Fractional osmolar clearance
DBP: Diastolic blood pressure
EDTA: Ethylenediaminetetra-acetate
EH: (Patients with) essential hypertension
EANF: Renal extraction of ANF
Ehip: Renal extraction of hippuran
ERBF: Effective renal blood flow
ERPF: Effective renal plasma flow
FF : Filtration fraction
GFR: Glomerular filtration rate
IMCD: Inner medullary collecting duct
irANF: immunoreactive ANF
kDa: Kilo Dalton
MAP: Mean arterial pressure
MBF: Medullary blood flow
NS: Not significant
NT: Normotensive subjects
PAC: Plasma aldosterone concentration
PAH: Para-amino-hippuric acid
PNa: Plasma sodium concentration
Posm: Plasma osmolality
PRA: Plasma renin activity
RAAS: Renin-angiotensin-aldosterone system
RBF: Renal blood flow
RIA: Radioimmunoassay
ROI: Region of interest
RVR: Renal vascular resistance
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SBP: Systolic blood pressure
SGOT: Serum glutamic-oxaloacetic transaminase
SGPT: Serum glutamic-pyruvic transaminase
TcH2O: Free water reabsorption
TcH2O/GFR: Fractional free water reabsorption
UCaV: Urinary calcium excretion
UClV: Urinary chloride excretion
UKV: Urinary potassium excretion
UMgV: Urinary magnesium excretion
UNaV: Urinary sodium excretion
Uosm: Urinary osmolality
UPhosV: Urinary phosphate excretion
UuaV: Urinary uric acid excretion
UVol: Urinary volume excretion
V/GFR: Fractional urinary volume excretion
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STELLINGEN
1. De invloed van de zoutstatus op het (anti-)hypertensief effect van atriaal natriuretische factor
(ANF) is onvoldoende onderzocht.
2. Bij de mens veroorzaakt ANF voornamelijk een afname in de totale renale doorbloeding.
3. Gedurende de gehele evolutie van "fish to philosopher" is ANF aanwezig gebleven zowel bij
planten als bij primitieve en meer ontwikkelde diersoorten. Dit duidt op een belangrijke rol voor
ANF in de regulering van de water- en zouthomeostase.
4. Momenteel heeft het bepalen van plasmaspiegels van ANF nog geen plaats in de routine-
diagnostiek of follow-up van bijvoorbeeld nier- of hartfalen.
5. De stijging in filtratie fractie en in albumine excretie tijdens infusie van ANF duidt op een
mogelijk door ANF veroorzaakte stijging in de intraglomerulaire druk. Gezien de huidige kennis
over renaal protectieve interventies belemmert dit het eventuele therapeutische nut van middelen
die de plasmaspiegels van ANF verhogen.
6. Veranderingen in renale medullaire doorbloeding zijn slechts groot wanneer ze in procenten
worden uitgedrukt.
7. De term "micro"-albuminurie berust slechts op de historische ontwikkeling van meettechnieken.
Het heeft mogelijk grote gevolgen.
8. Vervanging van het Latijn door een wiskundige taal kan leiden tot vooruitgang in de medische
wetenschap. Daarbij dient meer nadruk te worden gelegd op werkpunten en non-lineaire
verbanden.
9. Artsen zonder Grenzen opereren vaak in grensgebieden.
10. Positieve discriminatie blijft discriminatie en heeft daarom onacceptabele negatieve kanten.
11. In de arts-patiënt relatie heeft de arts de rol van hulpverlener. Met het toenemend aantal
managers in de gezondheidszorg wordt de arts steeds vaker in de rol van hulpvrager gedwongen.
Deze rol vereist andere communicatieve vaardigheden dan die waarin de arts momenteel getraind
wordt. In de opleiding dient daarom meer aandacht besteed te worden aan de arts-manager
relatie.
12. Het dieet behoort tot de belangrijkste therapievormen van de internist.
13. Al ondermijnt een rokende dokter alle voorlichtingscampagnes nog zo snel, de statistiek
achterhaalt hem wel.
14. Niets onmenselijks is de mens vreemd.
Stellingen behorende bij het proefschrift "ATRIAL NATRIURETIC FACTOR. Integrated effects on
blood pressure, natriuresis, and renal medullary blood flow in man" door Wilbert M.T. Janssen.
Groningen, 5 oktober 1994.
